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Vibrational spectroscopic diagnostic techniques have significant potential to improve 
the care of women with benign, premalignant and malignant vulval diseases by 
reducing the reliance on traditional biopsy and histopathology. These techniques 
also have the potential to augment clinicians’ ability to differentiate different types of 
vulval disease at the time of surgery for neoplastic vulval disease. In addition, 
vibrational spectroscopic techniques offer the opportunity to assess molecular 
changes associated with the development of vulval cancer that are not apparent on 
routine histopathological assessment. 
The work outlined in this thesis evaluates the role of emerging techniques in 
vibrational spectroscopy to address this need within three key themes: 
1. Development of a vibrational spectroscopic diagnostic technique to reduce the 
reliance on traditional biopsy and histopathological diagnosis. 
2. Development of a vibrational spectroscopic diagnostic technique for improving 
the delineation of disease margins at the time of surgery for pre-malignant 
and malignant vulval conditions. 
3. Evaluation of a vibrational spectroscopic tool for augmenting and automating 
aspects of vulval histopathology. 
Raman spectroscopic mapping of 91 fresh frozen vulval tissue sections combined 
with multivariate spectral analysis was used to demonstrate that malignant vulval 
disease could be differentiated from non-neoplastic and premalignant vulval disease 
with a sensitivity of 97% and specificity of 78%. The technique was then tested in 
experimental conditions closer to in-vivo application, measuring spectra from 91 
whole fresh frozen tissue blocks using microscope and probe Raman systems. This 
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demonstrated the technique could differentiate malignant from non-neoplastic and 
premalignant vulval disease with sensitivities of 84% to 92% and specificities of 84% 
to 64% respectively. In a separate investigation vulval tissue blocks from 27 women 
with suspected lichen sclerosus underwent Raman spectroscopic point 
measurements. Multivariate analysis demonstrated Raman spectroscopy could be 
used to differentiate lichen sclerosus from other vulval disorders with a similar clinical 
appearance with a sensitivity of sensitivity of 91% and specificity of 80%. 
Fourier transform infrared (FTIR) spectroscopic mapping of 93 fixed paraffin 
embedded tissue sections was used to demonstrate that malignant vulval disease 
could be differentiated from non-neoplastic and premalignant with vulval disease with 
an approximate sensitivity of 100% and specificity of 79%. In addition FTIR 
spectroscopy was used to differentiate molecular changes in vulval intraepithelial 
neoplasia (VIN) and lichen sclerosus (LS) found in association with vulval squamous 
cell carcinoma (SCC). Analysis of FTIR spectroscopic tissue maps from 48 patients 
demonstrated the technique could differentiate LS associated with SCC with a 
sensitivity of approximately 100% and specificity of 84% and VIN associated with 
SCC with a sensitivity of approximately 100% and specificity 58%. 
This thesis demonstrates the considerable potential of vibrational spectroscopy in 
this clinical setting. The research has made significant progress in each of the three 
themes outlined above and indicates that further work is warranted to develop the 
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Chapter 1 The Vulva and Vulval Disease 
1.1 The normal vulva 
1.1.1 Anatomy of the vulva 
The human vulva consists of the female genitalia including and immediately external 
to the hymen of the vagina.  It is composed of the mons pubis, clitoris and external 
urethral meatus anteriorly; the labia minora and labia majora laterally and the 
fourchette posteriorly (Figure 1-1) (Standring, 2016). 
 
 
Figure 1-1 – Illustration of the anatomy of the vulva (Image courtesy of the The Association for Lichen 





The epithelium covering the vulva displays significant regional differences in 
anatomical and histological structure due to the variation in embryonic derivation. 
Embryonic ectoderm forms the skin bearing areas of the mons pubis, labia majora 
and perineum whereas the vulval vestibule is formed of embryonic endoderm (Berek, 
2012). 
1.1.1.1 Vulval vestibule 
The area between the hymen of the vagina, the labia minora, clitoris and posterior 
fourchette is termed the vulval vestibule. The vestibule is formed from the embryonic 
endoderm of the urogenital sinus. The area is non hair bearing and is covered in non 
keratinised stratified squamous epithelium containing several mucous secreting 
glands including Bartholin’s, Skene’s and periurethral glands as well as the urethral 
and vaginal orifices. The hymen forms the vaginal border of vestibule and consists of 
folds of fibrous tissue covered in non keratinised stratified squamous epithelium. The 
junction between the non keratinised epithelium of the vestibule and the medial 
surface of the keratinised epithelium of the labia minora is marked by Hart’s line 
(Farage and Maibach, 2016; Standring, 2016). 
1.1.1.2 Mons pubis and vulval labia 
The mons pubis or mons veneris is a rounded protuberance anterior to the pubic 
symphysis comprising an assemblage of adipose tissue covered by keratinised 
stratified squamous epithelium. Superiorly the mons pubis borders the anterior 
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abdominal wall and inferiorly it joins the anterior labial commissure, the most anterior 
portion of the labia majora. 
The labia majora extend posteriorly from the anterior commissure to form two 
prominent swellings on either side of the vulva. The prominence of the labia majora 
is created by subdermal fibro-adipose tissue deposition and this diminishes with age 
as the fat atrophies. The labia majora like the mons pubis are covered with 
keratinised stratified squamous epithelium containing sweat glands and sebaceous 
glands. The lateral surface of the labia majora are rugose, pigmented and contains 
hair follicles whilst the inner surface is smooth and hair free. The labia majora 
diminish posteriorly and merge with the surrounding skin below the level of the 
fourchette. 
The labia minora are two lesser cutaneous folds lying medial to the labia majora 
extending laterally either side of the vaginal orifice. Unlike the labia majora they are 
composed of dense subdermal connective tissue without adipose deposition. 
Anteriorly each labia minora divides with the lower part forming the frenulum of the 
clitoris and the upper part forming the clitoral sheath. The posterior part of the labia 
minora surrounds the vulval vestibule and fuse at the fourchette. 
The perineum lies between the vulval fourchette with its associated labia and the 
anus and consists of the hair bearing keratinised stratified squamous epithelium 




1.1.2 Histology of the normal vulva 
1.1.2.1 Normal human skin 
Normal human skin consists of three key layers.  The most superficial layer is the 
epidermis, this covers the dermis, underneath which lies the hypodermis. The 
histological and biochemical structure of the epithelium covering the vulva closely 
resembles skin found elsewhere on the body with a few adaptive differences 
(Frienkel and Woodley, 2001). 
1.1.2.1.1 Epidermis 
The epidermis is the outmost layer of cells and is composed of stratified squamous 
epithelium. The epidermis varies in thickness depending on its position on the body 
from around 40 µm on the eyelid up to 1 mm in area of high mechanical stress (e.g. 
palms and soles of feet) (Jianhua Zhao et al., 2008). The epidermis forms a barrier 
for water and protects the body from the external environment.  
Keratinocytes are the principal cell type of the epidermis. These cells mature as they 
progress from the basal layer of the epidermis towards the surface of the skin. The 
epidermis is divided into four strata, the stratum germinosum, the stratum spinosum, 
the stratum granulosum and the stratum corneum (Figure 1-2).  The stratum 
germinosum (single layer of cells) contains mitotically active cells necessary for the 
regeneration of the epidermis.  After mitotic division the newly formed cells undergo 
progressive maturation as they migrate toward the surface of the skin.  The stratum 
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spinosum (8-10 layers of cells) is the next layer the newly formed cells enter.  The 
cells within this layer have many desmosomes covering their surface.  These 
desmosomes anchor the cells together and contain thick tufts of keratinous 
filaments.  Within the next most superficial layer (stratum granulosum, 3-5 layers of 
cells) cells begin to lose their nuclei and cytoplasmic organelles and develop into the 
keratinised squames of the stratum corneum.  The stratum corneum is the outer 
most layer and contains non viable but biochemically active corneocytes densely 
packed with keratin (Frienkel and Woodley, 2001; Gartner, 2017). 
The layers of the epidermis contain differing amounts of keratin.  The stratum 
germinosum contains 30% keratin whilst the stratum corneum is 80% keratin. 
Studies have shown that epithelial keratins can be grouped into acidic (type I) or 
neutral-basic (type II) (Moll, 1991; Tobin, 2006). Cells express at least one type of 
type I keratin in combination with a type II partner keratin. Proliferative cells within 
the epidermis are associated with K5 and K14 keratin whilst maturing cells 





Figure 1-2 – H&E stained tissue section of normal vulval skin 
The dermis is separated from the epidermis by a thin basement membrane.  The 
epidermis contains extensions called Rete ridges that project into the dermis 
between dermal papillae.  These dermal papillae form part of the more superficial of 
the two zones of the dermis, the papillary dermis.   Beneath this lies the reticular 
layer that constitutes the bulk of the dermis.   
1.1.2.1.2 Dermis 
The dermis is a fibroelastic connective tissue which primarily contains fibroblasts 
which secrete collagen, elastin and other substances necessary for the support of 
the skin (Caspers, 2003). The dermis merges with the hypodermis that lies 
underneath the dermis.  The hypodermis contains mostly adipose tissue and sweat 
glands. 
The major structural proteins within the dermis are collagen and elastin (Table 1-1) 
and these are responsible for the tensile strength of human skin.  Collagen 
represents around 75% of the dry weight of the dermis (Caspers et al., 1998).  
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Dermal collagen is primarily type I (85-90%), type III (8-11%) and type V (3%) 
(Tobin, 2006). Collagens are crucial in ensuring the epidermis is anchored to the 
dermis. Collagen VII anchors the basement membrane to the extracellular matrix of 
the dermis and collagen XVII links basal keratinocytes with the basement 
membrane. The second major structural dermal protein is elastin.  Elastin fibres can 
be extended by more than their full resting length without breaking and provide skin 
with its elasticity.  
The portion of the extracellular matrix of the dermis not consisting of collagen or 
elastin fibres is termed the extrafibrillar matrix.  This extrafibrillar matrix consists 
primarily of water, proteoglycans, glycoproteins and hyaluronic acid.  Proteoglycans 
are formed by binding glycosaminoglycans to a protein.  The main 
glycosaminoglycans in the dermis are hyaluronic acid, chondroitin sulphate, keratin 
sulphate, heparan sulphate, dermatan sulphate and heparin.  An example of a key 




Table 1-1 – Primary biomolecular constituents of human epidermis and dermis 
Epidermis Dermis 
Keratin Collagen (types I and III) 
Urea Elastin 
Phenylalanine Lipids 
Ceramid hyaluronic acid 
Cholesterol chondroitin sulphate 
Lactate keratin sulphate 
Carotenoids heparan sulphate 
Lipids dermatan sulphate 
 heparan 
1.1.2.1.3 Skin pigmentation 
Melanin is the primary skin pigment responsible for variations in skin colour.  Melanin 
synthesis occurs within melanosomes found within melanocytes in epidermis 
(Slominski et al., 2004; Tobin, 2006). Melanocyte pigmentation is affected by various 
intrinsic and extrinsic factors which include body location, ethnicity, gender, age, 
chemical exposure and exposure to ultraviolet radiation. 
1.1.2.2 Histology of the labia majora and mons pubis 
The histological appearance of the epithelium within the labia majora and mons 
pubis closely resembles skin found elsewhere on the body with keratinised stratified 
squamous epithelium containing hair follicles with eccrine, apocrine and sebaceous 
glands (Burkitt, Young and Heath, 1995). 
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1.1.2.3 Histology of the labia minora, vulval vestibule and 
hymen 
The epithelium of the labia minora, vulval vestibule and hymen is also a stratified 
squamous epithelium however it contains minimal keratinisation.  This epithelium 
does not have hair follicles or underlying adipose tissue but still contains eccrine, 
apocrine and sebaceous glands. 
1.1.3 Lymphatics drainage of the vulva 
Vulval lymphatics drain to the superficial inguinal nodes and then to the deep 
inguinal lymph nodes (LNs) with the exception of clitoris that drains directly into the 
deep inguinal nodes.  The deep inguinal nodes drain to the external iliac nodes and 
on to the paraaortic lymph nodes (Farage and Maibach, 2016). 
1.1.3.1 The histology of lymph nodes 
Lymph nodes are small bean shaped organs connected by lymphatic vessels. 
Lymph nodes have two main functional regions, the cortex and medulla, surrounded 
by an outer collagenous capsule.  The capsule is punctured by several afferent 
lymphatic channels bringing incoming lymph.  A single efferent channel at the hilum 
drains the lymph from the node.  Inguino-femoral lymph nodes typically contain a 
large concentration of lipids compared with lymph nodes elsewhere in the body 




1.2 Benign diseases of the vulva 
Benign vulval skin disorders are common and community based studies indicate that 
about one fifth of all women report significant vulval symptoms (ACOG, 2008).  
These symptoms and signs, including pruritis, pain and alterations in skin 
appearance are frequent reasons for presentation to primary and secondary care. 
Within secondary care the commonest causes of vulval symptoms are benign 
conditions such as vulval dermatitis, lichen simplex, vulval candidiasis, lichen 
sclerosus and lichen planus (ACOG, 2008). 
Several of these benign vulval disorders have long term implications for the affected 
women both due to the direct effects of the disease and the risk of malignant 
transformation.  In lichen sclerosus and lichen planus the risk of developing invasive 
vulval cancer is increased and long term surveillance is required (Carli et al., 1995; 
Carlson et al., 1998; Powell and Wojnarowska, 1999; RCOG, 2014). 
1.2.1 Vulval lichen sclerosus 
Lichen sclerosus (LS) also known as leucoplakia, lichen albus and lichen sclerosus 
et atrophicus is an inflammatory condition that can affect any skin site but is most 
commonly found in the vulva (Powell and Wojnarowska, 1999).  The true prevalence 
of LS is unknown as however community studies in the elderly have demonstrated a 
prevalence as high as 3% (Leibovitz et al., 2000). The aetiology of LS is unknown 
although there is some evidence to suggest that the lichen sclerosus has an 
autoimmune aetiology (Meyrick Thomas et al., 1988).  It has been observed that 
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auto immune conditions are more prevalent in women with lichen sclerosus 
compared unaffected women (Harrington and Dunsmore, 1981).  In addition to this 
antibodies to extracellular proteins have been demonstrated in women with this 
condition (Oyama et al., 2003). 
Typical symptoms of lichen sclerosus include pruritis, irritation and soreness 
although the condition can be asymptomatic.  Lichen sclerosus typically appears 
pale and atrophic although blistering, erosions, purpura and hyperkeratosis can be 
present.  Vulval scarring leads to destruction of normal anatomical features and can 
result in fusion of the labia, stenosis of the interoitus as well as burying of the clitoris 
(Powell and Wojnarowska, 1999). This scarring can lead to significant physical, 
psychological and psychosexual morbidity in those affected (Haefner et al., 2014).  
LS is complicated by development of squamous cell carcinoma in approximately 4% 
of women (Carlson et al., 1998; Powell and Wojnarowska, 1999). This compares to a 
background risk of vulval cancer in the UK of 0.3% (Cancer Research UK, 2016). 
Vulval lichen sclerosus may occur at any age but typically either appears in 
prepubertal girls or post menopausal women (Meffert, Davis and Grimwood, 1995). 
Diagnosis can be clinical although biopsy and histology is necessary if the diagnosis 
is uncertain or if there is a failure to respond to adequate treatment (Neill and Lewis, 
2010). Histology typically shows a thinned epidermis, sub-epidermal hyalinisation 
with a deeper inflammatory infiltrate (Figure 1-3).  
The mainstay of treatment is ultrapotent topical corticosteroids ointment applied 
regularly to the affected area.  This treatment produces remission of symptoms in 
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ninety-five percent of women and maintenance treatment has the potential to the 
reduce the risk of progression to vulval cancer without significant adverse effects 
(Neill and Lewis, 2010; Chi et al., 2012; Fistarol and Itin, 2013). 
 
Figure 1-3 – H&E stained tissue section demonstrating histological changes in lichen sclerosus 
After initial treatment patients require long term follow up either with regular review or 
self monitoring by the patient due the increased risk of progression to squamous cell 
carcinoma (RCOG, 2014). 
1.2.2 Vulval lichen planus 
Vulval lichen planus is a rare inflammatory condition of unknown aetiology that 
typically presents with vulval pruritis, irritation and soreness although similar to lichen 
sclerosus the condition can be asymptomatic.  As with lichen sclerosus there is a 
small risk of progression to squamous cell carcinoma in patients with lichen planus 
(Cooper and Wojnarowska, 2006). 
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Diagnosis is based on the characteristic but varied clinical appearance. When the 
diagnosis is in doubt vulval biopsy is required.  Histology shows irregular saw-
toothed acanthosis, band like dermal infiltrate (primarily lymphocytic) and increased 
granular layer and basal cell liquefaction.  Treatment is with topical corticosteroids 
ointment applied regularly to the affected area. As with lichen sclerosus patients 
often require long term follow up either with regular review or self monitoring by the 
patient (Cooper and Wojnarowska, 2006). 
1.2.3 Vulval dermatitis 
As with skin elsewhere in body the vulva can be affected by irritant, allergic, atopic or 
seborrhoeic dermatitis.  Other, secondary causes of dermatitis include iron 
deficiency and infection. Diagnosis of vulval dermatitis is primarily based on clinical 
presentation and response to treatment. The condition may be mistaken for lichen 
sclerosus in some cases and clinical assessment can be supplemented by vulval 
biopsy if the diagnosis is not clear.  After treatment long term follow up is not 
required provided the patient is asymptomatic as there is no significant increased 
risk of progression to vulval cancer (Bourke, Coulson and English, 2009). 
1.3 Vulval intraepithelial neoplasia (VIN) 
Vulval intraepithelial neoplasia (VIN) is a premalignant vulval skin condition with a 
reported risk of malignant transformation as high as 40-60% for untreated disease 
(Jones, Rowan and Stewart, 2005; Van Seters, Van Beurden and de Craen, 2005). 
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For this reason long term follow up of this condition is required (RCOG, 2014). VIN 
can affect women of any age, however a recent systematic review has suggested 
the mean age at diagnosis is 46 years (Van Seters, Van Beurden and de Craen, 
2005).  Women under 50 years comprise 75% of cases and the incidence in this age 
group is increasing (Jones, Rowan and Stewart, 2005; Judson et al., 2006). Typical 
symptoms include pruritis and vulvodynia, which can be severe.  VIN presents with 
multifocal disease in 80% of affected women and in these women premalignant 
neoplastic changes are more likely to be found elsewhere in the lower genital tract 
(van Beurden et al., 1995). 
The incidence of VIN is difficult to assess, as many women will not seek medical 
assessment of their vulval symptoms.  In the United States the incidence has been 
estimated at 3 per 100,000 women (Judson et al., 2006). VIN is often first detected 
alongside concurrent vulval SCC and it is postulated that the recent increase in 
vulval cancer in women under the age of 50 is linked to an increasing incidence of 
VIN (Jones, Baranyai and Stables, 1997; Eva et al., 2009). 
1.3.1 Classification of VIN 
The categorisation of VIN has changed in recent years.  Traditionally various names 
have been used for VIN type disease including Queyrat’s erthroplasia, carcinoma 
simplex, early vulval cancer, carcinoma in situ (CIS), vulval atypia and dysplasia.  
The nomenclature was simplified in 1976 by the International Society for the Study of 
Vulvovaginal Diseases (ISSVD) and the terms vulvar atypia and carcinoma in situ 
were suggested (ISSVD, 1976). Following this, in 1986, the ISSVD introduced the 
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term VIN to replace the previous classifications.  Initially the term VIN was split into: 
VIN 1 for mild dysplastic changes; VIN 2 for moderate dysplasia and VIN 3 to 
encompass severe dysplasia, carcinoma in situ and differentiated VIN.  In light of a 
lack of evidence that VIN 1-3 exist in a biological or morphological continuum the 
classification was changed by the ISSVD in 2005 to encompass two types of VIN, 
usual type and differentiated type.  These two types of VIN are thought to differ in 
pathogenesis, morphology and prognosis (Table 1-2). Both these types of VIN are 
considered to be high grade (VIN2-3) and use of the term VIN 1 is no longer 
supported. Newer terminology has now been recommended by the ISSVD in line 
with other HPV related anogenital lesions, however this terminology has not yet been 
widely adopted. Within the new terminology usual type VIN is renamed high-grade 
squamous intraepithelial lesion (HSIL) and the terminology for HPV independent 
(differentiated) VIN remains unchanged (ISSVD, 2015). 
Table 1-2 – Features of the primary histological subtypes of VIN, adapted from Walker et al. 2012 
(Walker and Mathews, 2012) 
 
 Usual Type VIN (HSIL) Differentiated VIN 
Age group Premenopausal Postmenopausal 
Overall Proportion of VIN (%) 95% 5% 
HPV Association Yes No 
Risk Factors Smoking 
Immunosuppression 
 
Distribution Often multifocal Usually unifocal 
Malignant Progression Warty, basaloid SCC Keratinising SCC 
1.3.2 Diagnosis of VIN 
Currently both the diagnosis of VIN and monitoring of patients with VIN are limited to 
visual assessment often supplemented by invasive tissue biopsies. The appearance 
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of VIN is highly variable and this can make it difficult to diagnose on clinical 
assessment alone. The lesions may appear as subtle pale or pigmented patches or 
more discrete papules and macules. There may be a single lesion or multiple lesions 
and they may be present in different anatomical locations. VIN on the keratinised 
outmost surface of the vulval typically appear as lichenified or hyperkeratotic plaque. 
By contrast lesions on the non-keratinised surfaces typically appear as pink or red 
macules. Pigmentation of lesions is also present in 10-15% of cases of VIN (Walker 
and Mathews, 2012). 
Acetic acid applied to the vulva is often used as an adjunct to clinical examination. 
After application lesions appear pale due to the reversible precipitation of nuclear 
proteins. This technique lacks specificity as aceto-white changes may represent not 
only areas of VIN but also viral changes associated with HPV and Epstein-Barr virus, 
areas of tissue trauma, ulcers and erosions. The aceto-white reaction also varies in 
intensity in different anatomical locations and between patients making it an 
unreliable test in isolation (Maclean and Reid, 2011). 
1% toluidine blue dye applied to the vulva has also been proposed as a diagnostic 
tool for the detection of premalignant and malignant vulval disease. Toluidine blue 
stains nuclei and increased staining is seen when it is applied to areas of neoplastic 
disease where cell nuclei are found closer to the surface. In one study a positive 
toluidine blue stain detected VIN with a sensitivity of 59% to 100% with specificity of 
40% to 85% depending on the level of staining interpreted as a positive test (Joura et 
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al., 1999). The subjective nature of the test and the low positive predictive value 
limits is utility in routine clinical practice. 
Cytology has been successfully employed on the cervix as a less invasive traditional 
technique for identifying those with premalignant conditions. Unfortunately as many 
vulval lesions have significant surface keratosis, cytological specimens from the 
vulval often consist of mainly enucleated squamous cells making accurate 
cytological diagnosis difficult. Studies assessing the use of cytology for the diagnosis 
of VIN reported that in 18% to 26% of cases the collected sample was inadequate for 
analysis (Levine et al., 2001; Van den Einden et al., 2012). The reported sensitivity 
of cytology for the detection of malignant and premalignant lesions varies from 32% 
to 96% with the study reporting the highest sensitivity also reporting a specificity of 
30% (Levine et al., 2001; Bae-Jump, Bauer and Van Le, 2007; Van den Einden et 
al., 2012). In addition, only half of vulval carcinomas penetrate through the outermost 
dyskeratotic layer of skin present in both VIN and vulval carcinoma making 
differentiation between premalignant and malignant disease difficult (Nauth and 
Schilke, 1982).  The low positive predictive value of the technique and its limitations 
in detecting invasive disease has meant cytology has yet to be established as a 
reliable technique for diagnosing vulval conditions (Smith, 2010). 
In practice, as the appearance of VIN can be subtle and occult malignancy can be 
found in up to 22% of women with VIN, a high degree of suspicion and low threshold 
for tissue biopsy is usually applied (Modesitt et al., 1998). 
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1.3.3 Usual type VIN 
Usual type VIN (uVIN) includes warty, basaloid and mixed lesions and is associated 
with oncogenic human papillomavirus (HPV) infection, commonly HPV 16 and less 
often HPV 18 or 33 (De Vuyst et al., 2009)(Hørding et al., 1995). Risk factors for the 
development of uVIN include human immune deficiency virus infection and tobacco 
smoking. uVIN is found predominantly in younger women in their fifth decade and is 
more likely to present as multifocal vulval disease with concurrent intraepithelial 
neoplasia in the cervix, vagina or anus. A major concern in those with uVIN is the 
development of vulval SCC and uVIN is a precursor for the majority of basaloid and 
warty type vulval SCC (Hampl and Sarajuuri, 2006; Van der Avoort et al., 2006; 
Reyes and Cooper, 2014). The rising incidence of vulval cancer is primarily due to 
an increase in vulval cancer in women aged 70 and below, suggestive of an increase 
in HPV related disease. This increase in HPV related disease may also account for 
the recent increase in the incidence of uVIN (Iversen and Tretli, 1998; Joura et al., 
2000). The recent introduction of routine immunisation against high-risk HPV 
subtypes may result in a decrease in the incidence of uVIN although the impact is 
not yet clear. 
Low grade uVIN usually presents as white macules which may be multifocal whereas 
high grade uVIN usually presents as multifocal plaques.  A minority of women 
present with hyperpigmented lesions. 
Increase rates of progression to invasive disease and recurrence of uVIN have been 
linked to multifocal disease (Fehr et al., 2013), large lesions (Wallbillich et al., 2012) 
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and smoking (Fehr et al., 2013). Immunocompromised women have also been 
reported to suffer from a higher rate of recurrence and progression to SCC 
(Wallbillich et al., 2012; Fehr et al., 2013). 
1.3.3.1 Histological features of uVIN 
Typical histological features of all types of uVIN include full thickness or near full 
thickness atypia with the loss of epithelial cell maturation associated with 
pleomorphism, cellular crowding, nuclear hyperchromasia, and abnormal mitotic 
figures. 
The characteristic features of warty type VIN is a condylomatous appearance, 
hyperkeratosis, parakeratosis, cellular pleomorphism with abnormal cell maturation.  
Rete ridges are typically wide and deep.  Multinucleation, acanthosis, koilocytosis, 
corps rounds and abnormal mitotic figure are also often found (Nucci, 2013; Gartner, 
2017). 
Basaloid VIN typically has a thickened epithelium which is flat and non 
papillomatous.  There is a proliferation of undifferentiated cells with a uniform 
basaloid appearance and numerous mitotic figures.  Corps rounds and koilocytotic 
cells may be present, however these are less prominent than with warty type VIN.  
Both basaloid and warty VIN can extend into the sub epithelial skin appendages and 
this should not be classified as invasion. When warty and basaloid VIN are both 
present in a single lesion this is called mixed type VIN. 
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Immunostains for p16 and MIB-1 can be used to support the histological diagnosis of 
uVIN. P16 staining can be used as a surrogate marker for HPV infection and MIB-1 
staining demonstrates the prevalence of the Ki-67 protein, a marker for cellular 
proliferation (Gartner, 2017). 
1.3.4 Differentiated type VIN 
Differentiated VIN (dVIN) accounts for less than 5% of VIN and in contrast to uVIN is 
not associated with HPV infection. It is more commonly found in older 
postmenopausal women.  dVIN, is less commonly multifocal and is associated with 
mutations in the p53 tumour suppressor gene. dVIN typically develops in women 
with chronic vulval dermatoses typically lichen sclerosus and lichen simplex (Del 
Pino, Rodriguez-Carunchio and Ordi, 2013a)(Rolfe et al., 2003).  There is a higher 
risk of progression to vulval SCC in dVIN compared with uVIN. dVIN does not have a 
distinctive clinical appearance and it is not unusual for dVIN to be first diagnosed 
adjacent to a more clinically recognisable vulval SCC. 
1.3.4.1 Histological features of dVIN 
In dVIN cellular atypia is confined to the basal layers of the epithelium and may be 
difficult to distinguish. The characteristic histological features of differentiated type 
VIN include prominent eosinophilic cells within the parabasal and basal area usually 
associated with keratin formation and characteristic ‘pearl-like’ changes in the rete 
ridges.  The premature differentiation of keratinocytes gives them a characteristic 
appearance with comparatively large vesicular nuclei with prominent nucleoli (Fox 
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and Wells, 2003).  The extensive cellular differentiation makes this type of VIN 
difficult to recognise and it can be mistaken for more benign disease.  When 
histological classification is difficult, staining for p53 protein can be helpful. P53 
staining of an area of dVIN typically shows prominent, diffuse nuclear staining in 
basal and parabasal cells. This increasing in staining has been shown to be 
concomitant with somatic p53 mutations, highlighting the different pathogenesis of 
dVIN (Gartner, 2017). 
1.3.5 Management of VIN 
The majority of patients with VIN are affected by distressing vulval complaints in 
addition to being at increased risk of developing vulval SCC and for these reasons 
the VIN is usually actively managed (Shylasree et al., 2008; Dominiak-Felden et al., 
2013). Traditionally the mainstay of therapy has been surgical excision although 
treatment is multimodal and topical medical therapy and laser ablation are accepted 
treatments.  
Surgical excision can be mutilating and disfiguring and is associated with 
somatopsychic reactions and sexual dysfunction proportional to the size of the 
excision (Shylasree et al., 2008). For this reason surgical excision of VIN remains 
standard management for small unifocal lesions (Edwards et al., 2015). Disease 
excision in cases of multifocal disease requires extensive surgery and is not an 
optimal treatment due to the associated morbidity and adverse impact on quality of 
life (Aerts et al., 2012; Edwards et al., 2015). Following surgical excision reported 
recurrence rates are around 15% for women with negative surgical margins and 50% 
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for women with positive surgical margins (Jones, Rowan and Stewart, 2005; Van 
Seters, Van Beurden and de Craen, 2005). 
Ablation of the vulval epithelium with for example, carbon dioxide laser vaporisation 
may reduce the morbidity of the treatment and produced preferable cosmetic results 
but a greater risk of treatment failure has been reported (Wallbillich et al., 2012). In 
addition no tissue is available for histological analysis and multiple pre-procedure 
biopsies are required to exclude invasive disease. 
Currently the extent of the surgical excision, or ablation, is guided by visual 
assessment and traditional tissue biopsies, as there is currently no established near-
real-time non-invasive diagnostic technique for assessing vulval disease. 
Historically numerous topical medical treatments have been used in the 
management of VIN. Agents including 5-flurouracil, bleomycin, trinitrochlorobenzene 
and alpha-interferon have all been used and for the most part disregarded either due 
to inefficacy or unacceptable side effects (Ta et al., 2016). More recently imiquimod, 
an immune response modulator, has been demonstrated to be able to achieve 
complete response at six months after treatment, however the long term safety and 
efficacy has not been established (Kaushik et al., 2015). Cidofovir a potent antiviral 
agent used to treat anal intraepithelial neoplasia has also been evaluated as a 
treatment of VIN. Initial studies have demonstrated comparable efficacy as 
imiquimod with a favourable safety and side effect profile, although long term data is 
awaited (Tristram et al., 2014). 
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Photodynamic therapy (PDT) where light is used is conjunction with a 
photosensitising agent to elicit cell death has been used to treat VIN. The technique 
is well tolerated with good preservation of the vulval anatomy, however produces 
inconsistent results (Martin-Hirsch et al., 1998; Hillemanns et al., 2000; Winters et 
al., 2008). A recent non randomised phase 2 trial evaluating imiquimod combined 
with PDT has indicated promising results with 64% of women displaying histological 
and clinical response to treatment (Winters et al., 2008). 
Vaccination with the bivalent or quadrivalent HPV vaccine has been demonstrated to 
reduce the risk of HPV related uVIN. Interestingly vaccination may also have a role 
in the treatment of uVIN. Initial studies have suggested that a synthetic peptide 
vaccination against oncogenic HPV 16 can clear HPV infection and produce a 
clinical and histological response in women with HPV 16 positive uVIN (Kenter et al., 
2009). 
Amongst all the available treatment modalities there is no clear standard 
management of VIN as treatment choice must be tailored to the sub type of disease 
and the individual needs of the patient. Factors including the location and extent of 
the disease along with the patient’s wishes will guide appropriate management. In 
many women a combination of treatment modalities will be core to ensuring 
remission of disease whilst minimising adverse effects of treatment, however if 
invasive disease is suspected clinically despite a biopsy indicating VIN then surgical 
excision is the standard management. 
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1.3.6 Guidance for the surveillance of VIN  
Current guidance recommends that women with a history of VIN be seen in a 
specialist gynaecology clinic every six months indefinitely (RCOG, 2014). At each 
appointment symptoms are explored and a full vulval examination performed. If any 
suspicious lesions are seen then vulval biopsy may be performed. 
1.4 Malignant disease of the vulva 
Vulval cancer is primarily a disease of elderly women with the mean age at diagnosis 
being approximately 70 years.   The incidence of vulval cancer is rising with an 
annual incidence rate of approximately 4 per 100,000 women within the UK (Office 
for National Statistics, 2013). Population based studies indicate that majority of 
vulval malignancies are squamous cell carcinomas (Platz and Benda, 1995). Other 
tumour types found on the vulva include malignant melanoma and rarely 




Figure 1-4 – Incidence of vulval cancer, Office for National Statistics. Cancer Statistics: Registrations 
Series. (Office for National Statistics, 2013) 
1.4.1 Squamous cell carcinoma 
Squamous cell carcinoma (SCC) is the commonest of all vulval malignancies 
accounting for more than 90% of all vulval malignancies and 4% of all 
gynaecological malignancies and there is evidence the incidence is rising (Judson et 
al., 2006).  The incidence of the disease increases with age and it is most common 
in women over 75 years old. 
Women with vulval SCC typically present with an ulcerated, indurated or exophytic 
mass with pruritis, pain and/ or bleeding.  Broadly vulval SCCs can be separated into 
two main groups, those associated with oncogenic HPV and those not associated 
with HPV infection.  Tumours associated with HPV infection are more commonly 
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seen in younger women and SCC is often found in association with VIN or lichen 
sclerosus.  The disease spreads by direct extension to adjacent structures in the 
vulva, vagina, rectum, deeper tissues or bone.  Lymphatic spread is to the femoral 
and inguinal nodes. 
Multiple morphological subtypes of invasive SCC are described, including non-
keratinising, keratinising, basaloid, warty, spindled and verrucous. The main clinically 
relevant distinction is between verrucous and non-verrucous subtypes. 
Verrucous carcinoma is rare and typically found in women in their ninth decade.  It 
characteristically has low metastatic potential and a good prognosis (Nucci, 2013). 
Histologically verrucous carcinoma is well differentiated and with little atypia and a 
blunt margin of invasion. The pathogenesis of verrucous carcinoma is not well 
understood and does not appear to be associated with oncogenic HPV infection, 
however many cases are associated with lichen sclerosus or lichen simplex 
(Nascimento et al., 2004; Nucci, 2013). 
Basaloid and warty subtypes of SCC are associated with oncogenic HPV infection 
and keratinising tumours have typical keratin pearl formation not present in non-
keratinising tumours. 
1.4.1.1 HPV dependent carcinogenesis in the vulva 
uVIN (HSIL) is a precursor for the majority of basaloid and warty type vulval SCC 
(Hampl and Sarajuuri, 2006; Van der Avoort et al., 2006; Reyes and Cooper, 2014). 
The rising incidence of vulval cancer is primarily due to an increase in vulval cancer 
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in women aged 70 and below, suggestive of an increase in HPV related disease 
(Iversen and Tretli, 1998). 
Malignant transformation of vulval epithelial cells by high-risk HPV subtypes is 
mediated through integration of the HPV DNA within the host genome leading to 
HPV induced expression of the E6 and E7 oncoproteins. These oncoproteins have 
numerous oncogenic effects including interference with control of the cell cycle, 
producing numeric and structural oncogenic chromosomal abnormalities (Vinokurova 
et al., 2005; Zekan, Sirotkovic-Skerlev and Skerlev, 2011). In addition, methylation or 
mutations of the host’s genome can occur that distorts transcriptional control, cell 
differentiation and viral gene expression resulting in altered molecular expression in 
tissues undergoing malignant transformation. 
1.4.1.2 HPV independent carcinogenesis in the vulva 
The typical precursor vulval disorders in cases of HPV independent vulval SCC are 
Lichen Sclerosus (LS) and differentiated VIN. LS and differentiated VIN develop into 
SCC through a HPV independent process which is not fully understood (Ueda et al., 
2011). Similar genetic and epigenetic changes have been noted to occur in areas of 
LS associated with SCC that are not present in LS found in isolation. These include 
mutation of TP53 and hypermethylation of MGMT and RASSF2A, suggesting a 
potential role for these genes in non HPV associated carcinogenesis however the 
exact mechanism is not well understood (Guerrero et al., 2011; Trietsch et al., 2015). 
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Overall the pathogenesis of vulval SCC is not as well described as that for more 
common cancers, however it is clear that in both the HPV dependent and HPV 
independent oncogenesis biomolecular changes occur in the vulval that lead to the 
development of invasive cancer. 
1.4.1.3 Molecular field change in the development of 
cancer 
The concept of field cancerisation was initially proposed by Slaughter et al. 1953 
when studying abnormal tissue surrounding oral squamous cell carcinoma. The 
theory has been developed to explain the development of multiple primary tumours 
and local disease recurrence at sites separate from a primary invasive tumour. It has 
been proposed that vulval tumours also develop within preneoplastic fields of 
cancerisation containing histologically benign but genetically or epigenetically altered 
cells (Dakubo et al., 2007). During the development of a preneoplastic field of 
cancerisation a stem cell acquires a genetic or epigenetic alteration that gives it a 
growth advantage over its neighbouring cells (Leemans, Braakhuis and Brakenhoff, 
2011). Replication of the stem cell results in an expanding patch of altered daughter 
cells. With additional genetic or epigenetic alterations this patch replaces the normal 
epithelium and develops into a field of cancerisation. Within the abnormal 
preneoplastic field the epithelium may appear histologically benign however 
molecular alterations within cells result in an increased risk of malignant 
transformation. The development of this preneoplastic field change can be used to 
explain the multiple primary tumours and distant tumour recurrences that are often 
 
 60 
observed in the vulva (Figure 1-5). The molecular basis for field cancerisation in the 
vulva has previously been explored by examining the distribution of X-chromosome 
inactivation, TP53 mutations and viral integration sites (Rosenthal et al., 2002; Rolfe 
et al., 2003; Vinokurova et al., 2005). The data published demonstrated molecular 
monoclonality of anatomically distant vulval lesions supporting the concept of field 
cancerisation in the vulva. These studies of specific molecular changes in the vulva 
only show us part of the picture as the transformation of normal cells to cancer is a 
complex multistep process involving more that just a few molecular variations. 
The development of fields of cancerisation and their persistence after surgery is 
problematic in the management of vulval SCC. Resection of the primary tumour 
including all histologically normal tissue may not remove all the molecularly abnormal 
cancer field leading to increased risk of local tumour recurrence and recurrence of 
cancer distant to the primary tumour (Figure 1-5).  In the vulva, field cancerisation 
may explain the high incidence of disease recurrence at sites distant to the primary 
tumour sometimes termed second primary tumours (Van Seters, Van Beurden and 
de Craen, 2005). Observational studies have demonstrated that in those who have 
recurrent vulval SCC between 72% and 89% will have disease at a site distant to the 
primary tumour (Rouzier et al., 2002; Woolderink et al., 2006). Molecular changes 
associated with preneoplastic and neoplastic disease of the vulval are not well 
described although some studies have demonstrated clonal molecular changes at 
anatomically distant sites within the vulva supporting this concept of field 




Figure 1-5 – Field cancerization and local relapse: The relationship between field cancerization 
and types of relapse is shown. Field cancerization is defined as the presence of one or more 
mucosal areas consisting of epithelial cells that have cancer-associated genetic or epigenetic 
alterations. A precursor field (shown in light blue) is monoclonal in origin and does not show 
invasive growth or metastatic behaviour, which are the hallmarks of an invasive carcinoma. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer (Leemans, 
Braakhuis and Brakenhoff, 2011), copyright 2011 
 
1.4.2 Vulval malignant melanoma 
Vulval malignant melanoma is the second most common vulva malignancy 
accounting for approximately 9% of vulval malignancies.  Malignant melanoma 
typically presents with the presence of a lump and/ or bleeding.  Pre-existing 
pigmented lesions may develop into malignant melanoma and this change may be 
associated with pruritis, or an alteration in the shape size or colour of the lesion.  
These tumours can undergo early lymphatic or haematogenous dissemination and 
early detection is therefore paramount. 
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1.4.3 Basal cell carcinoma 
Basal cell carcinomas of the vulva are uncommon and account for less than 5% of all 
vulval malignancies (Nucci, 2013). They occur predominantly in postmenopausal 
women with peak incidence in the eighth decade (Nucci, 2013).  BCC may present 
as a deep ulcer with raised rolled margins, a superficial waxy slightly erythematous 
macule or as a polypoidal non-ulcerated lesion.  These tumours primarily spread by 
direct invasion and rarely undergo lymphatic or haematogeneous spread. 
1.4.4 Management of squamous vulval cancer 
The primary treatment modality for vulval cancer is surgical excision of the disease. 
Treatment is individualised and in early stage disease usually consists of excision of 
the tumour with ipsilateral or bilateral inguinofemoral lymphadenectomy in all but 
FIGO stage Ia disease (Table 1-3) (RCOG, 2014). 
Excision of the primary tumour should include the removal of an adequate margin of 
tissue without invasive disease. The rational for this is that the incidence of 
recurrence has been demonstrated to be directly related to the disease free surgical 
margin as assessed in the fixed histopathological specimen, with a decreased risk of 
recurrence with increased disease free margin.(Hacker et al., 1981; Heaps et al., 
1990) Taking into account the contraction of tissue during excision and fixation, 
current guidelines recommend a 15 mm margin of non-invasive tissue is obtained on 
fresh surgical specimens (RCOG, 2014). Surgical excision of lichen sclerosus and 
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VIN in other parts of the vulva is considered during surgery to remove other possible 
foci of invasion and areas that pose an increased risk of recurrence (Regauer, 2011). 
This treatment of vulval carcinoma is associated with significant physical, 
psychological, sexual and psychosexual morbidity both from the excision of the 
primary disease and from the inguinofemoral lymphadenectomy (Andersen et al., 
1988; Andersen, 1993). These adverse effects of the surgery are proportional to the 
extent of the surgery with the largest resections being associated with the highest 
morbidity. 
The decision to undertake inguinofemoral lymphadenectomy is based on the risk of 
lymph node metastasis. In FIGO stage 1a disease (Table 1-3) the risk of lymph node 
metastasis is minimal and lymphadenectomy is not generally recommended (Hacker 
and Van der Velden, 1993; RCOG, 2014). 
Inguinofemoral lymphadenectomy is therefore recommended for those women with 
FIGO stage 1b or above squamous cell carcinoma. Complete inguinofemoral 
lymphadenectomy is indicated in women with unifocal vulval tumours of more than 4 
cm maximum diameter or where multifocal disease is present.  The high rates of 
lymphoedema, infection and wound breakdown associated with complete nodal 
dissection has led to the development of sentinel node biopsy to avoid excision of 
disease free lymph nodes (Hauspy et al., 2007). There is increasing evidence that 
women with a unifocal vulval tumour of less than 4 cm maximum dimension may be 
safely managed with excision of the sentinel lymph nodes before deciding on further 
management (Decesare et al., 1997; Van Der Zee et al., 2008; Levenback et al., 
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2009).  Currently assessment of sentinel node for the presence of micro metastasis 
is by ultrastaging with immunohistochemistry following fixation and sectioning of 
paraffin embedded lymph nodes. Currently the intraoperative assessment of lymph 
nodes is limited to visual inspection and palpation augmented with frozen section 
and cytological analysis although the diagnostic accuracy of these techniques is not 
well established. 
Table 1-3 – International Federation of Gynecology and Obstetrics (FIGO) staging system 
Stage I Tumour confined to the vulva 
Stage Ia Lesions ≤ 2 cm in size, confined to the vulva or perineum and with stromal 
invasion ≤ 1 mm. No nodal metastasis 
Stage Ib Lesions > 2 cm in size or with stromal invasion > 1 mm confined to the vulva or 
perineum. No nodal metastasis 
Stage II Tumour of any size with extension to adjacent perineal structures (lower 
1/3 urethra; lower 1/3 vagina; anus) with negative node 
Stage III Tumour of any size with or without extension to adjacent perineal 




(i) With 1 lymph node metastasis (≥ 5 mm), or  
(ii) 1–2 lymph node metastasis(es) (< 5 mm) 
Stage IIIb 
 
(i) With 2 or more lymph node metastases (≥ 5 mm), or  
(ii) 3 or more lymph node metastases (< 5 mm) 
Stage IIIc With positive nodes with extracapsular spread  
Stage IV Tumour invades other regional (upper 2/3 urethra; 2/3 vagina) or distant 
structures 
Stage IVa Tumour invades any of the following 
(i) Upper urethral and/or vaginal mucosa; bladder mucosa; rectal mucosa 
or fixed to pelvic bone, or 
(ii) Fixed or ulcerated inguinofemoral lymph nodes.  
Stage IVb Any distant metastasis including pelvic lymph nodes 
 
The management of women found to have malignant disease within a sentinel lymph 
node is the subject of the ongoing GROINSS-V II trial (Eerens, 2010). Prior to this 
trial complete inguinofemoral lymphadenectomy was often performed when women 
were found to have metastatic disease within their sentinel lymph node. The 
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GROINSS-V II trial is an observational study assessing if women found to have 
sentinel lymph node metastases less than or equal to 2 mm in diameter could safely 
be spared the morbidity of full lymphadenectomy by treatment with primary 
radiotherapy (with or without chemotherapy). Within the GROINSS-V II trial those 
women with sentinel lymph node metastases greater then 2 mm with have complete 
inguinofemoral lymphadenectomy. 
1.4.5 Management of non-squamous vulval cancers 
Verrucous carcinoma and basal cell carcinoma of the vulva are rarely associated 
with lymph node metastasis and can usually be managed with wide local excision. In 
cases where resection would cause significant functional impairment basal cell 
carcinomas can also be successfully treated with radiotherapy. 
Women with malignant melanoma also do not benefit from inguinofemoral 
lymphadenectomy and wide local excision of areas of disease is preferred. Relapse 
of malignant melanoma is common and there are limited strategies available to 
minimise the risk of relapse in this group.  
1.5 Summary 
The diagnosis and monitoring of vulval disease is undertaken by clinical evaluation 
supplemented by invasive tissue biopsies and histopathological analysis. Currently 
there is no established real time, objective technique for the assessment of vulval 
conditions. Vibrational spectroscopy, the topic of this thesis, offers the opportunity to 
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develop non-invasive probes for real time optical assessment, diagnosis and 
management of vulval conditions. The next sections of the thesis will detail the 
technique and progress to date in its use in the clinic. 
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Chapter 2 Vibrational Spectroscopy 
2.1 Introduction 
Light incident on matter may be absorbed, scattered or reflected by its constituent 
molecules.  The interaction of the light with the molecular constituents of matter is 
defined by the structure of the molecules and wavelength of the incident light.  Using 
the vibrational spectroscopic techniques of Raman spectroscopy and infrared 
spectroscopy we can measure the spectrum of the inelastic scattering or absorption 
of light from a tissue sample allowing us to analyse the molecular composition of the 
tissue. 
2.1.1 Basic science and molecular vibration 
Molecular vibration occurs when the atoms within the molecule are in periodic 
motion.  Higher energy vibrational states can be excited when the molecule absorbs 
a photon or gains energy from an inelastic scattering event.  It is this process of 
vibrational excitation that is exploited by vibrational spectroscopic techniques. The 
interaction between the light and a molecule is determined by both the composition 
of the molecule and the wavelength of the incident light. Photons striking a molecule 
may be absorbed, scattered or may not interact.  Absorption of light by a molecule 
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only occurs at discrete wavelengths of light dependent on the composition and 
structure of the molecule. The wavelengths of light absorbed are dictated by the 
vibrational modes of the molecule. Molecules have a defined number of possible 
vibrational modes dependent on the number of atoms they contain (Equation 2-1) 
and the energy required to change the vibrational mode is different for each 
molecule (provided they are non-linear molecules, whereby they would have 3N-5 
modes).  Molecular vibrations can be excited by both the absorption of photons and 
scattering of photons.  When the energy of the incident photon matches the 
difference between two molecular vibrational energy levels the photon is absorbed 
and the vibrational energy state of the molecule is increased. 
 
Equation 2-1 
By contrast to absorption, scattering of light from a molecule can occur when the 
energy of the incident photon does not match the difference between two molecular 
vibrational energy levels. 
Raleigh ‘elastic’ scattering occurs when the incident light causes the molecule to 
vibrate with the same frequency of the incident light, scattered light is emitted of the 
same wavelength as the incident light.  This elastic scattering is the predominant 
form of scattering. In Raman scattering energy from the incident light is gained or 
lost by a change in molecular vibrational energy.  This ‘inelastic’ process results in 
scattered light of a different energy, and therefore wavelength to the incident light.  
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Inelastic Raman scattering is a small effect and only accounts for 1 in 108-109 of all 
scattered photons. 
 
Figure 2-1 – Three forms of scattering 
(Reprinted from http://www.doitpoms.ac.uk/tlplib/raman/raman_scattering.php, accessed March 2016) 
In infrared spectroscopy a transition from one vibrational state to another only occurs 
in association with absorption of light.  By contrast in Raman scattering there is 
change in the polarisation of the electron cloud associated with change from one 
vibrational energy state to another. 
The vibrational energy change is different for each different molecule hence 
vibrational spectra can provide information about the molecules under analysis. 
The two techniques of infrared spectroscopy and Raman spectroscopy are 
considered complementary as molecules that give strong bands in the IR spectrum 
may give weak bands in the Raman spectrum and visa versa.  The electrical 
characteristics of the molecular vibrations are responsible for this complimentary 
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nature. Vibration of strong polar bonds (e.g. C-O, N-O and O-H bonds) will only have 
a small effect on polarisation and hence a relatively weak Raman effect. These 
strong polar bonds carry their charge during vibrational motion and can produce a 
large change in the dipole moment and strong IR absorption, unless neutralised by 
molecular symmetry. The converse is also true for weakly polarised bonds (e.g. C-C, 
C-H, C=C bonds). In simple symmetrical molecules such as carbon dioxide each 
vibrational mode will result in IR absorption or Raman scattering but not both (Figure 
2-2). In complex asymmetrical molecules all the vibrational modes may be strongly 
absorptive in the IR region and Raman active. 
 
Figure 2-2 – Possible vibrational modes of carbon dioxide demonstrating complementary nature of IR 
and Raman spectroscopy. 
(Reprinted from http://www.chemvista.org/ramanIR4.html, accessed March 2016) 
2.2 Raman spectroscopy 
2.2.1 Raman scattering 
In Raman scattering the scattered photons can have a higher or lower energy than 
the incident light this is known as the ‘Raman shift’. Two types of Raman scattering 
have been described dependent on the vibrational energy state of the target 
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molecule when the scattering occurs.  When light interacts with a molecule in its 
ground or unexcited state and the scattered photon has a lower energy than the 
incident photon this is termed Stokes Raman scattering.  When the target molecule 
is already in a vibrationally excited state and the scattered photon has a higher 
energy than the incident photon this is termed anti-Stokes Raman scattering (Figure 
2-1). 
The change in energy in the scattered light can be detected, determining the 
difference in energy between the vibrational energy states of the molecules, by 
recording the intensity of the collected light against wavenumber shift to give a 
Raman spectrum. The Stokes and anti-Stokes scattered light undergoes an equal 
shift either side of the incident or elastically scattered light. This results in a 
symmetrical Raman spectrum apart from the difference in intensity of the scattered 
light.  The number of molecules at each energy state, from thermal excitement, 
follows the Boltzmann distribution (Equation 2-2) so there are significantly fewer 
molecules in higher energy states. As a result the Stokes half of the spectrum, which 
doesn’t require states to be pre-excited, is typically of greater intensity and this is the 







Equation 2-2 – Boltzmann distribution, where N is the number of molecules at a given energy state E 
and kT is the product of Boltzmann's constant and thermodynamic temperature. 
2.2.2 The Raman spectra 
A Raman spectrum is a plot of the intensity of the scattered the light (y axis) against 
the ‘Raman shift’ (x axis).  By convention the ‘Raman shift’ is measured in 
wavenumber rather than wavelength and this is advantageous as it is directly 
proportional to the energy changed and it aids comparison between spectra 
produced with different wavelength of incident light. For a given material the position 
of the peaks on the Raman spectrum are the same irrespective of the wavelength of 
the incident light. The recorded spectrum may however be affected by variation of 
the incident light due to other interactions between the light and the material being 
examined, for example resonance Raman, fluorescence and absorption of light. In 
resonance Raman the wavelength of the excitation laser is close to that of electron 
transition in the compounds under examination, this can lead to greatly enhanced 
Raman scattering intensity. Conventionally the x axis varies from the positive 
wavenumber shifts produced by anti-Stokes Raman scattering on the left, through 
zero which represents the energy of the incident light, to negative wavenumber shifts 
produced by Stokes Raman scattering on the right. 
Peaks within the Raman spectrum correspond to changes in vibrational energy of 
specific molecular bonds.  Certain wavenumber shift spectral peaks can therefore be 
assigned to specific molecular bonds (Table 2-1).  Furthermore the intensity of the 
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peak is proportional to the concentration of the molecular bond within the target 
material and within simple materials it is possible to produce a precise quantitative 
molecular fingerprint of the target.  In molecularly complex material the wavenumber 
peaks may coalesce to form bands on the spectra and this can make the 
identification of individual peaks difficult.  In this situation the overall shape of the 
spectra can be analysed as a molecular fingerprint of the target material. 
Table 2-1 – Selection of Raman band assignments 
(Reprinted from Applied Spectroscopy Reviews (Dieter Naumann, 2001), copyright 2001) 
 
The Raman spectroscopic analysis of known substances has allowed known 
biorelevant molecules to be mapped to Raman spectral peaks.  This information can 
then be used to assess the molecular content of a sample under study or predict 
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expected changes in Raman spectra in different tissues (Stone et al., 2007; Isabelle, 
2009). 
2.2.3 The Raman spectrometer 
A basic Raman spectrometer requires a light source, collection optics, a filter to 
reject the excitation light and a spectrograph. Commonly the instrument will consist 
of a laser light source focused through a modified conventional microscope with a 
computerised stage.  The scattered light is then collected through the microscope 
optics and directed through a notch filter onto a diffraction grating that splits the light 
onto a charge-coupled detector (Figure 2-3). 
 
Figure 2-3 – Schematic representation of Raman microscope (Renishaw RM1000) 
(Reprinted with permission from Scientific Examination of Art (Clark, 2005), copyright 2005) 
2.2.4 Variants of Raman spectroscopy 
In addition to standard dispersive Raman spectroscopy such as that described in 
2.2.3 there are a number of variants that have been developed to overcome some of 
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the limitations of the standard technique.  These include spatially offset Raman 
spectroscopy (SORS), coherent anti Stokes Raman spectroscopy (CARS), Hyper 
Raman, stimulated Raman spectroscopy (SRS), surface enhanced Raman 
spectroscopy (SERS) and Tip enhanced Raman spectroscopy (Begley, Harvey and 
Byer, 1974; Snow, Qian and Chang, 1985; Ziegler, 1990; Matousek et al., 2005; 
Moskovits, 2005; Deckert, 2009). It is beyond the scope of this thesis to provide 
detail on these variants of the standard technique. 
2.2.5 Raman spectroscopy of biological materials 
With the development of improved laser technology Raman spectroscopy underwent 
a revival in the late 1960 and early 1970s. During this time there was increasing 
interest in the application of the technique to biological materials. Lord, Yu and 
Hartmann were pioneers in this area and their early work in the early 1970s 
measuring Raman spectra from native biological proteins and viral RNA laid the 
foundation for the modern application of Raman spectroscopy for the analysis of 
complex tissues (Lord and Yu, 1970; Hartman, Clayton and Thomas, 1973). Thanks 
to these early pioneers and those that followed the analysis of biological samples 
using Raman spectroscopy is now well established. Biological materials present 
numerous challenges to Raman spectroscopy. These include the relatively weak 
nature of the signal and the requirement for a highly sensitive detector making 
Raman spectrometers susceptible to interference from ambient light (Kendall et al., 
2009). In addition, visible wavelength light sources can elicit strong fluorescence in 
biological materials that may mask the much weaker Raman signal. Near infrared 
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wavelengths generally do not induce significant fluorescence, hence they are often 
used on biological applications. 
As the vibrational modes of water, one of the primary constituents of tissue, produce 
only weak Raman signal the technique can be used to analyse tissue samples both 
in vivo and ex vivo without tissue preparation. This makes the development of 
Raman spectroscopic probes for in vivo diagnosis an attractive concept.   
2.3 Fourier transform infrared spectroscopy 
2.3.1 Infrared absorption spectra 
The energy required to change the vibrational energy state of most molecular bonds 
within tissue corresponds to that of the mid-IR region of the electromagnetic 
spectrum (Haris and Chapman, 1992). Consequently infrared radiation is readily 
absorbed and the pattern of absorption can be used to produce an absorption 
spectrum on which the attenuation of infrared light can be demonstrated across a 
range of wavelengths. Similarly to the Raman spectrum this absorption spectrum can 
be used to analyse the molecular composition of tissue samples under study. In 
tissues many molecules will share the same molecular bond types so in complex 
materials infrared spectroscopy cannot be used to identify specific molecules but can 
be used to identify larger groups of molecules present (e.g. proteins and nucleic 
acids) creating a biomolecular finger print for the sample under analysis (Mackanos 
and Contag, 2010). 
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2.3.2 Fourier transform absorption spectra 
In dispersive infrared spectroscopy the absorption spectra can only be measured for 
a narrow range of wavelengths at a time.  This makes dispersive infrared 
spectroscopy a more time consuming technique and less practical for measuring 
clinically relevant biomaterials (Lasch and Kneipp, 2008).  The use of array detectors 
including focal plane arrays and linear arrays to simultaneously detect multiple 
wavelengths increases the speed of spectral acquisition however Fourier transform 
infrared spectroscopy remains a quicker technique (Kazarian and Chan, 2013). In 
Fourier transform infrared spectroscopy, the wavelength of the light incident on a 
sample is varied within a set range though the use of an interferometer (Figure 2-4).  
This allows us to use Fourier transform infrared spectroscopy to measure the 
absorption of a wide range of wavelengths quickly.  Using a discrete Fourier 
transform it is possible to then convert the raw data measured into a spectrum 
representing light transmitted at each wavelength. The transmission decreases 
exponentially with increasing absorbance by the sample under analysis according to 
the Beer-Lambert law (Equation 2-3). The absorbance can then be calculated from 
the measured transmittance using a logarithmic transformation.  
Equation 2-3 – Beer-Lambert law, T is transmittance (relative amount of light passing through 
sample), ε is molar absorptivity, b is path length, c is molar concentration and A is absorbance. 




Figure 2-4 – Schematic of interferometer. (Reproduced from Biochimica et Biophysica Acta (Barth, 
2007)) 
2.3.3 FTIR instrumentation 
FTIR spectrometers require a polychromatic infrared radiation source, interferometer 
and detector. Light emitted from the infrared source is split by a beam splitter and 
approximately half directed towards a fixed mirror and the other half passes through 
to a moving mirror (Figure 2-4). The light incident on the fixed mirror is reflected back 
toward the beam splitter where approximately half passes through towards the 
detector. The light incident on the moving mirror is reflected back towards the beam 
splitter where approximately half is reflected towards the detector. The two beams 
passing from the beam splitter towards the detector combine and interfere. This 
interference is constructive or destructive depending on the optical path difference. 
The intensity of the light is measured at the detector relative to the position of the 
moving mirror and this creates the interferogram. The interferogram is the Fourier 
transform of the spectrum. By placing a sample of tissue between the interferometer 
and the detector we are then able to quickly measure an infrared absorbance 
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spectrum by converting the interferogram measured at the detector into a spectrum 
using a Fourier transform.  
In contrast to dispersive infrared spectroscopy FTIR does not split the incident light 
into its spectral components but uses the interferometer to create light at different 
wavelengths whilst maintaining the intensity of the light passing through to the 
detector. This results in higher light intensity at the detector, faster data collection 
and higher signal to noise ratio (Barth, 2007). The majority of modern infrared 
spectroscopy is performed using the Fourier transform technique (Kendall et al., 
2009). 
2.3.4 Modes of FTIR 
There are three major modes of FTIR: transmission, transflection and attenuated 
total reflection (ATR). In transmission mode the sample is placed on a substrate that 
has low absorption of infrared radiation. The infrared radiation passing through the 
samples is then measured from the opposite side to the incident beam and the 
absorption inferred. In transflection mode the sample is placed on an infrared 
reflective slide and the transmission measurements are taken after the bean passes 
through the sample to the reflective slide and is reflected back though the sample. In 
ATR mode the beam is passed through an internal reflection element (IRE) with high 
refractive index. An evanescent wave is produced that extends beyond the IRE 
penetrating the sample that must be in contact with the element. The wave 
penetrates to a depth of 1-3 microns in biological substances for the 900 to 1,800 
cm-1 spectral region (Baker et al., 2014). This together with the high absorption of IR 
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radiation by water significantly limits the utility of the technique for in vivo 
diagnostics. 
A comparison of the key differences between infrared spectroscopy and Raman 
spectroscopy is shown in Table 2-2. 
Technical Considerations 
Property Raman FTIR 
Commonly used 
wavenumber range (cm-1) 400-4000 800-4000 
Light source Monochromatic laser Polychromatic 
Detected light Inelastic scattered Mid infrared transmission 
Molecular bond 
sensitivities Non-polar bonds Strong polar bonds 
Signal to noise ratio over 
same timescale Lower Higher 
Spatial resolution <1 µm ≈1 µm with newer devices 
   
Samples Considerations 
Restriction Raman FTIR 
Sample contact Required for in vivo probes 
Not required in 
transmission 
Sample thickness Measurements possible Thick samples can cause spectral saturation 
Water content Weak scattering signal Strong absorption 
Paraffin content Strong scattering signal in fingerprint region 
Narrow spectral bands in 
finger print region 





Chapter 3 Application of Vibrational 
Spectroscopy to Medical Diagnostics and the 
Clinical Need for Advanced Vulval Diagnostics 
3.1 Vibrational spectroscopy of biological samples 
The potential role of vibrational spectroscopy to accurately determine different 
histopathological groups has been well established at a number of different human 
anatomic sites. In the oesophagus Raman spectroscopy and FTIR have both been 
applied ex vivo and the ability of the technique to differentiate between normal, 
metaplastic, dysplastic and cancerous changes has been demonstrated (Shetty et 
al., 2006; Almond, 2012; Almond et al., 2014). Furthermore the ability of Raman 
spectroscopy to accurately distinguish different oesophageal tissue types in vivo has 
also been demonstrated (Bergholt et al., 2011).  Similarly studies on cellular changes 
in the stomach have demonstrated the ability of vibrational spectroscopic techniques 
to differentiate normal, metaplastic, dysplastic and cancerous changes both ex vivo 
and in vivo (Bergholt et al., 2011, 2013; Li et al., 2013; Huang et al., 2014; Ito et al., 
2014). Raman spectroscopy has also been shown to be able to detect ductal 
carcinoma from normal breast tissue. Highlighting potential for the technique to be 
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used to assess the margins of surgical resection specimens from breast conserving 
surgical treatment of breast cancer (Kast et al., 2008; Kong et al., 2014).  The 
potential for Raman spectroscopy to be used to assess tumour margins in surgical 
neuro-oncological treatments is currently the object of extensive investigation and 
studies to date have shown the technique has potential in this area (Toms et al., 
2006; Gajjar et al., 2012; Ji et al., 2013; Bahreini, 2015). Vibrational spectroscopic 
techniques have also been applied in the head and neck and studies have 
established the ability of the techniques to identify oral, oropharyngeal, laryngeal and 
para thyroid tumours (Stone et al., 2000; Das et al., 2006; Harris et al., 2010; Singh 
et al., 2012; Menzies et al., 2014). 
To date there has been very limited research published that has evaluated the role of 
vibrational spectroscopic techniques in the detection and assessment of vulval or 
vaginal diseases. In the search performed for this literature review no published 
papers in this area of study were identified. Due to the lack of previous study in this 
area it is necessary to assess the current evidence from other dermatological 
application of the techniques.  
The epithelium of the vulva shares many characteristics with other skin on the 
human body, and hence vibrational spectroscopic research in this area is directly 
relevant to the vulva. It should be noted the spectrum of disease in the vulva is quite 
different from other skin sites with increased risk of SCC and decreased risk of BCC 
and melanoma (Gartner, 2017). The relevant research to date exploring the role of 
vibrational spectroscopy in the assessment of skin disease is reviewed below. 
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3.2 Vibrational spectroscopy for the characterisation of  
dermatological disease 
3.2.1 Clinical diagnosis of dermatological disease and the role 
of advanced diagnostics 
Traditionally the diagnosis of skin conditions has been by naked eye visual 
examination, magnified dermatoscopic examination and invasive biopsy where there 
is suspicion of malignancy or in cases of diagnostic uncertainty. Crucially this 
approach is dependent on the skill and experience of the clinician making the 
assessment. Variation in diagnostic accuracy amongst dermatologists has been 
demonstrated in numerous studies (MacKenzie-Wood, Milton and de Launey, 1998; 
Morton and Mackie, 1998; Lui et al., 2012). Reported sensitivity for the diagnosis of 
melanoma by trained dermatologists varies from 49% to 81% with around a third of 
melanomas being inappropriately diagnosed as benign lesions (Lui et al., 2012). 
Heal et al. found the sensitivity of clinical diagnosis of skin cancers was 63.9% for 
BCCs, 41.1% for SCCs and 33.8% for malignant melanomas (Heal et al., 2008). Due 
to the inaccuracy of visual assessment the current gold standard for diagnosis of 
dermatological conditions is biopsy and histological examination.  This process is 
invasive, remains subjective and slow as sample preparation and histology takes 
significant time.  In addition a large number of benign lesions are needed to be 
excised to detect a few malignant ones. This issue was highlighted by a 
retrospective study of 4,761 excised pigmented lesions from patients attending 468 
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general practitioners. The study revealed that new practitioners excised 58 benign 
lesions per malignant lesion compared to 21 lesions excised by experienced 
practitioners per malignant lesion. The need for a near real time non-invasive 
technique for the diagnosis of skin conditions has driven research into the role of 
vibrational spectroscopy as a solution. 
3.2.2 Vibrational spectroscopy for the assessment of 
dermatological conditions 
Skin is a highly accessible area of the body and as such there is considerable 
interest in the use of vibrational spectroscopy as a near real time, non invasive, 
objective technique for the diagnosis of dermatological conditions (Gniadecka, Wulf 
and Mortensen, 1997; Nijssen et al., 2002; Gniadecka et al., 2004; Choi et al., 2005). 
The structure of skin has been examined using both Raman and FTIR spectroscopy 
and current areas of research include: assessing drug absorption, solar radiation 
induced skin damage and the diagnosis of benign, premalignant and malignant skin 
diseases (Caspers et al., 2001; Cartaxo et al., 2010; Calin et al., 2013; Cinotti et al., 
2013; S M Ali et al., 2013). 
3.2.3 Raman spectroscopy for the assessment of 
dermatological disease 
Raman spectroscopy has some significant advantages over FTIR spectroscopy for 
the assessment of skin diseases.  Raman spectroscopy produces spectra with a 
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high level of spatial detail that can provide a clearer demarcation between tissue 
layers (S. M. Ali et al., 2013). As Raman spectroscopy only relies on the scattering of 
light, the excitation light and scattered light can be collected from the same tissue 
surface, allowing the technique to be applied in vivo (Barth, 2007). In addition, 
compared to FTIR spectroscopy Raman spectroscopy is relatively insensitive to the 
water present in skin. 
Early studies by Gniadecka et al. that assessed a small number of biopsies from 
subjects with benign and malignant skin conditions highlighted Raman spectroscopy 
is able to detect differences in protein and lipid content of different skin conditions. 
These differences were seen in the spectral regions 1065-1094 cm-1 and 1243-1258 
cm-1 (Gniadecka et al., 1997; Gniadecka, Wulf and Mortensen, 1997).  Knudsen et 
al. investigated the variation in Raman spectra taken from 13 different subjects at 
different bodily sites and at different times of the day (Knudsen et al., 2002). The 
group found the relative intensities of amide bands I and III varied only slightly 
between individuals and on different days. The small spectral changes seen were 
thought to be due to changes in collagen structure and hydration status. The study 
concluded Raman spectra obtained from normal human skin are reproducible with 
limited variation.  Caspers et al. demonstrated confocal Raman spectroscopy could 
be used to analyse the molecular composition and hydration status of different layers 
of the skin both in vitro and in vivo (Caspers et al., 1998, 2001; Caspers, 2003; 
Caspers, Lucassen and Puppels, 2003). Raman spectroscopy has also been 
investigated as a potential tool for assessing the risk of developing skin cancer.  
Hata et al. validated the use of Raman spectroscopy for assessing carotenoid 
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concentrations and suggested those individuals with low skin carotenoid 
concentrations may be at increased risk of skin cancer (Hata et al., 2000). The 
conclusions of the study were not confirmed by longitudinal data to assess causation 
and remain speculative.  
These early studies were restricted to a small number of subjects; focused on 
analysing specific molecular changes and did not look to classify pathology based on 
spectral characteristics. The molecular changes observed indicated the technique 
had promise for the non-invasive diagnosis of skin conditions. Subsequent studies 
have applied statistical analytical techniques to automate the classification of 
disease from measured spectra.  
One of the most investigated uses of Raman spectroscopy for disease classification 
is the discrimination of basal cell carcinomas and melanomas from normal skin 
(Gniadecka, Wulf and Mortensen, 1997; Nijssen et al., 2002, 2014; Gniadecka et al., 
2004; C. a Lieber et al., 2008; Cartaxo et al., 2010; Ly et al., 2010; Oliveira et al., 
2010; Bodanese et al., 2012; Silveira Jr et al., 2012; Philipsen et al., 2013). In 
contrast to cancers of the vulva, basal cell carcinomas constitute over 80% of all 
non-vulval skin cancers, with squamous cell carcinomas and malignant melanomas 
only constituting 15% and 5% respectively.  As a result of this the majority of 
research undertaken exploring the role of Raman spectroscopy in the assessment of 
skin cancer has focussed on BCCs rather than SCCs, which are more common in 
the vulva (Gniadecka, Wulf and Mortensen, 1997; Nijssen et al., 2002, 2014; Choi et 
al., 2005; C. a Lieber et al., 2008; Ly et al., 2010; Silveira Jr et al., 2012; Philipsen et 
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al., 2013). Spectral markers associated with cancer have been identified using 
Raman spectroscopy and the diagnostic ability of the technique has been 
demonstrated, with sensitivities and specificities of greater than 90% and 80% 
respectively reported by many groups (Table 3-1) (Gniadecka, Wulf and Mortensen, 
1997; Sigurdsson et al., 2004; C. a Lieber et al., 2008; Calin et al., 2013). 
Sigurdsson et al. demonstrated Fourier transform Raman analysis of the skin surface 
in vitro combined with artificial neural networks could be used to discriminate BCC 
and melanoma from actinic keratosis, normal skin and benign pigmented naevi with 
a >94% sensitivity and >98% specificity (Sigurdsson et al., 2004). Nijssen et al. 
utilised confocal Raman spectroscopy on 15 sections of basal cell carcinoma and 
were able to identify BCC from normal perilesional tissue with a sensitivity of 100% 
and specificity of 93% after leave one spectrum out cross validation (Nijssen et al., 
2002).  It should be noted that in this study 18 BCC, 31 dermis and 10 epidermis 
spectra from 15 samples were included in the cross validated classification model 
increasing the probability of the result being due to a type one error (Nijssen et al., 
2002).  Lieber et al. also evaluated the ability of Raman spectroscopy to discriminate 
cancerous lesions (9 BCCs and 4 SCCs) from adjacent normal tissue and reported a 
sensitivity of 100% and specificity of 91% (C. a Lieber et al., 2008). 
These early diagnostic studies are significantly limited by their small sample sizes 
and the resultant difficulty in producing reliable estimates of diagnostic accuracy.  
More recently, larger studies have focused on producing more reliable measures of 
diagnostic accuracy and the transition to in vivo application. Silveira et al. analysed 
47 samples skin biopsies using a portable dispersive Raman system comprising 15 
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normal skin samples, 29 BCCs, and 4 melanomas (Silveira Jr et al., 2012). They 
used a classification model applied to the relative contributions of collagen III, 
elastin, and melanin using Euclidean distance as a discriminator. This technique 
could differentiate normal from BCC and melanoma with a sensitivity of 98.2% and 
specificity of 96.6%. 
The largest study published to date comes from Lui et al. and warrants detailed 
analysis (Lui et al., 2012). The authors collected Raman spectra from 848 patients 
using a hand held optical fibre probe, coupled to a 785 nm excitation laser, 
spectrometer and charge coupled device. The effective spectral range was 500 to 
1800 cm-1, integration time 1 second and spectra were processed in real time.  The 
spectral measurements were compared to a gold standard of either: expert clinical 
diagnosis by an experienced dermatologist (44%) or histopathological analysis 
(56%), in cases where biopsy was taken after Raman analysis. Only melanomas, 
SCCs, BCCs, actinic keratoses and lesions that visually mimic these conditions were 
included in the analysis. In total 518 lesions from 453 subjects were included in the 
analysis. This included 44 melanomas, 47 SCCs, 109 BCCs and 32 actinic 
keratoses. The reproducibility of the Raman measurements was assessed with 
repeated measurements of 30 different sites. Minimal variance was found between 
repeated measurements below 1055 cm-1, with the higher wavenumber range being 
subject to more significant fluctuation in signal intensity. The spectra were analysed 
by full spectra and also by low variance (500 cm-1 – 1055 cm-1) and high variance 
(1055 cm-1 – 1800 cm-1) regions. Multivariate analysis for classification was by 
principal component analysis with generalised discriminant analysis (PC-GDA) and 
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concurrent partial least squares. Both analyses were validated with a leave one 
sample out cross validation. The study reported the diagnostic accuracy of Raman 
spectroscopy and multivariate analysis by three dichotomous groupings. The first 
grouping discriminated skin cancer and actinic keratosis from benign lesions with a 
sensitivity of 99%, specificity of 17% and corresponding area under the receiver 
operator curve of 0.879 (p<0.0001). The second grouping discriminated melanoma 
from benign pigmented lesions with a sensitivity of 99%, specificity of 15% and 
corresponding area under the receiver operator curve of 0.823 (p<0.0001). The third 
grouping discriminated melanoma from seborrheic keratoses with a sensitivity of 
99%, specificity of 25% and corresponding area under the receiver operator curve of 
0.898 (p<0.0001). In this study it appears the sensitivity of the classification model 
was optimised at the expense of specificity. This results in high negative predictive 
values of up to 0.99 with modest positive predictive values 0.49. The authors 
concluded that if implemented in the clinical environment Raman spectroscopy could 
reduce the need for invasive biopsy by around 50% whilst maintaining sensitivity for 
detection of malignant disease. These results are encouraging and highlight a real 
role for Raman spectroscopy in the assessment of dermatological conditions. The 
primary strengths of this study are the large numbers of samples included in the 
analysis and the application of a technology that could be used in a clinically relevant 
way, with short integration times and a handheld probe. There are some features of 
the study that should be noted when interpreting the results. The number of patients 
included in the study was reduced from the initial 848 patients recruited to 453 based 
on the benign lesion’s visual similarity to premalignant or malignant disease. It is not 
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clear in the study how the included benign lesions were selected, however it appears 
selection was based on expert dermatological assessment. Excluded lesions not 
characterised in the study may appear to the inexpert clinician as visually similar to 
malignant lesions. This may limit the applicability of the results to expert 
dermatological practice, whereas the greatest reduction in the number of biopsies 
performed is likely to result from application to generalist clinical practice. In addition, 
the final data set consisted of 518 validated lesions from 453 subjects, therefore an 
unknown number of subjects in the analysis had multiple lesions assessed. This was 
not accounted for in the leave one lesion out analysis and may increase the 
likelihood of a type one error: if multiple benign or malignant lesions were included 
from individual subjects. Although the authors discuss the reproducibility of the 
spectral measurements for individual lesions the reproducibility between different 
spectrometer systems is not discussed. The ability to reproduce spectral 
measurements on different systems is crucial for the application of a Raman based 
diagnosis across a number of sites (Isabelle et al., 2015). 
This study combined with other work from the same research group has resulted in 
the production of the Verisante Aura, a commercial Raman spectroscopic medical 
device for the diagnosis of skin conditions in vivo (J Zhao et al., 2008; Jianhua Zhao 
et al., 2008; Zhao et al., 2010; Wang et al., 2012). This device has not been 
evaluated for the diagnosis of vulval skin conditions and the manufacturer advises 
against its use for vulval diagnostics. The reason for this is not stated, but as vulval 
skin has a significantly different spectrum of disease compared with other skin sites 
 
 91 
and as this device is not validated on vulval skin samples, the current classification 
models are unlikely to be transferable to the vulva. 
The studies discussed and those summarised in Table 3-1 evaluate the ability of 
Raman spectroscopy to replicate the existing diagnostic tests. As pathological 
molecular changes precede histological changes and the symptoms of disease 
Raman spectroscopy may also prove a useful tool for the early diagnosis of disease, 
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Analysis of spectra from 55 healthy persons with different 
skin pigmentation, 25 BCCs, 41 pigmented nevi and 15 
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Benign and malignant skin lesions (n=518) from 453 
patients were measured, including melanomas, basal cell 
carcinomas, squamous cell carcinomas, actinic keratoses, 
atypical nevi, melanocytic nevi, blue nevi, and seborrheic 
keratoses. Lesion classification was made using a principal 
component with general discriminant analysis and partial 
least-squares. Comparisons included skin cancers and 
precancers from benign skin lesions, receiver operating 
characteristic (ROC)=0.879; melanomas from 
nonmelanoma pigmented lesions (ROC=0.823); and 
melanomas from seborrheic keratoses (ROC=0.898). For 
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22 samples of melanoma, 41 of pigmented nevi, 48 of BCC, 
23 of seborrheic keratosis and 89 of normal skin were 
analysed.  Neural network analysis of Raman spectra 
achieved a diagnostic sensitivity of 85% and specificity of 
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Analysis of 10 normal skin samples, ten melanoma samples 
and 9 lymph node metastasis allow correctly classification 
of the samples in 93.1% based on Phenylalanine, DNA, and 
Amide-I spectral features. 
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3.2.4 Fourier transform infrared spectroscopy for the 
assessment of dermatological disease 
Unlike Raman spectroscopy the role of FTIR for the diagnosis of skin disease has 
been less well studied. It is likely that this is due to the challenges posed by strong 
absorption of mid-infrared radiation by water. This makes the technique difficult to 
apply in vivo, as penetration of infrared radiation using ATR FTIR is limited to 2-3 
microns and transmission analysis would be limited to samples 20 microns thick and 
be impractical (Eikje, Aizawa and Ozaki, 2005).  FTIR is well suited to the non-
destructive analysis of dehydrated fixed cytological or histological tissue samples as 
it offers rapid analysis with high signal to noise ratio. The IR spectral characteristics 
of different components of human skin have been well described and an increasing 
number of studies have demonstrated the IR spectra contain sufficient information to 
offer valid and useful diagnostic information about a number of different types of skin 
tumour (McIntosh et al., 1999; Skrebova, Aizawa and Aras, 2003; Eikje, Aizawa and 
Ozaki, 2005). FTIR spectra of benign (melanocytic naevi), premalignant (Bowen’s 
disease, solar keratosis) and malignant (SCC, BCC and melanoma) disease indicate 
the most significant differences in the IR spectrum occur in the 800-1800 cm-1 
region, when compared to normal skin tissue spectra (Skrebova, Aizawa and Aras, 
2003).  Spectra differences are thought to be due to variations in proteins, chromatin, 
and DNA peaks with spectral features due to DNA and Amide III at 965-970 cm-1, 
1071 cm-1, 1084 cm-1, 1095 cm-1, 1220 cm-1and 1245 cm-1 being modified and 
enhanced as tissues progress towards malignancy (Wong et al., 1993; Skrebova, 
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Aizawa and Aras, 2003). In vivo investigations have been undertaken using ATR 
mode FTIR, however due to the limited penetration depth of the evanescent field, 
analysis is limited to the stratum corneum. Barry et al. and Brancaleon et al. 
investigated hydration and lipid concentration in the stratum corneum and identified 
differences in these parameters according to anatomical site (Barry, Edwards and 
Williams, 1992; Brancaleon et al., 2001). Sukuta et al. investigated use of a modified 
form of ATR FTIR, Fourier transform infrared fibre optic evanescent wave (FTIR-
FEW) spectroscopy and chemical factor analysis for the classification of melanoma 
and BCC from normal tissue. The study included 6 samples in each pathology group 
and demonstrated good agreement between pathological analysis and spectroscopic 
analysis for the differentiation of melanoma from normal tissue, highlighting the 
potential of FTIR as a diagnostic tool. Ex vivo studies using sections of routinely 
prepared paraffin embedded tissue have been performed to identify bimolecular 
markers of malignancy. Mordechai et al. analysed tissue from seven patients with 
melanoma and ten with cervical cancer using FTIR micro spectroscopy. Comparing 
spectra from malignant tissue with control tissue spectra from the same patients the 
study identified the RNA / DNA ratio as a possible common marker of malignant 
disease, thought to be due to a higher transcription rate during carcinogenesis 
(Mordechai et al., 2004). Tfayli et al. undertook a feasibility study on 6 sections of 
paraffin embedded fixed skin from melanoma and benign epidermal naevi. The study 
again demonstrated the ability of FTIR micro spectroscopy and multivariate analysis 
for differentiating benign and malignant lesions (Tfayli et al., 2005). This work was 
expanded in a study by Hammody et al. which analysed 55 sections of paraffin 
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embedded fixed skin containing melanoma using FTIR micro spectroscopy 
(Hammody et al., 2008). In this study the authors identified eight sites of spectral 
variation between melanoma and adjacent unaffected tissue that were then used as 
spectral biomarkers. These corresponded to amide I and II, RNA/ DNA ratio; 
phosphate level; cytosine + guanine/ total absorbance intensities of all nucleic acid 
bases ratio; thyamine/ amide II ratio; tyrosine/ amide II ratio; DNA level and thiamine 
level. Using these biomarkers they were able to successfully differentiate malignant 
melanoma from normal skin with sensitivity of 86% and specificity of 82.5%. The 
authors proposed that these biomarkers could be used to determine the boundary of 
melanoma and normal tissue on the surface of the skin. If successful this technique 
could be used to determine resection margins at the time of surgery. 
The studies discussed highlight the potential of FTIR for the ex vivo and in vivo 
characterisation and diagnosis of dermatological conditions. The studies are 
however limited by the small numbers of samples / patients included. To date there 
are no published studies examining the role of FTIR in the diagnosis of SCC on the 
vulval or other anatomical locations. 
3.2.5 Alternative optical technologies for dermatological 
diagnosis 
As previously discussed, the clinical diagnosis of dermatological disease is 
unreliable, necessitating frequent recourse to invasive tissue biopsy and histological 
analysis (chapter 3.2.1).  Due to their accessibility skin disorders are amongst the 
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most investigated using optical diagnostic techniques. A range of optical techniques 
have been explored for the study of skin structures and diagnosis of skin disease. 
These include optical coherence tomography, fluorescence spectroscopy, diffuse 
reflectance spectroscopy, confocal microscopy and laser scanning microscopy. 
3.2.5.1 Optical coherence tomography 
Optical coherence tomography (OCT) has been investigated as a tool for the non-
invasive diagnosis of skin lesions. OCT uses back scattered light to produce a cross 
sectional image of the skin up to 2 mm in depth. In the transition towards invasive 
cancer the epidermis thickens and the basement membrane becomes interrupted 
and discontinuous. It has been speculated that the appearance of the epithelium 
combined with a measurement of the epidermal thickness and the attenuation 
coefficient can be used to differentiate between healthy and premalignant vulval 
tissue. Wessels et al. performed in vivo OCT imaging in 16 patients with 
subsequently histologically confirmed VIN (Wessels et al., 2012). The VIN OCT 
images were compared with that of adjacent normal skin. The authors report a 
sensitivity and specificity of 100% using the tomographically measured epidermal 
thickness and a sensitivity of 88% and specificity 94% using the attenuation 
coefficient, for differentiating VIN from normal skin. This study only compares VIN to 
normal skin and does not evaluate the efficacy of the technique for differentiating 
VIN from other causes of thickened skin or skin that may have an altered attenuated 
coefficient. The results are of interest but the comparison between VIN and normal 
skin is not one that is clinically useful.  
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Other studies have assessed the role of visual examination of the images produced 
by OCT to diagnose skin cancers. Olmedo et al. evaluated 27 patients with BCC and 
matched the images with the histopathology. They described the typical appearance 
of BCC OCT images and were able to correctly match 20 of the 27 images with the 
correct histopathology using the typical OCT features identified (Olmedo et al., 
2006). This study was not a blinded diagnostic test accuracy study and did not 
demonstrate the actual predictive value of OCT in diagnosing malignant disease. 
Further studies have shown the accuracy of OCT as a diagnostic tool varies with the 
experience of the person interpreting the images. Mogensen et al. compared OCT 
images of 104 skin cancers and 105 controls with histological diagnosis and found 
that the sensitivity and specificity achieved varies according to the experience of the 
observer (Mogensen et al., 2009). Sensitivity varied from 57% to 94% and specificity 
from 43% to 96%, with the higher sensitivities and specificities being achieved by the 
most experience observers. This observation has led to research into machine 
learning analysis of OCT images. In a proof of concept study Bazant-Hegemark and 
Stone demonstrated an OCT prediction algorithm using principal component analysis 
combined with linear discriminant analysis could be used to differentiate different 
porcine tissue types with high classification accuracy (Bazant-Hegemark and Stone, 
2008). Jogensen et al. implemented a machine learning approach for the 
differentiation of BCC from actinic keratosis. In this study blinded observers analysed 
the OCT images for the presence of set features including: layer thickness; position 
and extension of dense back scattering section; maximum depth of a local white 
spike; maximum depth of backscatter/ reflection; maximum depth of fading signal; 
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graininess; variation in penetration depth; appearance of dark circular lobules; 
number, depth and size of lobules; turbidity/ homogeneity; dark elongated vessel 
structures; reflectivity of vessel structures; intact epidermis, and separate top-layer. 
The set features from 78 lesions (41 BCC and 37 actinic keratosis) were fed into the 
machine-learning algorithm. With this approach the algorithm was able to correctly 
identify 81% of the actinic keratoses and 73% of BCCs (Jorgensen et al., 2008). 
In summary, several studies have demonstrated the ability of OCT to differentiate 
between benign, premalignant and cancerous skin lesions, using analysis of OCT 
images and determination of the optical attenuation coefficient. The technique is 
however largely limited by the need for subjective assessment of OCT images and 
the fact that classification is based on structural rather than biochemical analysis of 
tissues. Future work may enable the automation of image analysis to reduce the 
interoperator variability, leading to a more objective technique. In addition, OCT 
combined with other modalities such as Raman spectroscopy or fluorescence 
spectroscopy may enable structural information to be combined with biochemical 
information for multimodal diagnosis.(Robles et al., 2011; Egodage et al., 2015) 
3.2.5.2 Fluorescence spectroscopy 
Fluorescence spectroscopic techniques encompass light induced auto fluorescence 
and the use of exogenous agents to augment the light induced fluorescence. Auto 
fluorescent imaging is an appealing tool for optical diagnosis, as the technique 
allows differentiation of pathology on the basis of biomolecular composition of the 
tissue and does not require contrast agents (Bigio and Mourant, 1997; Kollias, 
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Zonios and Stamatas, 2002; Drakaki et al., 2009; Borisova et al., 2010). Different 
skin components fluoresce with different excitation wavelengths. Deep UV (260 to 
300 nm) excites fluorescence from amino acids such as tyrosine, tryptophan and 
phenylalanine. 320 to 400 nm light excites fluorescence from structural proteins 
including collagen and elastin as well as nicotinamide adenine dinucleotide and 
flavins (Drakaki et al., 2013). Cutaneous melanin fluoresces with excitation in the 
near infrared region (Han et al., 2010). Researchers such as Panjehpour et al. have 
demonstrated laser induced (410 nm) fluorescence emission is reduced in SCC and 
BCC of the skin. This change in fluorescence profile can be used to classify SCC 
and BCC with an accuracy of 93%, however this is reduced to 78% in those with 
more pigmented skin due to the higher absorption of melanin (Panjehpour et al., 
2002). In addition to intensity shift in the fluorescence spectral profile can be used to 
characterise disease states. Drakari et al. observed BCC results in a red shift of the 
fluorescence spectrum produced with a 337 nm excitation source (Drakaki et al., 
2009). Exogenous florescent markers can be use when the endogenous 
fluorescence is weak or there is increased absorption such as that produced by 
melanin pigmentation (Borisova et al., 2012). This photodynamic diagnostic 
approach has been investigated as a technique for the delineation of disease 
margins prior to surgical excision of skin cancer. Lee et al. applied aminolevulinic 
acid and protoporphyrin IX to 142 patients with facial SCC, BCC or Bowen’s disease 
and used a Wood’s lamp to identify the disease boundary, which was not visible with 
out the fluorescent imaging. The authors reported the technique was limited by the 
low specificity due to uptake of the dyes by scars and sites of inflammation or 
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infection. In addition, the fluorescence was found to vary according to the thickness 
and depth of the tumour, making identification of margins difficult (Lee, Kim and Kim, 
2010). The complex, laminate and inhomogeneous nature of skin produces optical 
characteristics that confound the quantitative analysis of fluorescence spectra. As 
such the intensity of the fluorescence is not consistent between individuals with the 
same pathology and this limits the techniques ability to classify disease type in vivo.   
3.2.5.3 Diffuse reflectance spectroscopy 
Diffuse reflectance spectroscopy utilises the scattering and absorption properties of 
skin to produce a reflectance spectrum. This spectrum is dependent on diffuse 
scattering and the absorption from pigments within the skin (Drakaki et al., 2013). 
Significant differences in the reflectance spectra have been demonstrated between 
SCC, BCC and actinic keratosis (Rajaram et al., 2010). The reduction in scattering 
seen in malignant disease is thought to be due to breakdown of the dermal collagen 
matrix. Although scattering from the malignant cell proliferation is increased the 
overall scattering is reduced due to the change in dermal collagen (Rajaram et al., 
2010). Regrettably, the heterogeneity of human skin between individuals and by 
anatomical site leads to large variations in the reflectance spectra, making the 
technique difficult to apply to the classification of malignant disease. 
3.2.5.4 Laser scanning confocal microscopy 
Laser scanning confocal microscopy allows detailed imaging of the different cell 
layers within skin. This allows analysis of skin architecture without the need for 
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invasive biopsy, at resolutions comparable to histopathology (Astner et al., 2008). In 
reflectance confocal microscopy (RCM) the illumination of the tissue and detection 
occurs at the same wavelength of light. This technique allows the skin to be explored 
in three dimensions by shifting the focal area. Characteristic RCM features have 
been described for SCC, BCC, melanoma and normal skin and the method has 
shown promise for the classification of malignant lesions and identification of tumour 
boundaries at the time of surgery (Gerger et al., 2005; Horn et al., 2007; Guitera et 
al., 2012). RCM imaging is dependent on the difference in refractive index between 
tissue structures to produce images whereas fluorescence confocal laser scanning 
microscopy (FCM) allows the imaging of endogenous or exogenous skin fluorophore 
distribution. FCM can be used to target imaging at specific cellular or subcellular 
molecules using specific fluorescent markers. Astner et al. used sodium fluorescein 
injected into the epidermis to image the morphological characteristics of malignancy 
seen on histology, including enlarged nuclei, tumour nests, pleomorphism, nesting of 
cells and abnormal vascularisation (Astner et al., 2008). The main limitations of RCM 
are the imaging penetration depth of 200 – 300 μm, the subjective nature of the 
image interpretation and deficiency of biochemical information. Confocal Raman 
laser scanning microscopy can be combined with RCM and FCM to provide 
additional biomolecular information from the tissue under investigation. 
The alternative optical diagnostic techniques discussed all have a potential role in 
the management of vulval skin diseases and the advantages and disadvantages are 
summarised in Table 3-2. 
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Table 3-2 – Comparison of alternative optical diagnostic techniques 
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vivo 
3.3 Vibrational spectroscopy in the assessment of lymph 
nodes 
The ability to detect metastatic disease in lymph nodes at the time of surgery has the 
potential to remove the need to perform a second operation should a sentinel lymph 
node be found to be diseased after histological examination. Various techniques 
have been used to facilitate the intraoperative assessment of lymph nodes including 
frozen tissue section and histology; touch imprint cytology and molecular assays. 
Frozen section is associated with a long processing time and the need for immediate 
access to an expert histopathologist. Touch imprint cytology is a rapid method for 
preparing a cytological sample for analysis. The technique involves pressing both cut 
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sides of a bisected lymph node onto a slide, staining, immediately followed by 
examination by an expert histopathologist. Das et al. applied vibrational 
spectroscopic techniques to the traditional touch imprint technique and demonstrated 
the feasibility of cytoimprint FTIR for intraoperative diagnosis (Das et al., 2008). 
Molecular assays use nucleic amplification techniques to detect tumour specific RNA 
markers. This technique is destructive and impedes the subsequent histological 
confirmation of the lymph node disease status. In addition there are currently no 
available assays for the detection of metastatic vulval SCC. 
Within the last decade there has been increasing interest in the use of Raman 
spectroscopy in the intraoperative assessment and classification of lymph nodes 
(Horsnell, 2012). Raman spectroscopy is an attractive solution as it offers the 
opportunity for non-destructive real time intraoperative assessment of the presence 
of cancer cells within nodes.   
The ability of Raman spectroscopy to differentiate between normal lymph nodes and 
those with lymphoma or metastatic carcinoma in the head and neck has been 
demonstrated, with reported sensitivities and specificities of over 81% and 89% 
respectively (Lloyd et al., 2013a). The technique has also been shown to be able to 
differentiate between axillary lymph nodes with and without metastasis in the working 
theatre environment, with sensitivities of 92% and specificity of 100% (Horsnell et al., 
2010, 2012; Horsnell, 2012). To date analysis of inguino-femoral lymph nodes from 




3.4 Clinical need for advanced vulval diagnostics 
As previously discussed, the diagnosis and management of vulval disease is based 
on clinical assessment and histopathological analysis (Chapter 1). Techniques 
enabling rapid molecular assessment of vulval disease could have wide ranging 
applications, from initial diagnosis and molecular risk assessment to helping 
delineate disease margins at the time of surgery. These potential applications and 
existing alternative techniques are discussed below. 
3.4.1 Diagnosis of vulval disease 
Currently, there are no established non-invasive techniques available for the 
objective diagnosis and monitoring of premalignant or malignant vulval skin 
disorders. At present diagnosis is based on clinical assessment supplemented by 
invasive tissue biopsy. Various non-invasive techniques have been proposed for the 
identification of neoplastic vulval disorders including Toludine blue staining of vulval 
skin and cytological examination of skin scrapings or swabs. 
Toludine blue offers high sensitivity for the detection of VIN, however the technique 
has a prohibitively low positive predictive value, found to be 100% and 24% 
respectively in a study by Joura et al. (Joura et al., 1999). 
The utility of cytological examination of cells from the surface of the vulva is limited 
by the significant keratosis present in many lesions. This results in the majority of 
cells collected being anucleate squamous cells which offer limited information 
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(Smith, 2010). Reported sensitivities vary significantly from 32% to 97% for the 
detection of premalignant vulval lesions (Nauth and Schilke, 1982; Levine et al., 
2001; Bae-Jump, Bauer and Van Le, 2007; Van den Einden et al., 2012). The higher 
reported sensitivities result from exclusion of non-diagnostic specimens, artificially 
elevating the reported diagnostic utility. Non-diagnostic specimens account for 
around one quarter of samples collected using a standard cytological brush 
collection system. 
Neither of the techniques discussed can offer the diagnostic performance required to 
make them a viable adjunct or alternative to invasive biopsy. Vibrational 
spectroscopy offers an alternative to traditional tissue biopsy for the diagnosis of 
vulval disorders. 
3.4.1.1 Raman spectroscopy for in vivo real time 
assessment of vulval disease 
As discussed (Chapter 3.2.3) Raman spectroscopy shows significant promise in 
differentiating different dermatological disorders. Investigation into the role of Raman 
spectroscopy in the vulva has been very limited to date and the potential applications 
of the technique will now be discussed. 
The most tangible application of the technique is as an investigation to be used 
alongside clinical assessment of the vulva to determine if further invasive biopsy is 
necessary. To be useful in this context the technique needs to be able to correctly 
identify those without clearly identifiable disease (test negative). If this is achieved 
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then those that test negative can have biopsies to explore the exact nature of the 
disease. 
Using women with suspected LS as an example. If we have a technique that can 
detect those patients without LS with high specificity, then those individuals testing 
positive for LS could be safely treated without biopsy and the remainder further 
investigated with biopsy. If we have 100 women with suspected LS in whom biopsy 
is indicated and in whom the prevalence of LS is 60%, the sensitivity of Raman 
spectroscopy is 75% and the specificity 98% then we will be able to correctly identify 
75% of those with LS and avoid the need for invasive biopsy in 45 women. This 
would reserve the majority of invasive biopsies (73%) for those women in whom LS 
is not the likely diagnosis and therefore those patients where biopsy is needed in 
order to obtain a diagnosis. 
In other clinical situations the requirements of the investigation will be different. 
When assessing women with suspected precancer or cancer we need to ensure 
women with cancer have the nature of the disease explored with invasive biopsy. In 
this circumstance a high sensitivity is required. These varying requirements need to 
be accounted for in the diagnostic design of a Raman spectroscopic system. 
A Raman diagnostic system also has the potential to guide where biopsies should be 
taken by identifying molecular changes associated with disease and increasing the 
chance of sampling the area of interest. This in turn could reduce the number of 
biopsies required to produce a definitive diagnosis. 
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Table 3-3 – Potential applications of Raman spectroscopy on the vulva 





Clinical decision aid 

























information to that 
provided by 
histopathology 













The ability to use the technique as a definitive optical biopsy and eliminate the need 
for invasive biopsy is currently limited, as Raman spectroscopy is unable to 
reproduce the full spectrum of information obtained by histopathological examination. 
The potential role of the technique is as an adjunct to standard assessment and to 
provide near real time assessment of pathology to guide further investigation and 
management.  
3.4.1.2 Raman spectroscopy for intraoperative 
assessment of disease margins 
During the surgical treatment of VIN or vulval cancer removing all cancer or VIN 
disease reduces the risk of the disease recurring. Current guidelines for the 
management of vulval cancer recommend the excision of primary tumours with a 
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minimum margin of 15 mm to ensure a histological margin of greater than 8 mm 
(RCOG, 2014). Inadequate excision margins have been repeatedly identified as an 
adverse prognostic factor and observational studies have identified the disease free 
margin to be an important predictor of primary tumour site recurrence. Heaps et al. 
study of 135 cases of vulval SCC reported that local control was achieved in 100% of 
cases where a histological margin of 10 mm or more was achieved and by contrast a 
margin of less than 8 mm was associated with a 47% local recurrence rate (Heaps et 
al., 1990). The association between histological margin and disease recurrence has 
subsequently been demonstrated by other authors and reported recurrence rates 
vary from 20 to 50% in those with a pathological margin less than 8 mm and from 0 
to 21% in those with a margin 8 mm or more (Burke et al., 1995; De Hullu et al., 
2002; Chan et al., 2007). More recent studies could not demonstrate the importance 
of a pathological margin >8 mm, however complete excision of the primary tumour 
remains an important prognostic factor (Groenen, Timmers and Burger, 2010; 
Höckel et al., 2010; Woelber et al., 2011). Observational studies have also 
demonstrated that despite the intention to attain a 8 mm pathological margin, this 
was only achieved in 14 to 40% of cases (Rhodes, Registrar and Lecturer, 1998; 
Rouzier et al., 2002; Groenen, Timmers and Burger, 2010; Woelber et al., 2011). 
There is currently, no non-invasive near real time objective diagnostic technique that 
can be used for the identification of vulval tumour margins during surgery. A 
technique capable of determining tumour margins intraoperatively would, have the 
potential to reduce incomplete excision rates and in turn reduce the rate of local 
vulval cancer recurrence, whilst minimising the extent of surgery.  Raman 
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spectroscopy has the potential to be developed as a valuable diagnostic aid in these 
circumstances. 
In addition, as Raman spectroscopy elicits molecular information from tissue it may 
be possible to define a molecular surgical margin containing histologically benign 
tissue with molecular changes that predispose to the development of cancer. 
Although it is outside the scope of this thesis future studies may assess the 
prognostic value in defining surgical margins in this way. 
3.4.2 Intraoperative assessment of lymph node metastasis 
Vulval SCC is typically treated with excision and inguinofemoral lymphadenectomy, 
dependent on the size and position of the tumour (Chapter 1.4.4). The 
lymphadenectomy is associated with significant morbidity in 70% of cases: related to 
poor wound healing, infection, lymphoedema and lymphocyst formation (Lawrie et 
al., 2014). This has led to significant interest in detection and assessment of sentinel 
lymph nodes in the treatment of vulval cancer. Sentinel nodes can be detected using 
a technetium tracer and blue dye injected around the primary lesion. Removal and 
analysis of the sentinel node can then be used to guide the need for further 
treatment. Currently the excised lymph node is either sent for immediate frozen 
sectioning and histopathological analysis or routine tissue fixation and paraffin 
histology. If the initial analysis of the sentinel node is negative then ultra-staging 
techniques can be used to detect micro-metastasis. If the node is found to contain 
cancer cells then further treatment with either full inguinofemoral lymphadenectomy 
or radiotherapy to the inguinofemoral lymph nodes is warranted. The safety of 
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omitting complete inguinofemoral lymphadenectomy in patients with a negative 
sentinel node is uncertain and currently the subject of the GROningen INternational 
Study on Sentinel nodes in Vulvar cancer (GROINSS-V) II observational study. 
Currently there are no objective techniques for the assessment of sentinel lymph 
nodes at the time of initial surgery for vulval cancer. It is not possible to perform 
routine histopathology or ultra-staging at the time of surgery due to the need for 
tissue fixation. Frozen section analysis is dependent on the availability of an expert 
histopathologist and only assesses single sections through the nodes, so may miss 
metastases at other points within the node. Raman spectroscopy offers an objective 
real time adjunct to histopathological examination of lymph nodes and shows 
promise for the detection of diseased lymph nodes at the time of surgery (chapter 
3.3). Such a technique could be performed in the absence of a histopathologist and 
would allow all surgery to be completed in one session without the need for a second 
operation, in situations where full inguinofemoral lymphadenectomy is required. 
3.4.3 FTIR spectroscopy for spectroscopic aided detection of 
disease and augmented pathology 
3.4.3.1 Spectroscopic aided detection of disease 
When caring for women with suspected vulval cancer it is clearly important that 
histological diagnosis is accurate and delivered in a timely manner. There is 
recognition that delays in reporting pathological specimens and errors in reporting 
can negatively impact on patient care (Frable, 2006; Hirschowitz, Wells and Lowe, 
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2013; Volmar et al., 2014). Studies analysing the rates of errors in histopathological 
practice by secondary review of the pathological specimens have revealed 
significant discrepancies exist between reports completed by different pathologists. 
The disagreement rate ranges from 9.0% to 18.7% for minor disagreements and 
from 1.4% to 6.8% for major disagreements (Kronz, Westra and Epstein, 1999; Weir, 
Jan and Colgan, 2003; Manion, Cohen and Weydert, 2008; Middleton et al., 2014). 
Major discrepancies were defined as errors that affected or had the potential to affect 
patient care. These errors may lead to over or under treatment of significant disease 
and is an important concern for patients. Double reporting where two pathologists 
examine specimens has been proposed as a mechanism for reducing this diagnostic 
error, although it is not standard practice within the UK. Current recommendations 
suggest double reporting should only be used routinely in certain scenarios, such as 
some cases of high grade dysplasia in the gastrointestinal tract, melanomas and 
severely atypical naevi. Double reporting should also be considered for rare or 
uncommon tumours (Hirschowitz, Wells and Lowe, 2013). Whilst consultant 
histopathologists are considered independent practitioners, secondary review or 
double reporting of specimens is often used in general histopathological practice 
before a final report is issued. The current system relies on the individual 
pathologist’s assessment of their own limitations and recourse to a second opinion 
when they judge this to be appropriate (Lind et al., 1995). 
With the increasing burden present on health services, an expanding repertoire of 
available tests, new clinical guidelines and fear of litigation, there is increasing 
pressure on the time available to histopathologists. In addition to this many 
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consultant histopathology posts and training posts within the United Kingdom are 
unfilled, further increasing time pressures (Centre for Workforce Intelligence, 2010). 
In light of these pressures a technique that would automate the process of 
pathological second opinion would be valuable. This would enable pathologists to 
obtain corroboration of their diagnosis and reduce the need for a second 
histopathologist. Automated analysis of digitised histopathological images, 
fluorescence imaging and vibrational spectroscopy have all been proposed as 
possible technological solutions (chapter 3.2.5). FTIR–S offers a computer aided 
detection technology based on the molecular composition of tissues and has real 
potential to offer a solution in this context (chapter 3.2.2). A FTIR–S aided detection 
system could be used by pathologists to help them reduce the occurrences of false 
positives and false negatives. Compared to chemical and immunohistochemical 
stains FTIR - S imaging has some distinct advantages, including minimal need for 
unusual sample preparation, no need for special stains or contrast agents and since 
the information is numeric it is highly amenable to objective computational analysis. 
Integrated into the pathology workflow spectroscopic analysis could sit alongside 
traditional histopathology to aid with histopathological decision making (Figure 3-1). 
The practical requirements of speed of data acquisition and processing have made 
the implementation of spectroscopic aided detection system in the healthcare setting 
difficult. These problems are being address and recent advances have made good 
progress towards enabling the technology to provide high throughput data 
acquisition within a compact unit at a realistic cost (Farries et al., 2015). 
 
 115 
When spectral analysis and data processing is quicker than traditional 
histopathology, the technique has the added advantage of being able to act as a 
triage mechanism, whereby those cases that are likely to contain an urgent 
diagnosis are flagged for priority pathological assessment. In the context of vulval 
disease the diagnosis of non-neoplastic, premalignant or malignant vulval disease 
could be confirmed using a spectroscopic aided detection technique. This has the 
potential to ensure malignant disease is not missed and that morbid surgical 
treatment of vulval cancer is not performed unnecessarily. An example of where the 
technique may be useful is in cases where a biopsy shows possible early invasive 
disease but the diagnosis cannot be clearly made. Currently in this situation a further 
biopsy and delay in diagnosis is usually necessary, however this may be avoided if 
spectroscopic aided detection of disease is available. In addition, FTIR spectroscopy 
has the potential to be used as a histopathological adjunct to improve the early 
diagnosis of SCC.  FTIR spectroscopy has the potential to detect molecular 
changes, which identify those in whom further investigation is likely to find an occult 
malignancy. Early diagnosis would be advantageous as it is associated with a 





Figure 3-1 – Overview of the use of vibrational spectrscopy for augmenting histopathological 
diagnosis 
3.4.3.2 FTIR spectroscopy for augmenting pathology 
Another area in which molecular spectroscopic analysis may be advantageous is in 
providing prognostic information based on the chemical properties of tissue 
specimens. A recent study assessing the role of FTIR spectroscopy for the 
identification of prostate cancer at increased risk of recurrence demonstrated 
chemical changes that could be employed to outperform traditional recurrence 
prediction methods (Kwak et al., 2015). Another study by Baker et al. investigated 
the use of FTIR spectroscopy in evaluating prostate cancer, and demonstrated the 
association between FTIR spectroscopic changes and clinically aggressive prostate 
cancer (Baker et al., 2008). To date research into the role of vibrational spectroscopy 
for the identification of prognostic markers is limited and no studies assessing the 
role of the technique in vulval disease were identified. 
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There is a broad range of molecular changes in the vulval that contribute to the 
development of vulval cancer (chapter 1.4.1). Vibrational spectroscopy not only 
examines molecular changes resulting from known provocations (e.g. TP53 mutation 
and HPV integration) but also assesses other undescribed molecular changes 
(Ostrowska et al., 2011). This gives a broader picture of the molecular changes 
present, but at the expense of detailed biomolecular causation, as vibrational 
spectroscopy does not allow us to determine the exact molecular alterations 
underlying the spectral differences identified. 
Traditional histopathological analysis gives limited information about the 
biomolecular changes associated with an increased risk of malignant transformation. 
Vibrational spectroscopy has the potential to augment traditional histopathology, 
giving pathologists additional prognostic molecular information from the tissue under 
examination. As previously described women with LS and VIN are at increased risk 
of developing vulval SCC. Using vibrational spectroscopic analysis for molecular risk 
stratification of patients with VIN or LS may facilitate the identification of those at 
high risk of developing vulval SCC. In addition, the analysis of cancerous vulval 
disease has the potential to facilitate risk stratification, which could be used to modify 
management to prevent recurrence and ensure recurrences are detected early. 
3.5 Conclusion 
In conclusion, vibrational spectroscopy offers techniques for molecular assessment 
that have a relatively low cost; that only require a small amount of tissue and that 
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can be performed in a short amount of time (Old et al. 2014). Based on the findings 
from diagnostic investigation on skin and other areas of the body vibrational 
spectroscopic techniques have the potential to be usefully applied to both the initial 
diagnosis of vulval skin conditions in clinic and the histopathology laboratory as well 
as for the monitoring for malignant changes in women with precancerous vulval skin 
conditions. 
In the management of vulval cancer spectroscopic probes offer a potential real time 
intraoperative diagnostic tool to detect non-visible disease margins and improve 
complete excision rates, and avoid disease recurrence, whilst minimising the extent 
of surgical excisions. In addition, vibrational spectroscopy offers a potential tool for 
intraoperative objective assessment of sentinel lymph nodes. 
Vibrational spectroscopy also offers the potential to give biomolecular prognostic 
information that can be used to evaluate the risk associated with different types of 




Section B: General Methods 
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Chapter 4 General Technical Considerations 
and Chemometric Analysis 
This chapter outlines the general technical considerations to be considered when 
applying vibrational spectroscopy for the diagnosis of disease. This includes 
discussion of sources of noise and other variation in spectral data that is 
independent of signal from the tissue under analysis. The strategies for processing 
the spectral data to minimise the impact of non-tissue signal are discussed alongside 
the multivariate chemometric analytical techniques used for the classification of 
tissue type based on vibrational spectra. 
4.1 Noise and interference 
4.1.1 Sources of noise  
The spectra obtained from both Raman and FTIR spectroscopy comprises the signal 
from the sample under analysis and noise.  The main identifiable origins of noise in 
vibrational spectra include shot noise, dark noise, readout noise, quantisation noise 
and background light noise, these are summarised in (Table 4-1).  This list is not 




The signal to noise ratio (SNR) is a useful measure of the intensity of the signal, 
relative to the noise.  A high SNR is desirable in order to be able to identify the signal 
spectra from the noise (Lewis and Edwards, 2001; Brereton, 2003). Experimental 
protocols in this study have been designed to maximise the signal to noise ratio in 
the spectra recorded whilst maintaining spectral resolution and further detail on this 
is given in subsequent chapters. 
The shot noise is a fundamental limit of photon spectroscopy.  Even with a 
spectrometer that eliminates all other sources of noise the SNR will still be subject to 






Summary Mitigation Spectroscopy 
technique 
affected 
Shot Noise resulting from the 
random nature of photons 
arriving at the 
spectroscope detector.  It 
is proportional to the 
square root of the number 
of photons arriving at the 
detector. 









Dark Noise produced by the 
thermal generation of 
electrons within the 
spectroscope detector, 
independent of photons 
striking the detector.  Dark 
noise is proportional to the 
duration of acquisition. 
Cooling the detector 
reduces the dark 
noise.  The Dark 
noise can also be 
measured and 




Readout Noise due to inaccuracies 
in measuring the number 




Quantisation Noise relating to the 
resolution of conversion of 
the analogue signal from 






Noise from light striking the 
detector that is not from 
the sample under analysis, 
for example light from the 
optical system or stay light 
from other sources. 
Reducing the 
background light 
and using optics 
that do not scatter 









4.1.2 Evaluating the signal to noise ratio 
The SNR is calculated by dividing the relevant signal intensity by a measure of the 
noise in the spectrum. Noise can be estimated by assessing the variation in spectral 
intensity in a section of the spectrum where there is little or no signal from the 
sample under analysis. There is no standard method for calculating the signal to 
noise ratio. For example, the signal can be taken as the difference between the 
height of a peak of interest and the baseline of the spectra adjacent to the peak or 
the baseline of the whole spectrum.  Likewise, the noise can be calculated as the 
simple range of an area of the spectrum with little or no signal or in more advanced 
ways such as the root mean squared of the difference from the mean in an area with 
no signal.  It is important that the method used for calculating the signal to noise ratio 
is appropriate to the technique under investigation and consistent when applied to 
assess different spectra.  The exact methods chosen for each application are 
discussed further in later chapters. 
4.1.3 Other non-analytical interference 
4.1.3.1 Cosmic rays 
During the acquisition of Raman spectra high energy cosmic rays can strike the 
spectroscope detector, causing a peak in the spectra which is not as a result of 
signal from the sample under analysis.  As the detector used in FTIR spectrometers 
is not sensitive to cosmic rays this type of interference is not relevant to FTIR 
spectroscopy. These unwanted signals can be avoided by taking the median spectra 
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from three consecutive acquisitions, as it is unlikely a cosmic ray will be present at 
the same place in two of the spectra.  The median is taken rather than the mean 
because the mean can be significantly altered by the presence of a cosmic ray in 
one of the spectra whereas the median is unlikely to be altered. This triple 
measurement to avoid cosmic rays does however significantly increase the time 
needed to acquire the Raman spectra. An advantage of this median of three spectra 
approach is that taking the median counts at each wavenumber reduces the noise in 
the final spectrum.  As three separate spectra are needed in this approach it takes 
longer to achieve the same signal to noise ratio as compared to a single acquisition 
(Figure 4-1 and Figure 4-2). With this cosmic ray reduction technique approximately 
double the acquisition time is necessary to gain spectra of similar quality to those 
obtained without this technique.  
In spectral maps, where spectra are taken in a grid or line from adjacent sites close 
together, another type of median filter can be used to remove the effect of the 
cosmic rays. In a median filtered two dimensional Raman map the spectrum at the 
centre of a median filtering grid is defined as the median of the spectra at that point 
and all surrounding spectra depending on the median filter grid size (Figure 4-3). 
When spectra are not taken from sites close together neighbouring spectra may 





Figure 4-1 – Chart of signal to noise ratio of 
spectra from PTFE block with varying 
acquisition time with and without automatic 
cosmic ray removal (ACR)  
Figure 4-2 – Spectra from PTFE block with varying 
acquisition time with and without automatic cosmic 
ray removal (ACR)  
 
 
Figure 4-3 – Example of a three by three median filtering grid. The spectrum at 1 is the median of all 




Figure 4-4 – Tissue spectrum with narrow cosmic 
ray 
Figure 4-5 – Tissue spectrum with broad cosmic 
ray 
Another approach to reduce the contribution from cosmic rays in spectra is to filter 
the measured spectra to remove the part of the spectrum consistent with cosmic 
rays. These areas of the spectrum distorted by cosmic rays can then be replaced 
with an approximation of what the spectrum is expected to be (Phillips and Harris, 
1990; Cappel, Bell and Pickard, 2010). When this approach is used in this study the 
areas of the spectrum removed due to cosmic rays are replaced using a 
reconstructed spectrum based on PCA loadings from the entire data set and the 
predicted scores of the individual spectrum without the cosmic ray (chapter 4.2.1). 
When the cosmic rays are narrow with high detector counts (Figure 4-4) this 
approach works well as the sections of the spectra due to cosmic rays are readily 
identified.  In addition when the cosmic ray is narrow the adjacent areas of the 
spectrum can be used to provide a good approximation of the expected spectrum 
where the cosmic ray is found.  This approach is limited as some cosmic rays 
produce broad peaks with relatively low counts (Figure 4-5). Filtering these spectra to 
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remove the cosmic rays is more challenging. Algorithms to remove broad based rays 
also risk removing peaks of interest within the spectra.   
4.1.3.2 Fluorescence 
When a photon incident on a sample has sufficient energy to excite an electron 
between two energy states a photon will be emitted when the electron relaxes to its 
ground energy state. This process gives rise to fluorescence and can produce 
photons at wavelengths similar to those photons produced by Raman scattering.  As 
fluorescence can result in a greater number of emitted photons than Raman 
scattering the Raman spectra can be concealed by the fluorescence.  This effect is 
especially relevant in pigmented skin that contains large amounts of melanin which 
fluoresces intensely with near infrared excitation (Bodanese et al., 2012; Silveira Jr 
et al., 2012; Wang et al., 2012). 
This phenomenon can be avoided by selecting a laser excitation wavelength that 
does not have sufficient energy to excite molecular fluorescence.  For this reason 
use of longer wavelength of laser should reduce the fluorescence from the samples.  
As the intensity of Raman scattering is inversely proportional to the excitation 
wavelength (to the fourth order), a longer excitation wavelength will not only reduce 
the background fluorescence but also the Raman signal.  Therefore using a longer 
excitation wavelength requires a higher power laser source or longer acquisition 
time.  It is for these reasons that an 830 nm laser is commonly selected for 
biophotonic applications (Stone, 2001; Butler et al., 2016). 
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Another strategy for the reduction of fluorescence is the use of photobleaching.  This 
technique is based on the principle that fluorescence from tissues decreases over 
time and that the Raman signal stays relatively constant.  Exposing tissue to light 
that invokes fluorescence for a period of time prior to capture of the Raman spectrum 
can potentially reduce the contribution of the fluorescence in the final spectrum 
(Wang et al., 2012).  
If fluorescence cannot be reduced prior to measurement of spectra then it can be 
partially corrected after measurement by utilising a polynomial baseline correction.  
Assuming the fluorescence can be approximated with a low order polynomial fitted to 
the baseline of the spectra then the contribution from the fluorescence can be 
removed by subtracting this polynominal from the spectrum (Figure 4-6). 
 
 
 Figure 4-6 – Example of the effect of polynominal 
fit fluorescence reduction on a point Raman 
spectrum taken from an area of vulval melanosis 
(acquisition time 60 seconds) 
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4.2 Chemometric analysis 
Vibrational spectra measured from biological samples contain contributions from a 
diverse range of different constituent molecules and as a result can appear complex. 
In addition, the spectral differences between different tissue types and pathology 
groups can be subtle and not obvious on visual inspection. Due to these factors 
multivariate analysis is required to explore the variance between spectra and 
develop classification models to identify subtle spectral differences. These 
classification models can then be used to determine the pathology present in tissue 
from the measured spectra (Defernez and Kemsley, 1997; Lloyd et al., 2013b; Old et 
al., 2014). From this the diagnostic performance can be assessed. Numerous 
statistical approaches have been used to interrogate spectral data in this way: 
including principal component analysis (PCA), linear discriminant analysis (LDA), 
partial least squares (PLS) and support vector machines (Lloyd et al., 2012). 
All these multivariate techniques used for the classification of tissue vibrational 
spectra require validation with an independent test set. This can be achieved using 
leave one sample out cross validation as this allows maximal use of the available 
data whilst minimising the risk of a type one error. Within this thesis spectral analysis 
was based on cross-validated PCA fed LDA and this is discussed in more detail 
below. All data analysis in this thesis was undertaken with Matlab® R2015b 
(Mathworks, USA) software using custom coded algorithms. 
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4.2.1 Principal component analysis 
PCA is an unsupervised technique for multivariate pattern recognition which is well 
suited to handling large datasets (Brereton, 2009; Lloyd, 2009). PCA converts the 
spectral data into a set of uncorrelated variables called principal components (PC).  
This results in principle component scores (T) and loads (P) that represent the 
original data matrix (X) with error E as shown in Equation 4-1. When all principal 
components are included the error E will be zero. 
 
Equation 4-1 
The principal components contain the main variation within the data set. The 
Eigenvalues calculated during PCA give a measure of the variation in the data 
accounted for by each PC and the PCs are ranked according to these values. The 
first principal component accounts for the greatest amount of variation within the 
data. Each PC is orthogonal to all other components and therefore represent 
independent sources of variation within the data, in data with only two sources of 
variation there will only be two principal components. In spectral data measured from 
tissue there are numerous sources of variation and these result in numerous 
principal components. For this reason, analysis is often limited to the PCs that 
account for the most variance within the data after the exclusion of other PCs that 




PCA is helpful in the analysis of spectral data as it reduces the dimensionality of the 
data without loss of important discriminating features. As PCA does not include 
information about pathology grouping, it is an unsupervised method and does not 
provide information on group membership. To classify spectra according to 
pathology group, a supervised analysis of relevant variation between spectra 
(principal components) is required. For the purposes of this thesis LDA is used to 
create the supervised classification model (Chapter 4.2.3). 
4.2.2 Selection of principal components for LDA 
Analysis of variance (ANOVA) can be applied to the principle component scores and 
the pathological groupings to assess which of the principal components are 
statistically significantly different between the pathological groups. These significant 
principal components can then undergo LDA to allow classification of pathology 
groups according to PC scores. 
4.2.3 Linear discriminant analysis 
Multiclass LDA can be used as a supervised method to maximise the variance in PC 
scores between pathology groups whilst minimising the within group variance. LDA 
analyses the PC scores of each of the pathology groups to produce LD scores and 
LDA loadings. This enables LDA to use the covariance of the whole dataset to define 
a linear discriminant border between the groups (Figure 4-7).  This resultant model 
uses the distance of the LD scores to the mean of each group to predict to which 
pathological group each spectrum belongs.  Each prediction is associated with a 
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given probability of that prediction being correct. This is based on the distance to the 
linear discriminant boundary and the mean of each group.  Unlike histopathological 
analysis where a sample may be unclassifiable, LDA will always attribute a spectrum 
to a pathological group irrespective of how likely that classification is. This can lead 
to misclassification of data that does not fit well within the model as all data points 
will be assigned a probability of group membership based on the distance to the LD 
boundary (Figure 4-7). For this reason it is also important to consider the 
Mahalanobis distance from the mean of each group as greater the distance the 
poorer the fit to the model and the lower the probability that the predicted group is 
correct. 
4.2.4 Group classification 
Spectra measured from a sample of unknown pathology can be classified by a LDA 
classification model by estimating the PCA scores from the spectra and the PCA 
loadings (Equation 4-2). The predicted LD scores can then be estimated from the 
LDA loadings and the estimated PCA scores (Equation 4-3). These predicted LD 
scores can then be projected onto the LDA classification model covariance matrices. 
The LDA classification is then based on the distance of the predicted LD scores to 
the mean LD scores of the groups scaled by the intragroup variance. This results in 




Figure 4-7 – Diagram demonstrating LDA classification of groups based on the scores of two PCs in a 
two group model. At point 1 (the mean of group 1) the predicted probability of membership of group 1 
is 1 and the probability of membership of group 2 is 0; at point 2 on the LD boundary the probability of 
membership of either group is 0.5;  at point 3 (the mean of group 2) the predicted probability of 
membership of group 1 is 0 and the probability of membership of group 2 is 1; and at point 4 the 
probability of membership of group 1 is 0 and the probability of membership of group 2 is 1 although 
the point is distant to the mean of group 2 and not a good fit to the LD classification. 
 
Xtest P = Testimated 
Equation 4-2 – Estimation of test set scores (Testimated) from test spectra (Xtest) and PCA loadings (P) 
 
D = Testimated (B)-1 





Figure 4-8 – PCA fed LDA classification model 
This PCA fed LDA classification approach (Figure 4-8) can be used to predict the 
pathology group of each individual spectrum measured from a tissue sample. In LDA 
it is possible to move the discriminatory boundary to adjust the performance of the 
test to the application. For example if a high sensitivity is required a classification 
that favours the ‘positive’ group can be achieved by choosing a discriminant 
boundary further from the mean of that group. This would be at the expense of the 
specificity of the classification. 
In addition, in clinical practice it is often the classification of the whole sample or 
patient that is important.  Therefore if multiple spectra are measured from each 
sample, the group can be classified according to the proportion of spectra with each 
classification within the sample.  This approach can also be individualised to the 
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clinical application. For example, when looking to identify cancer then a high 
sensitivity may be prioritised at the expense of specificity by using a lower threshold 
number of abnormal spectra to classify the sample as cancer. 
4.2.5 Validation of results 
It is important to validate predictions given by the PCA LDA classification model as 
testing the performance of the classification model using spectral data used to train 
the model may result in classification based on factors unrelated to the pathology 
groups of interest. Failure to adequately validate may result in an over estimation of 
the diagnostic performance and a type one error. If a large number of samples and 
spectral measurements were available then it would be possible to create a model 
from a training set of data and validate with data from an entirely different test data 
set. This approach requires a large number of participants and is not suitable when 
the number of participants is limited. When the number of participants is limited 
sequentially excluding some data as a test set and using the remaining data as a 
training set to create the classification model that is then tested on the excluded data 
is an alternative approach (Lloyd et al., 2012). This approach allows most efficient 
use of the available data while reducing the risk of a type one error. We can use this 
principle in a leave one sample out cross validation loop in which each sample 
analysed is excluded in turn from the whole data set and tested against a 
classification model created from the remaining training set (Figure 4-9). By 
excluding all the data from a given participant in each loop then classification based 





Figure 4-9 – Leave one sample out cross validation loop 
4.2.6 Methods for the exclusion of outlying spectra 
When multiple spectra or spectral maps are measured from a sample, the spectral 
data recorded may contain spectra that do not describe features typical of the type of 
sample under analysis and may not fit well within a PCA LDA classification model 
(Figure 4-7). These outlying spectra may result from non-tissue signal such as 
atmospheric water or contamination of the collection optics. It is important to exclude 
these outliers from PCA because if the spectral signal is significantly different from 
other tissue spectra this irrelevant variance will be described by the principal 
components. As this variance is not relevant to the classification of tissue groups it 
may impede the performance of the resultant LDA classification model. 
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4.2.6.1 D - and Q - statistic 
To identify spectra for exclusion from the classification model that are not 
characteristic of tissue spectra a measure of the PC reconstruction error (Q statistic) 
and the difference from the mean spectrum (D statistic) can be used (Brereton, 
2009; Brereton and Lloyd, 2016). Both these techniques are applied to spectral data 
after PCA has been performed (Figure 4-10). The identified outliers can then be 
excluded from the original spectral data set and PCA repeated for the purposes of 
the PCA LDA classification. 
 
Figure 4-10 – Application of D and Q statistics for the exclusion of spectral data significantly different 
to all raw data 
The application of the D statistic allows the calculation of the Mahalanobis distance 
from the mean of the PC scores and gives a specific confidence that a sample is a 
member of that group (e.g. a spectrum typical of the majority of spectra).  The 
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spectra whose corresponding scores are outside of this distance can be excluded 
from the original data set (Figure 4-11). 
  
Figure 4-11 – Diagram showing D statistic 
confidence band where point 1 is within the 
confidence band and point 2 is outside the 
confidence band 
Figure 4-12 – Diagram showing the Mahalanobis 
distance confidence band from the means of the 
LD scores groups where points 1, 2 and 3 are 
included in the confidence band and points 4 and 
5 are outside of the band. 
The Q statistic or squared prediction error can be used to estimate how well a 
spectrum fits into a PC model of all data. It is calculated from the sum of squares of 
the residual error (E) obtained from the PCA model of the raw data. This is 
compared to a normal distribution of residual errors and threshold defined by the 
specific confidence that a sample is a member of that group or tissue type. When the 
Q statistic for a spectrum is outside of the set confidence limit this means the PCA 
model does not describe the spectrum well and that a different type of variation, not 
predominant in the raw data set, is present within the spectrum. 
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4.2.6.2 Mahalanobis distance 
Once PCA LDA has been performed the resultant model will provide a prediction for 
all spectral data regardless of whether the data fits well within the model (Figure 
4-7). A confidence interval derived from the combined Mahalanobis distance from 
the mean of each of the classification groups can be used to exclude predictions for 
spectra that do not fit well into the LDA model (Figure 4-12). By using this method we 
can restrict predictions to spectra that fit well within the LDA model and pathology 
groups present in the model. 
4.2.7 Reporting diagnostic accuracy 
Receiver operator curves are widely accepted as the standard method for reporting 
and comparing the accuracy of medical diagnostic tests (Zhou, Obuchowski and 
McClish, 2011). The performance of a diagnostic test is described by the sensitivity 
(i.e. ability to detect disease when present) and the specificity (i.e. ability to 
recognise disease absence when disease not present). The receiver operator curve 
(ROC) describes the sensitivity of the test over all possible false positive rates (i.e. 1-
specificity). The ROC allows us to derive measures of accuracy that can be used to 
compare different diagnostic tests independent of the prevalence of the disease 
under investigation. The area under the ROC curve (AUC) combines both the key 
measures of accuracy (sensitivity and specificity) into a single measure of diagnostic 
accuracy and is the primary measure of diagnostic accuracy used in this thesis. 
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Section C: Raman Spectroscopy for the 
Assessment of Vulval Disease 
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Chapter 5 Introduction, aim, objectives, ethics 
and recruitment 
5.1 Introduction 
As discussed in chapter 3.4.1 there are currently no established alternatives to 
invasive biopsy for the assessment of women with vulval disease. The diagnosis of 
vulval disease can be clinical, although invasive tissue biopsy and histopathological 
evaluation is necessary if the diagnosis is uncertain; if there is suspicion of cancer or 
if there is a failure to respond to adequate treatment (Neill and Lewis, 2010). 
Invasive biopsy is unpleasant for women and its assessment relies on traditional 
tissue fixation and histopathological analysis. Although histopathological examination 
is considered to be the gold standard diagnostic procedure, the process is time 
consuming and expensive. In addition, invasive tissue biopsy followed by 
histopathology is subject to sampling errors as the number of areas of the vulva that 
can be mapped by this technique is limited by the morbidity of the biopsy procedure 
itself. In a review of 64 cases of stage I vulval cancer, Ross et al. demonstrated 
significant discordance between the depth of invasion on biopsy and that found in 
resection specimens (Ross and Ehrmann, 1987). 
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A reliable non-invasive diagnostic technique would reduce the need for invasive 
biopsy and allow a greater area of the vulva to be evaluated. Use of an objective 
technique for non-invasively assessing the vulva may in turn increase the sensitivity 
of vulval histopathology by targeting biopsies to the most abnormal areas. 
During surgical management of vulval cancer and VIN it is important that all the 
disease is removed, when technically possible, as complete excision is associated 
with reduced disease recurrence (chapter 1.4.4). At present clinicians rely on visual 
assessment alone for the evaluation of disease margins at the time of surgery. A 
non-invasive tool for assessing the presence or absence of premalignant or 
malignant disease could aid the complete excision of disease whilst minimising the 
extent of the surgery necessary. 
A non-invasive technique for objectively monitoring biochemical response to 
treatment may also allow clinicians to tailor management of precancerous vulval 
conditions to biomolecular disease response and reduce the risk of progression to 
vulval cancer. An example of where this approach may be useful is in the treatment 
of vulval lichen sclerosus with ultra potent topical corticosteroids (Chapter 1.2.1).  
Long term observational studies of women with vulval LS have not identified clinical 
features associated with malignant progression (Cooper et al., 2004; A Lee, Bradford 
and Fischer, 2015). As treatment of LS is currently guided by reported symptoms 
and structural vulval changes, it is feasible that there is a cohort of patients who are 
undertreated, as these features have not been found to correlate well with a 
progression to malignant disease. Non-invasive biomolecular assessment of 
 
 143 
response to treatment in LS may provide useful additional information when deciding 
on preventative treatment regimes.  
In summary, Raman spectroscopy and multivariate analysis has the potential to 
reduce the need for invasive tissue biopsy for the assessment of vulval disease and 
to provide a valuable tool for the intraoperative assessment of disease margins 
during surgery for vulval cancer. Other potential applications of the technique include 
biomolecular assessment of response to non-surgical management of precancerous 
vulval conditions to allow treatment to be tailored to biomolecular rather than clinical 
response. 
5.2 Aim 
To investigate the ability of Raman spectroscopy to classify vulval pathology 
including vulval intraepithelial neoplasia, lichen sclerosus, vulval squamous cell 
carcinoma. 
To achieve this aim the following objectives were set to progress experimentation 
with the technique from a purely scientific evaluation, under optimised laboratory 
conditions, towards application of the technique under conditions that more closely 
approximate in vivo use. This was designed to allow the subsequent development of 
a probe suitable for in vivo evaluation. The development of an in vivo probe is 




1. Evaluate the ability of Raman spectroscopy to classify vulval disease using 
Raman streamline mapping of transverse tissue sections at high resolution 
and explore underlying spectral differences. 
a. To investigate the ability of streamline Raman mapping at high 
resolution to classify non-neoplastic vulval skin, premalignant and 
malignant disease of the vulva. 
b. To identify the underlying spectral differences between the tissue types 
and explore the molecular basis for the classification of disease based 
on the Raman spectra. 
2. Evaluate the ability of Raman spectroscopy applied to the surface of fresh and 
fresh frozen bulk tissue to classify vulval disease. 
a. Evaluate Raman spectroscopy applied to fresh vulval tissue for the 
diagnosis of clinically inconclusive vulval lichen sclerosus. 
b. Evaluate Raman spectroscopy applied to fresh frozen tissue for the 
classification of non-neoplastic vulval skin, premalignant and malignant 
disease of the vulva. 
3. Evaluate the ability of a fibre optic probe and portable Raman spectrometer in 




The practical assessment of objective 1 is addressed in Chapter 6 which evaluates 
the differentiation of vulval SCC, VIN and non-neoplastic vulval tissue using 
streamline Raman mapping at high resolution. Chapter 7 addresses objectives 2a 
and 2b by evaluating the ability to differentiate clinically inconclusive vulval lichen 
sclerosus, and separately non-neoplastic vulval skin, premalignant & malignant 
disease of the vulva using trans-epidermal micro-spectroscopic Raman spectral 
measurements. Objective 3 is assessed in Chapter 8 which assesses the efficacy of 
a fibre optic Raman spectroscopic probe for evaluating and differentiating non-
neoplastic vulval skin, premalignant & malignant disease of the vulva. 
5.4 Ethical approval and consent 
Ethical approval for the collection and analysis of fresh and fresh frozen vulval tissue 
was granted by the National Research Ethics Service Committee South West – 
Exeter (REC reference - 14/SW/1077). Written informed consent was sought from 
each participant only after a full explanation had been given, an information sheet 
offered (Appendix C.1) and time allowed for consideration. Signed participant 
consent (Appendix C.2) was obtained prior to analysis of tissue samples.  
Samples for all arms of this investigation were collected using the same ethical 
approval and consent procedure, except those samples obtained from the Imperial 
College Tissue Bank, London and the Exeter NIHR Clinical Research Facility, which 
were collected using each tissue banks general ethical approval. 
 
 146 
5.5 Recruitment and sample processing 
Fresh frozen samples obtained for this research study were analysed by micro 
spectroscopic streamline mapping, micro spectroscopic point measurements and 
probe measurements to fulfil objectives 1, 2b and 3. Fresh samples collected from 
participants undergoing diagnostic biopsy were analysed with micro spectroscopic 
point measurements to fulfil objective 2a. Outlines of both of these tissue-processing 
pathways are shown in Figure 5-1. 
A 
Sections cut from block 
Block formalin fixed for paraffin 
section and confirmatory H&E 
stain for histopathology 
Block defrosted 
Frozen sample collection 
Whole tissue 
micro spectroscopic point 
measurements 
Whole tissue Raman probe 
measurements 
Raman micro 
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Chapter 6 Ex Vivo Evaluation of Vulval Skin 
Disease Using Streamline Raman 
Spectroscopic Mapping 
6.1 Introduction 
In order to establish if Raman spectroscopy has the potential to differentiate non-
neoplastic vulval skin, premalignant and malignant disease of the vulva it is desirable 
to obtain high quality Raman spectra from the area of the tissue that contains the 
molecular changes associated with the diseases under analysis. The primary cellular 
changes that occur with progression from normal or non-neoplastic vulval tissue to 
premalignant or malignant vulval tissue occur in the vulval epidermis (Walker and 
Mathews, 2012; Isaac and Young, 2013; Nucci, 2013). Analysing the Raman 
spectral changes isolated from these epidermal cells should demonstrate both the 
potential for the technique in differentiating the different pathologies and the spectral 
basis for differentiation. 
Raman microspectroscopic mapping of tissue sections allows isolation of cellular 
layers that contain the pathological changes associated with disease (Lewis and 
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Edwards, 2001; Hutchings et al., 2009). This is in contrast to point or probe 
measurements of bulk tissue samples where the Raman signal from the abnormal 
cellular layers is found in combination with signal from surrounding tissue structures. 
Using Raman microspectroscopic mapping disease classification can be related to 
specific cellular layers of the vulval epithelium. This should result in a clearer picture 
of the biomolecular changes that permit classification of disease from Raman 
spectra. 
To date Raman microspectroscopic mapping based disease classification has been 
successfully applied to the analysis of multiple skin pathologies including basal cell 
carcinoma, solar radiation induced damage and malignant melanoma (Ly et al., 
2010; Ali et al., 2012; S M Ali et al., 2013; S. M. Ali et al., 2013) There are no reports 
in the literature of the separation of skin layers for analysis and classification of SCC 
of the skin or pre malignant vulval disease using this technique. 
6.2 Objectives 
This investigation assesses objective 1a and 1b of the aims and objectives outlined 
in Chapter 5. 
6.3 Overview of investigation 
An outline of this investigation is shown in Figure 6-1 and the experimental methods 
for each step in the study are explained in more detail below. 
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Surgical specimen collection 
Routine histopathology of H&E 
stained section 
Multivariate analysis 
Classification accuracy assessed 
Biopsies taken from specimen 
for snap freezing and storage 
Participant consent 
Frozen sections for streamline 
Raman mapping and H&E stain 
Streamline Raman mapping of 
unstained section 
Participant identification 
Remainder of surgical specimen 
sent for routine histopathology 
 
Figure 6-1 – Outline of the collection and analysis of vulval tissue for Streamline Raman mapping and 
analysis  
6.4 Participant identification and sample collection 
Tissue samples were collected from women undergoing excisional vulval surgery as 
part of their routine care in five hospitals across the south west of England (Figure 




Figure 6-2 – Recruitment sites for the collection of vulval tissue.  
*tissue bank collection 
Patients with planned vulval excisional surgery were identified by clinicians providing 
specialist gynaecological care. Those identified gave written informed consent for 
inclusion into the study.  Prior to surgical resection the participant’s vulva was 
cleaned and prepared with 0.9% saline, 10% iodinated povidone solution or 0.05% 
chlorhexidine acetate solution according to the preference of the hospital and 
surgeon.  Figure 6-3 shows the Raman spectra from each of these solutions placed 
on a calcium fluoride slide.  All these solutions are water-soluble and can be readily 




Figure 6-3 – Raman spectra of skin cleansing solutions used in vulval excisions and biopsies 
(preparations placed within CaFl2 vessel and spectra collected for 90 seconds through x50 HWD 
objective) 
Immediately after the excisional surgery had been performed, research tissue 
samples were taken from the surgical resection specimen with a 6 or 8 mm Keyes 
biopsy punch. The size of the biopsies and the number of samples taken from each 
surgical specimen was dictated by the size of the specimen. It was necessary for 
adequate tissue to remain on the specimen to allow diagnostic histopathology for the 
patient’s routine care. Key features reported by histopathologists that are used in 
determining the ongoing care of patients include the involvement of the margins of 
the excision specimen with tumour and the distance of the closest disease free 
tissue margin. Tissue samples collected therefore did not include the margin of any 
specimen and samples were not taken between the primary lesion and the closest 
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surgical margin to ensure reporting of key findings was not affected. For smaller 
specimens (≤3 cm max diameter) a single punch was taken from near the edge of 
the disease lesion.  For larger specimens multiple punches were taken, including 
tissue from the primary lesion, tissue near the lesion and presumed non-neoplastic 





Figure 6-4 – A - Schematic of example tissue collection sites,  B - Photograph of anterior vulvectomy 
specimen showing tissue collection sites 
The samples taken were washed in 0.9% physiological saline; bisected; mounted 
onto cellulose acetate sheets (Sigma PC38378) to retain their correct orientation; 
placed into a 2ml Cryovial (Thermo Scientific) and snap frozen in liquid nitrogen prior 
to storage at -80OC. 
Tissue was also obtained from two tissue banks, the University of Exeter Clinical 




contributing to these tissue banks were consented by the recruiting teams using the 
standardised nonspecific tissue bank consent procedure. Tissue collected by the 
University of Exeter Clinical Research Facility was collected according to the 
protocol above. Tissue samples collected by the Imperial College Hospitals Tissue 
Bank did not follow the same procedure. In these cases strips of tissue were cut from 
surgical resection specimens, wrapped in aluminium foil and snap frozen in liquid 
nitrogen prior to storage at -80OC. These samples were transferred to the laboratory 
for processing frozen and packed in carbon dioxide pellets at a temperature of -
79OC. 
6.4.1 Sample preparation and selection 
Sections from the tissue samples collected were cut onto 1mm thick calcium fluoride 
windows using a standard low temperature cryostat. The cryostat mounting blocks 
were washed with detergent and rinsed with water prior to use and no cryo-
embedding media (e.g. optimal cutting temperature compound) except water was 
used to mount the samples. The use of optimal cutting temperature compound 
(OCT) was avoided to minimise the biomolecular differences between the tissue 
samples under analysis and tissue in vivo. OCT has been shown to contribute 
significant Raman signal in the fingerprint region and this alters Raman spectrum 
measured from tissue sections (Shim and Wilson, 1996). The use of OCT was not 
necessary in order to obtain satisfactory tissue sections. This technique has been 
demonstrated to preserve the biochemistry of the tissue samples closer to that of live 
tissue (Smith, 2005). 
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Frozen tissue sections between 5 and 25 microns thick were evaluated to assess the 
impact of increasing section thickness on the signal to noise ratio (chapter 4.1.2) 
(Figure 6-5). The thicker 20 and 25 microns sections produced the highest SNR 
however these sections were technically difficult to cut and place on calcium fluoride 
with a high incidence of failure. For this reason section thickness of 15 microns was 
chosen for the analysis. 
 
Figure 6-5 – Change in signal to noise ratio with changing frozen section thickness 
 
Standard 4 micron tissue sections were cut on to glass before and after each section 
cut onto calcium fluoride. These sections underwent H&E staining by a biomedical 
scientist followed by histopathological analysis by a specialist gynaecological 
histopathologist to select samples of non-neoplastic vulval skin, VIN and SCC for 
further spectroscopic analysis. Vulval skin that did not display histological features of 
intraepithelial neoplasia or malignancy was designated as non-neoplastic. 
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In total 231 vulval tissue samples from 73 participants were assessed for inclusion in 
the study. As the intended mechanism for validation of the classification model 
produced from the spectral data was an internal leave one out cross validation 
(chapter 4.2.5) duplicates of the same pathology in multiple samples from the same 
participant were excluded to avoid a type one error.  Samples containing malignant 
pathology not under investigation (e.g. adenocarcinoma) and samples where 
sections were of insufficient quality to allow histopathological diagnosis were also 
excluded from analysis. This left 91 samples from 64 participants that were suitable 


















Figure 6-6 – Summary of the participants included in the investigation (VIN – vulval intraepithelial 
neoplasia, SCC – squamous cell carcinoma & NON – non-neoplastic vulval skin) 
6.5 System instrumentation and experimental methods 
A modified Renishaw system 1000 Raman microspectrometer adapted to facilitate 
streamline map acquisition was used for the measurement of the tissue.  The 
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excitation laser was a Renishaw high power near infrared diode laser which supplies 
light at a wavelength of 830 nm. The laser generates 330 mW of power.  The 
excitation light is focussed through a Leica microscope fitted with a Leica x50 long 
working distance lens giving 70 mW of power at the sample. The elastically scattered 
light was rejected with a dielectric coated edge filter and a 300 line/mm grating was 
used to disperse the light onto the CCD. When operated in streamline imaging mode 
a laser line is projected onto the sample and the motorised stage is used to step the 
sample in the direction of the laser line. The movement of the motorised stage is 
synchronised with the readout on the CCD and when the entire line has passed over 
a single point on the sample a Raman spectrum is recorded. The recorded spectrum 
comprises an accumulation of the entire signal recorded by the CCD as the laser line 
passes over the sample. The streamline technique allows high spatial resolution 
maps to be acquired faster than with conventional point mapping without a reduction 
in spectral intensity. 
6.5.1 System calibration 
The streamline Renishaw System 1000 dispersion micro spectrometer required 
calibration prior to each use. Calibration allowed accurate recording of the Raman 
shift allowing the comparison of spectra collected at different times.  Without this 
calibration differences in the spectra may be present and these could be 




The calibration involved ensuring the grating of the detector is aligned so that the 
wavenumber shift recorded is accurate.  This was achieved by measuring the 
spectrum of a silicon standard that has a distinct peak at 520.4 cm-1 and, if required, 
adjusting the offset of the spectrometer to align the peak correctly.  The second 
calibration undertaken was an instrument response correction. For this correction, 
the Raman and fluorescence spectrum from a fragment of green glass (Figure 6-7) 
was measured. Illumination of the green glass with the 830 nm laser produced a 
broad fluorescence across the bio relevant wavenumber range (400 – 1800 cm-1). 
The true or standard spectrum of the green glass sample is calculated from 
calibration against a tungsten filament lamp, which in turn is calibrated against a 
calibrated spectrometer at the National Physics Laboratory, Teddington, UK. The 
instrument response correction adjusts for the varying sensitivity of the spectrometer 
across the wavenumber range by applying a correction based on a ratio of the true 
or standard green glass spectrum and the measured green glass spectrum (Figure 
6-8). The green glass is therefore a tertiary standard well suited to a regular 
instrument response correction, as a tungsten filament lamp is not required. In 
addition, the spectrometer laser beam can easily be focused on the glass and 
fluorescence recorded. This allows accurate instrument response correction under 





Figure 6-7 – Green glass standard spectrum and 
example of green glass calibration measurement 
Figure 6-8 – Green glass correction applied to 
spectra to compensate for variation in 
spectrometer sensitivity across the wavenumber 
range 
Further measurements of cyclohexane, a neon argon lamp and a polymer pipette tip 
were taken to cross check the calibration of the spectrometer. Characteristic 
wavenumber peaks are present in these standards across the bio relevant spectral 
range allowing identification of distortions in wavenumber spacing in the resultant 
spectra. The XYZ electronic stage was calibrated against a standard Vernier stage 
(Melles Griot, USA) to confirm accurate movement of samples under the microscope 
objective. 
6.5.2 Acquisition parameters 
The parameters of the system were optimised for the measurement of vulval tissue 
spectra.  The smallest available streamline step size of 1.1 microns was chosen as 
this facilitated accurate correlation between the streamline Raman spectral maps 
and the H&E stained sections. The effect of changing the streamline composite 
acquisition time was assessed using a 15 µm section of histologically normal vulval 
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tissue this showed a linear relationship between increasing acquisition time and 
signal to noise ratio (Figure 6-9). 
 
Figure 6-9 – Change in signal to noise ratio with changing spectral acquisition time 
An acquisition time of 60 seconds was chosen to allow spectral mapping of regions 
of interest on tissue sections within a practical timeframe whilst delivering good SNR. 
In the streamline mapping arrangement the spectral acquisition time equivalent to 
the acquisition time of static measurement (teq) is a function of the time it takes to 
translate the laser line across each pixel. The time taken (t) for the system to 
translate the laser line across a pixel of interest and the step size (Δx) is set when 
configuring the instrument to acquire a map. Using an x50 objective the laser line 
has a length of approximately 50 µm. Therefore for the x50 objective teq is given by 
Equation 6-1. Therefore the selected streamline acquisition time of 60 seconds is 




Equation 6-1 – Equation for calculating equivalent time for static acquisitions during streamline 
acquisitions 
The size of the spectral map acquired varied according to the individual sample as 
the shape and distribution of the epidermal cells varied considerably. When setting 
the acquisition area the objective was to acquire spectra from an area of the 
epidermis in which the pathology could be identified on the corresponding H&E 
stained section. 
6.5.3 Spectral preprocessing 
When the spectrometer is centered on 1150 cm-1 the range of the spectrometer is 
from 456 cm-1 to 1790 cm-1. This encompasses the majority of the biomolecular 
fingerprint region of the spectrum and the analysis used all available spectral data 
(Chapter 2.2.2). No adjustment was made to reduce the impact of cosmic rays 
during data acquisition however the spectral maps were median filtered after 
collection using a three by three filtering grid to reduce the impact of the cosmic rays 
(Chapter 4.1.3.1).  All spectra underwent an instrument response correction using 
the spectrum measured from the green glass as previously described (chapter 6.5.1) 
(Grimbergen et al., 2010). The spectra then underwent an extended multiplicative 
scatter correction (EMSC) to normalize the data to the mean of all the spectral data 
and correct the baseline created by auto fluorescence using a third order polynomial 
fit (Chapter 4.1.3.2) (Lieber and Mahadevan-Jansen, 2003). 
 
 161 
6.5.4 Constituent analysis 
The ability of Raman spectroscopy to identify the biochemical constituents of the 
tissue sections was assessed by comparison to standard commercially available 
compounds. The following constituents were selected as they represent the different 
areas within cells and the extracellular environment of vulval skin (Table 6-1).  DNA 
is representative of the cell nucleus and the contribution of DNA is clearly seen in 
Raman spectra (Talari et al., 2015). Other constituents present in the nucleus such 
as RNA and ribosomes have been demonstrated to only contribute minimally to the 
Raman scattering from the nucleus (Shafer-Peltier et al., 2002). Cholesterol is 
required to form membranes within cells and is a key component of the extracellular 
lamellae in the stratum corneum. Cholesterol is also associated with tissue necrosis. 
Glycogen is present within metabolically active cells and has also be found to be 
diminished in malignant tissue (Hata et al., 2000; Shafer-Peltier et al., 2002).  
Collagen is an abundant structural protein in the extra cellular matrix of the dermis 
and basement membrane. Type 1 collagen accounts for 85-90% of all dermal 
collagen and it is distributed in a fibrillar pattern within the dermis providing tensile 
strength to the skin (Epstein and Munderloh, 1978; Nguyen et al., 2013; Patterson, 
2016). 
The constituents were measured on the same modified Renishaw Raman system 
1000 as the tissue maps and the same x50 microscope objective used to focus the 
laser light on the surface of the sample. The monochromator slit was set to 50 µm 
and the laser was set to full power for all the samples.  The acquisition time was 
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optimised for each constituent in order to produce spectra with a high signal to noise 
ratio.  The individual spectra were time normalised to match the intensity of the 
tissue spectra. 
Constituent Raman shift (cm
-1) 
(Talari et al., 2015) 
Commercial 
compound Key physiology 
Collagen type I 1447-1450 Sigma C774-5MG 85-90% of dermal collagen 
Glycogen 1048, 1083, 1256 & 
1333 
Sigma G0885-5G Present within 
metabolically active cells 
Deoxyribonucleic 
acid 
722,752,782 & 1663 Sigma D4522-
5MG 
Representative of the 
cellular nucleus 
Cholesterol 699,882 Sigma C8667-1G Required to form 
membranes in cells & 
extracellular lamellae in 
the stratum corneum 
Table 6-1 – Summary of major bio molecular constituents of vulval skin 
The estimated relative concentrations of the measured constituents were plotted 
onto spectral streamline maps measured from vulval tissue sections. The relative 
concentrations of the constituent were estimated by the following technique. A green 
glass instrument response correction was applied to the constituent and tissue 
spectra. Following this the baseline of the tissue spectra were corrected by the 
subtraction of a second order polynomial and all data was vector normalised. The 
relative concentration of the measured constituents within the tissue was then 
estimated using a non-negative least squares technique. Figure 6-10 shows the non-
negative least squares coefficient plot for a section of normal vulval skin. This 
indicates that as expected the spectrum from the stratum germinosum and stratum 
spinosum demonstrates similarities with the spectrum from DNA, glycogen and 
cholesterol. The whole of the highly cellular epidermis shows similarities with 
cholesterol, consistent with the expected biochemistry. The spectra from the dermis, 
which is predominantly collagen, shows significant similarities with the spectrum of 
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type 1 collagen, the main type of collagen with the dermis. Also shown in Figure 6-10 
is a plot of the non-negative least squares coefficient of the spectrum of a calcium 
fluoride slide showing as expected high correlation with the non-tissue bearing area 
of the slide. This analysis demonstrates that Raman spectra can be used to 
delineate the biomolecular differences within vulval skin and shows promise for the 
detection of the biomolecular changes associated with carcinogenesis such as 
increases in DNA concentration and decreases in glycogen and collagen 








































































































































































Figure 6-10 – Non-negative least squares coefficient plot of tissue spectra compared to the 
constituents of the tissue spectra. A – H&E stained tissue section; B -  DNA spectrum; C – Type 1 
Collagen spectrum; D – Glycogen spectrum; E – Cholesterol and F – Calcium fluoride slide spectrum. 
6.5.5 Classification analysis 
For the purposes of this study epidermal cells were selected as the primary site for 
investigation as these cells are the most likely to contain measurable biomolecular 
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changes that relate to the pathological processes under investigation. To select the 
spectra to be used for the classification analysis the data from each individual map 
were separated using k means clustering with eight centroid clustering with seeded 
spectra from manually selected epidermal, dermal and stratum corneum spectra and 
five other tissue spectra randomly selected from the spectral map. This enabled 
manual selection of the spectra measured from the epidermal cells by reference to 
the H&E stained section and white light image of the unstained tissue section (Figure 
6-11). The spectra from the resultant k means relating to the epidermal cells were 
then saved for analysis. 
A 














Figure 6-11 – Example of area of epidermal cells selected by k means for further analysis. A – The 
three k means corresponding to the the epidermal cells in green, yellow and blue; B – the 
corresponding H&E stained section. 
Significant differences between those samples collected at remote sites was 
explored by applying ANOVA to the PC scores of the spectral data to assess if there 
were any significant spectral differences between groups. The F ratios for the 
individual PC scores did not reach significance for any of the external tissue sources 
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when compared to samples collected in the base hospitals of Cheltenham General 
Hospital and Gloucester Royal Hospital (Table 6-2). This suggested there is no 
significant difference in the spectra acquired from samples obtained from external 
sources compared with those collected locally. 
Table 6-2 – ANOVA F ratios for scores of first 24 principal components for external sample sources 





Bank vs. all other 
spectral data 
Musgrove park 




Hospital Bath vs. 
all other spectral 
data 
Royal Devon and 
Exeter Hospital 
vs. all other 
spectral data 
1 2.4535 0.0083 0.1903 0.1997 
2 0.1243 0.3293 0.0639 0.5753 
3 0.2642 0.0829 0.2932 0.0021 
4 1.3797 0.0573 0.0305 0.1414 
5 0.2067 0.0344 0.064 8.78E-04 
6 0.0237 0.0572 0.6639 0.6147 
7 0.0013 0.0092 0.0697 0.1126 
8 2.04E-05 0.167 0.0255 0.0964 
9 0.6778 0.0329 0.0963 0.0235 
10 0.0213 8.90E-04 0.0063 0.0357 
11 0.4312 0.0301 1.3483 0.3611 
12 0.0232 0.0335 0.1424 0.1111 
13 0.0126 0.0228 0.2391 0.0676 
14 0.0019 0.2051 0.0597 0.7858 
15 0.0536 0.0203 0.1535 0.3908 
16 0.407 0.0557 0.3665 0.0152 
17 0.0834 0.0039 0.0199 0.8154 
18 0.2201 0.0056 0.0075 7.03E-04 
19 0.5466 0.0528 0.8016 0.122 
20 0.3656 0.0033 5.18E-04 1.3599 
21 0.0131 0.0394 0.0643 0.0084 
22 0.0012 0.0438 0.0026 0.9913 
23 0.6755 0.001 0.0446 0.5609 
24 0.0151 0.1951 0.0191 0.7171 
 
The regions of interest as determined by k means clustering were then spatially 
binned to improve the signal to noise ratio of the spectra used for the analysis. The 
effect of the binning on the classification accuracy of the technique was assessed 
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using simple PCA LDA classification analysis and the increased binning was found 
to increase the performance up to bins of eleven beyond which there was only 
marginal benefit to increasing the binning further with the loss of spatial resolution 
(Figure 6-12). 



















Figure 6-12 – Area under the curve for identifying SCC from VIN using PCA fed LDA with increasing 
bin size. 
The tissue spectra were then mean centred and filtered for outlying spectra using the 
D and Q classifiers (Chapter 4.2.6.1). Analysis of the effect of filter in the data with 
the D and Q statistic shows a modest improvement in the diagnostic performance 
with exclusions (Figure 6-13 and Figure 6-14). In both the D and Q exclusions, the 
most significant improvement in diagnostic performance appears to occur up to a 


























Figure 6-13 – Variation in the area under the ROC curve for identifying SCC from VIN using non-cross 






















Figure 6-14 – Variation in the area under the ROC curve for identifying SCC from VIN using non-
crossvalidated PCA fed LDA with increase exclusions using Q statistic 
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Classification performance was initially assessed using PCA LDA in a leave one 
sample out cross validation loop (Chapter 4.2.5). The data analysis performed is 
summarised in Figure 6-15 with details of the cross validation used given in Figure 
6-16. Application of a final filter for spectra that do not fit well within the LDA 
classification model using the Mahalanobis distance with a confidence threshold of 
0.95 also results in a modest increase in diagnostic performance. The area under the 
AUC curve for identifying non-neoplastic tissue from SCC and VIN using non-cross 
validated PCA fed LDA increased by 0.02 when excluding spectra with a confidence 
of 0.95.  Final predictions were therefore filtered by Mahalanobis distance to the 
mean of each of the LDA groups (4.2.6.2). The classification performance of the 
PCA-LDA model was assessed on its ability to correctly classify the histological 




Unprocessed tissue spectral data with 
associated pathologies 
K means selection of epidermal 
regions 
EMSC for normalisation to the mean 
spectrum and third order polynomial 
baseline correction 
Leave one out cross validation 
Final predications: spectral and 
sample classification 
Corrected data 
Interpolation to standardised 
wavenumber range 
Green glass instrument response 
correction 
Classification of spectra and 
assignment to pathology group  
Binning of spectral data 
 
Figure 6-15 – Flow chart of data analysis of streamline Raman mapping measurements see Figure 
6-16 for details of cross validation loop 
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Mean of each sample mean centered 
PCA PC loadings 
All data centered to mean of training 
sample means 
Scores for PC loadings 
Scores for PC loadings 
ANOVA to select significant PC 
loadings (95% confidence) Significant PC loadings 
Scores from significant PC loadings 
LDA 
Classification of spectra and 
assignment to pathology group  
Complete set of corrected data 
Mean centered TRAINING set 
(individual spectra) 
Mean centered TEST set 
(mean of training set) 
PCA of mean spectrum from each 
sample 
Scores and loading of training set 
DQ exclusion of spectra that are not 
well described by training PCs 
DQ filtered training set 
DQ exclusion of spectra that are not 
well described by training PCs 
DQ filtered test set of individual 
spectra 
Mean of training sample 
means 
(Each	sample	excluded	in	turn)	
Exclusion of whole sample test set 
Recombination of data 
Combined classification of spectra 
and assignment to pathology group  
Exclusion of predictions by 
Mahalanobis distance from mean of 
each group  
Figure 6-16 – Leave one whole sample out cross validation loop used for analysis of streamline 
spectral data 
6.6 Results 
A total of 91 different samples measured from 64 different participants underwent 
spectroscopic mapping and a total of 8,409,500 individual epidermal spectra were 
measured (Table 6-3). No participant contributed more than one sample of the same 




Table 6-3 – Summary of mapping measurements recorded 
Pathology group 
Number of 






Non-neoplastic 30 2,190,221 
Vulval intraepithelial 
neoplasia 30 2,327,556 
Squamous cell 
carcinoma 31 3,891,723 
 
To investigate the basis of the classification in cross-validation an initial PCA LDA 
analysis of the whole spectral data set was undertaken. This revealed that 90% of 
the variance in the data was accounted for in the first 12 PCs with 85% of the 
variance in the first 6 PCs (Figure 6-18). When ANOVA was applied to the PC 
scores and the known pathology groups of the whole data set, the significance of 
each PC for the classification of the disease state was assessed. The ANOVA F 
ratios for each PC are shown in Figure 6-19. Much of the variance in the data set is 
due to noise, variation within individual spectral maps or variation between spectral 
maps of the same pathology rather than due to pathological differences. As a result 
the most significant PCs as selected by ANOVA do not correspond to those that 
describe the most variance in the data. 
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Figure 6-17 – Mean spectra of the pathology groups. Non-neoplastic vulval skin; VIN – vulval 
intraepithelial neoplasia and SCC – squamous cell carcinoma. 
 
LDA of the significant PC scores demonstrated that the pathology groups could be 
separated by LD scores as shown in the histogram of the LD scores by pathology 
























Figure 6-18 – Variance in data described by each principal component. 
 



































Figure 6-20 – Histogram of linear discriminant scores (VIN – vulval intraepithelial neoplasia, SCC – 
squamous cell carcinoma & non-neoplastic vulval skin) 
The LD scores plot showed some overlap between the groups with more significant 
overlap between the non-neoplastic group and the VIN group. Of note the non-
neoplastic group also appears to have bimodal appearance suggestive of the 
possibility of two subgroups. This is unsurprising given this group will encompass a 
range of benign vulval conditions such as lichen sclerosus. 
The weightings given to each PC loading by the two linear discriminant functions are 
illustrated in Figure 6-23. There are several principal components with scores that 
show relatively small difference between the pathology groups using ANOVA but that 
are highly weighted in the linear discriminant model (e.g. PC score 20, Figure 6-24). 
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An explanation for this is that ANOVA is performing a univariate analysis of 
orthogonal principal components to assess which component scores contain the 
largest difference between the pathology groups. Therefore the loadings of the most 
significant ANOVA selected principal components are representative of differences 
in the spectra between the pathology groups. In addition as the principal components 
are orthogonal each loading represents a separate set of spectral differences 
between the pathology groups. The multivariate LDA does not treat the principal 
components as orthogonal and uses a combination of components to achieve 
separation of the pathology groups. In this process components are combined to 
achieve the maximum between group variance whilst minimising the intragroup 
variance. This combination of components means that assessing the loadings of 
individual components to understand the spectral differences between the groups is 
best achieved by examining the most significant loadings by LDA weighting rather 
than the most significant by ANOVA. To assess the overall spectral differences 
important in the LDA group classification we can consider the composite of all the 
PC loadings weighted by contribution to the LDA classification. In a three group 
model this results in two composite loadings to be interpreted alongside the 
distribution of the LD scores of the pathology groups, the mean spectra and the 















0.15 PCA LDA Loading 1
PCA LDA Loading 2
 
Figure 6-21 – Composite PCA LDA loading 
 
The leave one out cross-validated PCA LDA classification model with DQ filtering of 
outlying spectra (Figure 6-15) demonstrated good classification of the three 
pathology groups. Table 6-4 shows the confusion matrix for the classification of the 
samples analysed with the linear discriminant boundary set midway between the 
pathology groups. Due to the larger number of spectra in the SCC and VIN groups 
the confusion matrix is likely to show unfavourable performance in the detection of 
SCC and to a lesser extent the VIN group. Importantly no samples of non-neoplastic 
tissue were misclassified as samples of SCC and no samples of SCC were 


































































Figure 6-23 – Weight of the contribution of each principal component score to the linear discriminant 
model. In a three group model two linear discriminant functions are required to separate the groups 
and these are represented by function1 and function 2. 
 















Table 6-4 – Confusion matrix for whole samples based on modal classification of spectra with linear 
discriminant boundary midway between the pathology groups, rows are true pathology group and 
columns are predictions. 






Non-neoplastic 23 7 0 
Vulval intraepithelial 
neoplasia 6 20 4 
Squamous cell 
carcinoma 0 2 29 
 
The overall probabilities of group membership were calculated from the combined 
individual discriminant distances of the spectra in each group and plotted on a 
ternary plot to allow visualisation of the distribution of correctly and incorrectly 
classified samples (Figure 6-25). The ternary plot demonstrates that it is possible to 
define alternative discriminatory boundaries to tailor the classification to the clinical 
need. Table 6-5 demonstrates the alternative classification performance that can be 
achieved through alteration on the discriminatory boundary (Figure 6-25). With the 
modified boundary SSC is detected with a sensitivity of 100% and specificity of 93% 







Figure 6-25 – Ternary plot of the predicted probabilities of a sample belonging to the three pathology 
groups under analysis. Non-neoplastic vulval skin, VIN - vulval intraepithelial neoplasia , SCC - 
squamous cell carcinoma. Legend indicates actual pathology of sample shaded areas show 
classification of samples based on discriminant boundary midway between groups. Solid lines 





Table 6-5 – Confusion matrix for whole samples based on combined probability of 
spectra with modified discriminatory boundary between the pathology groups, rows 
are true pathology group and columns are predictions. 






Non-neoplastic 23 7 0 
Vulval intraepithelial 
neoplasia 6 20 4 
Squamous cell 
carcinoma 0 0 31 
 
To further assess the classification performance of the technique, receiver operator 
curves were plotted whilst varying the linear discriminant boundary. Comparisons 
were undertaken of the most clinically useful classifications as outlined in chapter 
3.4.1. The first comparison looked at the ability of the technique to determine 
disease margins at the time of surgery for excision of VIN or SCC. The performance 
for the correct identification of non-neoplastic tissue from VIN or SCC using binned 
individual spectra is shown by the receiver operator curve in Figure 6-26. For 
individual binned spectra the area under the receiver operator curve is 0.95 and 
sensitivities of 82-98% can be achieved with specificities of 92-72%. 
Each sample was also classified as SCC or VIN or non-neoplastic based on a 
threshold number of spectra that were classified as SCC or VIN. Using this approach 
and varying the threshold proportion of spectra used to classify the sample as SCC 
or VIN a receiver operator curve was created (Figure 6-27). The area under the 
curve is 0.89 indicating good performance for the identification of samples of SCC or 
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VIN from non-neoplastic vulval skin. Using this approach a sensitivity of 
approximately 97% can be achieved with a corresponding specificity of 71% with the 
number of abnormal spectra used to classify the sample of 3%. 















Figure 6-26 – Receiver operator curve for the 
detection of non-neoplastic tissue from SCC and 
VIN per spectrum. Area under curve, 0.95,  
Probability of falsely rejecting null hypothesis, 
<0.05 
 















Figure 6-27 – Receiver operator curve for the 
detection of non-neoplastic tissue from SCC and 
VIN per sample. Area under curve, 0.89,  
Probability of falsely rejecting null hypothesis, 
<0.05 
The second comparison undertaken assessed the role of correctly identifying SCC 
from VIN as this would be useful when monitoring women with VIN for progression to 
SCC. In this comparison the receiver operator curves for the technique are shown in 
Figure 6-28 and Figure 6-29. The results indicate that the technique shows promise 
for the identification of malignant change in premalignant vulval disease. 
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Figure 6-28 – Receiver operator curve for the 
detection of SCC from VIN per spectrum. Area 
under curve, 0.92,  Probability of falsely rejecting 
null hypothesis, <0.05 
 















Figure 6-29 – Receiver operator curve for the 
detection of SCC from VIN per sample. Area 
under curve 0.97,  Probability of falsely rejecting 
null hypothesis <0.05 
 
Similarly the technique also has good performance in the separation of SCC from 
non-malignant vulval skin (non-neoplastic and VIN). This is illustrated in the ROCs in 
Figure 6-30 and Figure 6-31. 















Figure 6-30 – Receiver operator curve for the 
detection of SCC from VIN and non-neoplastic 
tissue per spectrum. Area under curve, 0.95,  
Probability of falsely rejecting null hypothesis, 
<0.05 
 















Figure 6-31 – Receiver operator curve for the 
detection of SCC from VIN and non-neoplastic 
tissue per sample. Area under curve, 0.96,  





6.7 Spectral analysis 
Analysis of the spectral differences between the non-neoplastic, premalignant and 
malignant vulva tissue was undertaken to understand the basis for disease 
classification using Raman spectra. Identification of specific biomolecular 
contributions to the spectral differences can be challenging, as at many wavelengths 
there is significant overlap between a number of possible bond vibrations and 
possible biomolecules present within the tissue. This overlap means that a given 
spectral appearance may have more than one possible molecular cause and hence 
assignment of spectral peaks to individual molecules is purely tentative. 
Understanding which biomolecules contribute to which peaks can be achieved 
though consulting the relevant reference literature and measurements of pure 
biomolecules made on the same Raman spectrometer (Barry, Edwards and 
Williams, 1992; Kendall, 2002; De Gelder et al., 2007; Isabelle, 2009; Talari et al., 
2015).  
Within the Raman vulval spectrum it is possible to tentatively identify some key 
molecular components. The major peaks present within the epidermal spectra can 
be assigned as follows: between 936 to 943 cm-1 there is a clear peak due to C-C 
stretching within proline and valine; from 1003 to 1005 cm-1 there is a peak due to a 
phenyl aromatic ring (breathing mode); between 1065 and 1094 cm-1 there is a 
combination of protein vibrations, phospholipids and nucleic acids; from 1243 to 
1258 cm-1 there is phosphate from phospholipids and nucleic acids; The amide II 
protein band is found between 1267 and 1279 cm-1; from 1301 to 1321 cm-1 there is 
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a peak caused by CH2 in lipids; the peak between 1449 and 1453 cm-1 a peak is 
present comprising signal from protein and lipid and the Amide I is found between 
1653 to 1669 cm-1 (Gniadecka et al., 1997; De Gelder et al., 2007). These spectral 
features are seen in the mean spectra of the pathology groups as shown in Figure 
6-32. 
Gniadecka et al. described changes in Raman spectra from whole non vulval skin 
found in association with the development of SCC of skin (Gniadecka et al., 1997). 
These include a right shift in the Amide I band of proteins at 1661 cm-1; decrease in 
the Amide III peak intensity at 1271 cm-1; widening of the protein and lipid peak at 
1451 cm-1; an increase in the intensity of the phenylalanine peak at 1003 cm-1; 
reduction in intensity of the peak at 939 cm-1 due to the C-C stretching mode of 
proline and valine and an increase in peak intensity at 1080 cm-1 due to phosphate in 
nucleic acids and phospholipids. This analysis was based on Raman spectra taken 
from whole tissue biopsies and was based on the analysis of just three participants 
with non-vulval SCC. 
Within the spectral data from this study many of the features associated with 
malignancy reported by Gniadecka et al. can be found (Gniadecka et al., 1997; De 
Gelder et al., 2007). These include the right shift in the 1661cm-1 Amide I band, 
widening of the peak at 1451 cm-1; a reduction in peak intensity at 939 cm-1, an 
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Figure 6-32 – Mean spectra of pathology groups with putative spectral peak assignments 
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In addition a number of further spectral differences can been observed when 
comparing neoplastic with non-neoplastic tissue spectra. These include increased in 
the prominence of the peaks at 723 cm-1, 782 cm-1, 830 cm-1, 1101 cm-1 likely to 
represent DNA (720-722 cm-1, 782 cm-1, 1101 cm-1), RNA (782 cm-1) and nuclei 
acids (724 cm-1, 830 cm-1) and this would be consistent with the increase rate of cell 
proliferation in neoplastic tissue (Talari et al., 2015). A reduction is seen in the 
mono/disaccharide peak at 899 cm-1 consistent with high metabolic activity in active 
neoplastic tissues.  There is also an increase in the peaks at 756 cm-1, 855 cm-1, 
1287 cm-1, 1558 cm-1 and a reduction in the peak prominence at 1622 cm-1. These 
peaks relate to amino acids including tryptophan, proline, tyrosine and cytosine as 
well as complex proteins including collagen. The 1622 cm-1 peak is most likely to 
represent tryptophan or the effects of hydrogen bond formation. Other identifiable 
changes in the spectra with malignant transformation are shown in Table 6-6. 
Table 6-6 – Spectral peaks contributing to disease classification 
Wavenumber 
(cm-1) 
Suggested biomolecular constituent allocation and change with malignant 
transformation where apparent 
529 Decrease in desmosine & isodesmosine (amino acids in elastin) 
548 Decrease cholesterol 
573 Decrease in tryptophan/cytosine, guanine 
621 Decrease C-C twisting mode of phenylalanine (proteins) 
639 Decrease in tyrosine ring breathing 
645 Decrease C-C twisting mode of phenylalanine (proteins) 
667-669 Increase C-S stretching mode of cystine (collagen type I), T, G (DNA/RNA) 
702 Decrease cholesterol, cholesterol ester 
720-722 Increased prominence of DNA peak 
756 Increased prominence of amino acids including tryptophan, proline, tyrosine and cytosine peaks as well as complex proteins including collagen 
782 Increased prominence of DNA peak 
813 Increase RNA and collagen 
830 Increased prominence of DNA peak 
855 Increased prominence of amino acids including tryptophan, proline, tyrosine and cytosine peaks as well as complex proteins including collagen 
899 Reduction in the mono/disaccharide peak 
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939 Reduction in intensity of the C-C stretching mode of proline and valine 
957 Decrease carotenoid, cholesterol 
980 Decrease in C-C stretching β-sheet (proteins) 
1006 Increase phenylalanine, δ(ring) 
1035 Decrease collagen 
1053 Increase C-O stretching, C-N stretching (protein) 
1080 Increase in peak intensity due to phosphate in nucleic acids and phospholipids 
1101 Increased prominence of DNA peak 
1128 Increase C-N stretching (proteins) 
1157 Increase β-Carotene accumulation (C C stretch mode) 
1177 Cytosine, guanine 
1210 tyrosine and phenylalanine 
1224 Amide III (β sheet structure) 
1245 Amide III 
1269 Increased prominence amide III band of proteins 
1287 Increased prominence of amino acids including tryptophan, proline, tyrosine and cytosine peaks as well as complex proteins including collagen 
1319 Guanine (B, Z-marker) CH3CH2 twisting (collagen assignment) 
1342 CH deformation (proteins and carbohydrates) 
1359 Increase in tryptophan 
1379 Increase in δCH3, δOH symmetric (lactic acid) 
1404 CH deformation (proteins and carbohydrates) 
1416 Decrease C=C stretching in quinoid ring 
1451 Widening of the protein and lipid peak 
1499 C-C stretching 
1526 Decrease in carotenoids 
1558 Increased prominence of amino acids including tryptophan, proline, tyrosine and cytosine peaks as well as complex proteins including collagen 
1586 Phenylalanine, hydroxyproline 
1608-10 Cytosine (NH2) 
1622 Decreased prominence in tryptophan peak or decreased effects of hydrogen bond formation 
1645 Right shift Amide I (α-helix) 
1661 Right shift in the Amide I band 
1697 Right shift Amide I (turns and bands) 
1743 Lipid in stratum corneum 
Wavenumber assignments from Kendall, Talari et al. and Nguyen et al. (Kendall, 2002; Nguyen et 
al., 2013; Talari et al., 2015) 
 
The technique applied in this study allowed for the isolation of the epidermis, the 
region of vulval skin affected by neoplastic change and a more detailed analysis of 
the changes present within this skin layer. Compared to the currently published 
literature assessing whole samples of non-vulval skin this study has identified a 
number of additional spectral changes associated with malignant transformation in 
the vulval as outlined above.  The relevance of these changes to malignant 
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transformation at other skin sites is less clear.  The different pathogenic process that 
lead to the development of vulval SCC may explain the distinctive spectral changes 
identified in this study compare with the published studies assessing squamous 
neoplasia at other anatomical sites (C. A. Lieber et al., 2008; J Zhao et al., 2008; 
Zhao et al., 2010; Lui et al., 2012). Analysis of the role of the identified spectral 
changes in the PCA LDA classification model using the composite PCA LDA 
loadings demonstrates these changes appear to be important in the biomolecular 
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Figure 6-33 – Composite PCA/ LDA loadings with putative spectral peak assignments 
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6.8 Interim discussion 
[Summative discussion and conclusions relating to the investigations outlined in 
Section C relating to Raman spectroscopy for the assessment of vulval disease can 
be found in Chapter 13] 
The primary aim of this investigation was to investigate the potential for Raman 
spectroscopy to provide a valuable clinical tool in the management of premalignant 
and malignant vulval disease.  This is the first reported study to analyse fresh frozen 
vulval tissue using streamline Raman mapping measurements. This study has 
demonstrated the ability of the technique to discriminate between non-neoplastic 
vulval tissue, vulval intraepithelial neoplasia and vulval squamous cell carcinoma 
with clinically relevant sensitivity and specificity. To our knowledge this is the first 
investigation to demonstrate this technique can be applied to these unique 
pathologies present within the human vulva. We have used novel methods of 
analysis developed for this study that combine classifications of grouped spectra 
across a spectroscopic map to give predictions for individual spectra and whole 
samples.  
This study demonstrates that Raman spectra measured from samples of SCC can 
be differentiated from those from VIN or non-neoplastic vulval skin combined with a 
sensitivity of 97% and specificity of 78% (Figure 6-30) and that SCC can be 
differentiated from VIN alone with a sensitivity of 93% and specificity of 70% (Figure 
6-28). This suggests the technique could deliver clinically useful diagnostic accuracy 
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for the purposes of diagnosis and monitoring disease progression. This study also 
demonstrates Raman spectra from neoplastic tissue and from non-neoplastic vulval 
skin can be classified with a sensitivity of 97% and associated specificity of 70% 
(Figure 6-26) suggesting the technique could deliver clinically useful diagnostic 
accuracy to determine disease margins in the surgical setting. 
The spectral multivariate analysis performed in this investigation demonstrates the 
potential utility of Raman spectroscopy in the management of vulval disease. This 
investigation demonstrates that Raman spectroscopy has real promise for the 
classification of vulval disease and that the technique is able to provide clinically 
useful diagnostic performance within the laboratory setting and therefore warrants 
further investigation. 
This investigation was performed under strictly controlled laboratory conditions with 
research grade spectrometers, selecting only epidermal cells for the multivariate 
analysis. The techniques utilised are of limited direct clinical application as the 
preparation of paraffin free tissue sections and streamline Raman mapping is 
technically challenging and time consuming. Analysis of tissue in this way could be 
used as an adjunct for routine histopathological analysis but it is likely that other 
techniques such as FTIRS would be better suited to this purpose (Chapter 11). 
Although the approach used in this investigation yielded high diagnostic performance 
it is necessary, within the bounds of ex vivo experimentation, to evaluate the 
technique in conditions that are a closer approximation to in vivo application. The 
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experiments outlined in the following chapters are designed to test the technique 
under conditions that more accurately reflect the clinical environment. 
Further discussion of future work and the steps necessary to translate these finding 
into clinical practice is located in Chapter 13. 
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Chapter 7 ExVivo Transepidermal Raman 
Spectroscopy for the Classification of Vulval 
Disease 
7.1 Introduction 
The investigation outlined in Chapter 6 demonstrated that Raman spectroscopy 
coupled with multivariate analysis is able to differentiate between Raman streamline 
micro spectra from the epidermis of non-neoplastic and neoplastic vulval skin. In 
order to be successful as a clinical diagnostic tool it is necessary to be able to 
differentiate between these tissue types using spectra collected in-vivo. Clearly it is 
not possible to perform mapping of tissue sections in-vivo so in working towards in-
vivo application it is crucial to evaluate the classification accuracy of the technique 
using Raman spectra collected from the surface of vulval skin without isolation of the 
epidermal cell layers. As we have previously demonstrated in chapter 6.5.4 the 
biomolecular composition of the stratum corneum epidermis and dermis varies 
significantly. Due to this variation the Raman spectra obtained from vulval skin using 
surface (trans-epidermal) measurement is different from those obtained from tissue 
sections as there is a contribution from all the tissue layers. This variation may 
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impact on the classification accuracy of the technique as key features may be 
distorted by features from biomolecules more abundant in the stratum corneum or 
dermis for example type 1 collagen, elastin and keratin. In light of this anticipated 
complication of the Raman spectra the next stage in the investigation was to analyse 
tissue samples using high quality laboratory bench based spectrometers even 
though these cannot easily be applied to the in vivo setting. This was done to build a 
foundation for further experimentation with probe systems that can technically be 
applied to the vulva in vivo. 
7.2 Objectives 
This investigation assesses objective 2a and 2b of the aims and objectives outlined 
in Chapter 5. 
To evaluate the ability of Raman spectroscopy applied to the surface of fresh and 
fresh frozen bulk tissue to classify vulval disease. 
a) Evaluate Raman spectroscopy applied to fresh vulval tissue for the diagnosis of 
clinically inconclusive vulval lichen sclerosus. 
b) Evaluate Raman spectroscopy applied to fresh frozen tissue for the classification 
of non-neoplastic vulval skin, premalignant and malignant disease of the vulva. 
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7.3 Overview of investigation 
In this investigation the disease classification capability of Raman spectroscopy 
applied directly to the surface of blocks of vulval epithelium was evaluated. This was 
accomplished by the analysis of blocks of fresh vulval epithelium taken at the time of 
diagnostic biopsy or blocks of fresh frozen vulval tissue collected at the time of 
surgical excision. These blocks of tissue underwent Raman spectroscopy prior to 
routine histopathological analysis. An outline of the investigation is shown in Figure 
7-1.  
 




Two separate comparison groups were analysed, simulating two different clinical 
scenarios where there is the potential for Raman spectroscopy to perform an 
important role as a tool capable of classifying the disease present within the tissues. 
7.3.1.1 Comparison one 
In the first comparison the role of Raman spectroscopy in the assessment of women 
suspected to have a diagnosis of LS, in whom a clinical diagnosis could not be 
established with confidence, was explored. National guidelines suggest when LS is 
suspected and a diagnosis cannot be made on clinical grounds alone then invasive 
biopsy is indicated (Edwards et al., 2015). Biopsy samples taken from women with 
suspected lichen sclerosus were analysed in this comparison. The main differentials 
when a patient is undergoing biopsy for suspected LS are non-specific inflammation 
due to other causes or variants of normal vulval skin. It is important to establish the 
correct diagnosis as this dictates the most appropriate management. Furthermore, 
LS is associated with an increased risk of malignant transformation and as such 
requires surveillance (Edwards et al., 2015). Comparison of spectral data collected 
from these tissue types allows us to investigate the role of Raman spectroscopy in 
reducing the need for invasive biopsy for the diagnosis of LS, a common vulval 
condition. The spectral characteristics of LS are explored and the diagnostic 
performance assessed. 
In addition to analysis of the study group it would have been desirable to investigate 
LS in patients in whom clinical diagnosis is possible in order to characterise the full 
range of the disease. In this preliminary ex vivo study this was not possible as taking 
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invasive biopsies for research purposes alone was reported to be unacceptable to 
women during initial consultation with patient representatives. This also meant that 
obtaining tissue for ex vivo analysis of a normal control group was unacceptable to 
women, limiting the experimental design. 
7.3.1.2 Comparison two 
The second comparison assesses the role of Raman spectroscopy in the 
identification of non-neoplastic, premalignant and malignant vulval disease. This 
comparison simulates the role of Raman spectroscopy for both the diagnosis of 
disease and the identification of disease margins at the time of surgery. In this 
comparison samples of tissue taken from women at the time of biopsy or surgery for 
VIN or SCC were analysed, comparing non-neoplastic, pre-malignant and malignant 
vulval tissue. The specimens used were from the same cohort of patient as the 
specimens used in the investigation outlined in Chapter 6. 
7.4 Participant identification and sample collection 
As shown in Figure 7-1 two types of sample collection were used in this study: 
diagnostic biopsy specimens and samples collected from surgical resection 
specimens. Only biopsy specimens were used in the analysis for comparison one 




7.4.1 Participant identification and sample collection – 
diagnostic biopsies 
Women referred to specialist gynaecology services at Gloucestershire Hospitals 
NHS Foundation Trust for assessment of vulval complaints were considered for 
recruitment to the study. Clinicians providing specialist gynaecological care identified 
women with a suspected diagnosis of lichen sclerosus who required invasive biopsy 
due to diagnostic uncertainty as part of their routine care. The women identified gave 
written consent for recruitment to the study. Vulval biopsies were collected using a 4 
mm Keye’s biopsy punch with physiological (0.9%) saline skin preparation and 2% 
lidocaine subdermal infiltration for anesthesia. 2% lidocaine solution was used as it 
has a less significant Raman profile compared to other commonly used local 
anesthetic solutions (Figure 7-2).  The Raman spectra from commonly used local 
anaesthetics: 2% lidocaine hydrochloride with adrenaline 1:80,000, 3% prilocaine 





Figure 7-2 – Raman spectra of commonly used local anaesthetic preparations (preparations placed 
within CaFl2 vessel and spectra collected for 90 seconds through x50 HWD objective) 
 
This tissue collection procedure results in a circular disc of vulval epithelium 3-4 mm 
in diameter, comprising the full thickness of the epidermis with underlying dermal 
tissue.  The location and number of biopsies collected was directed by clinical need 
rather than the requirements of the research. Biopsies were washed and transported 
in physiological (0.9%) saline to prevent dehydration to the on-site spectroscopy 
laboratory for immediate analysis. After spectral analysis samples were marked with 
dye to allow orientation and fixed in formalin for paraffin embedding, sectioning, H&E 
staining and histopathological analysis. No additional tissue was taken from patients 
solely for the purposes of the research. 
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7.4.2 Sample collection – surgical resection specimens 
Samples were collected from women undergoing vulval excisional surgery as 
described in chapter 6.3. 
7.5 Instrumentation and experimental methods 
The Raman spectrometer used for the collection of the transepidermal spectra from 
the vulval tissue was a modified Renishaw system 1000 dispersion micro 
spectrometer optimised for tissue analysis in the near infrared range.  The 
spectrometer excitation beam came from an 830 nm laser with a power output of 330 
mW.  This was connected to a Leica confocal polarise light microscope with a 
motorised stage and selection of objective lenses, chosen for their minimal 
fluorescence and Raman signature.  The elastically scattered light was rejected with 
a dielectric coated edge filter and the inelastically scattered light passed through a 
monochromator slit set to 50 µm onto a 300 line/mm grating which was used to 
disperse the light onto the CCD. The spectrometer and stage were controlled via a 
computer interface running Renishaw WIRE software (version 2.0, service pack 9). 
7.5.1 System calibration 
As with the streamline Renishaw system 1000 microspectrometer the system 
required calibration prior to each use with silicon standard as previously described 
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(chapter 6.5.1). A green glass and other standards were also measured to enable 
correction for variations in instrument response (chapter 6.5.1). 
7.5.2 Spectroscope objective characteristics 
The choice of microscope objective determines the size of the acquisition volume 
and the quality of the spectra produced.  An objective with a strong Raman signal 
may mask subtle tissue spectra.  The Raman spectra of the standard objectives 
used with this system were tested by focussing the objective on a polished chromium 
surface in order to measure the Raman signal from light traveling in both directions 
through the objective, these are shown in Figure 7-3.  Both the x2.5 and the x5 
objectives have significant Raman signal, which could mask the tissue spectra.  The 
x50 and x80 objectives have relatively low Raman signal and were found to be 
suitable for the collection of tissue spectra. A larger beam size makes 
histopathological correlation more practical as the Raman signal is collected from a 
larger area and is more likely to be representative of the tissue as a whole.  As the 
x50 objective had the largest beam size of the two lowest Raman signal objectives it 
was chosen for the analysis. Advancing the beam produced by the x50 objective into 
a silicon wafer whilst recording the resultant Raman spectra was used to assess the 





Figure 7-3 – Raman spectra of different microscope objectives with 60 second acquisition time. 
 
























Figure 7-4 – Counts at 520.4 cm-1 as silicon wafer is advanced towards x50 HWD objective,  full width 
half maximum of peak is 17 microns. 
7.5.3 Sample mounting 
Samples needed to be securely mounted to facilitate reproducible spectral 
measurements across the sample and to prevent the sample drying out.  In order to 
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allow reproducible standardised collection of spectra at set depths through the vulval 
skin samples they needed to be mounted perpendicular to the beam from the 
spectroscope.  Initial experiments with samples placed directly onto calcium fluoride 
slides within a droplet of 0.9% saline resulted in drying of the tissue.  This drying led 
to disorientation of the sample surface during spectral acquisition.  Samples were 
also mounted within a polymer cone (pipette tip) and this allowed appropriate sample 
orientation, however samples were still subject to drying over the long acquisition 
times.  In addition the surface of the samples was not level and this made acquisition 
of adjacent spectra challenging.  The addition of a 250 micron calcium fluoride cover 
slip both retained the moisture within the samples and produced a level surface for 
the acquisition of multiple spectra across the sample (Figure 7-5). Figure 7-6 shows 
the spectra acquired from the materials that made up the trial sample mount (calcium 
fluoride, polymer cone, polymer black foam and coated alloy). A laser power meter 
was used to assess the impact of the calcium fluoride cover on the laser power.  
With the x50 objective the laser power at the sample is on average 5.9 mW, when a 
0.25 mm calcium fluoride window is placed in front of the power meter the power 
remains at 5.9 mW, therefore the window does not adversely affect the intensity of 





Figure 7-5 – Prototype tissue mount for Raman spectroscopy (not to scale) 
 
 
Figure 7-6 – Raman spectra of materials comprising prototype mounting system 
This mounting system was tested using chicken skin biopsies, Figure 7-7 shows 
point spectra from a 4 mm punch biopsy in the prototype mounting without cover slip, 
in the prototype mounting with 0.25 mm calcium fluoride cover slip and placed on a 
calcium fluoride slide.  The primary drawback with this mounting method was the 
lack of a mechanism for ensuring the proximity of the sample and the calcium 
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fluoride window.  When the sample was not in close contact with the calcium fluoride 
window the spectra acquired from the tissue are significantly affected (Figure 7-8).  
 
Figure 7-7 – Raman spectra of 4 mm chicken skin biopsy using different mounting methods 
 
 




To overcome the problem of consistent contact of the sample with the calcium 
fluoride window a second mounting system was designed to allow increased and 
even pressure of the sample on the window (Figure 7-9). The threaded plunger and 
secured calcium fluoride window allowed the sample to be pressed against the 
window, reducing poor contact between the two. 
 
Figure 7-9 – Design for sample mount (not to scale) 
7.5.4 Optimisation of parameters for spectral measurement of 
fresh bulk tissue 
The signal to noise ratio (SNR) of measured tissue spectra was used to optimise the 
experimental setup and acquisition parameters. The signal was calculated as the 
height of the main tissue peak between 1420 and 1480 cm-1 above the median value 
of an area of adjacent spectrum between 1400 and 1420 cm-1.  The noise was 
calculated from the median of the absolute difference between the actual spectrum 
and a median filtered spectrum using a section of the spectrum with little 
biomolecular signal (1700-1800 cm-1). The median values of the absolute difference 
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were used, as it was necessary to remove the effect of cosmic rays, which are 
beyond the control of instrument optimisation. 
For fresh vulval tissue one of the key considerations in setting measurement 
parameters is the time taken to collect the spectra.  If a typical 4 mm punch biopsy is 
under Raman analysis for greater than three and a half hours there is a risk of the 
sample drying and this risked adversely affecting the quality of the histopathological 
assessment of the tissue.  The spectral collection parameters were therefore 
optimised to provide adequate number of spectra with good spectral quality within 
three and a half hours per sample. 
7.5.4.1 Spectral acquisition time 
The time taken to acquire a spectrum directly affects the SNR of the resultant 
spectrum.  The gain in SNR is most significant between 0 and 30 seconds, above 20 
seconds there is only a modest increase in the SNR, which appears to plateau at 50 
seconds (Figure 7-10). A shorter acquisition time is desirable to enable the analysis 
to be undertaken in a time frame that minimises drying & distortion of the tissue and 
reduces the chance of thermal damage from the laser.  For these reasons an 




Figure 7-10 – SNR for increasing acquisition time for spectra taken from normal vulval skin 
7.5.4.2 Fluorescence 
To combat problematic fluorescence (chapter 4.1.3.2) found in skin with high 
concentration of melanin the effects of photo bleaching were investigated.  Using the 
830 nm laser to photo bleach the tissue did not seem to have any significant effect 
on the amount of fluorescence from the tissues.  For this reason photo bleaching 
was not used during spectral collection.  An iterative polynomial curve fitting baseline 
correction was applied to all spectra to remove the effect of fluorescence present in 
the spectra (Lieber and Mahadevan-Jansen, 2003). 
7.5.4.3 Cosmic ray removal 
From the measurement of fifty 20 second spectra the chance of a cosmic ray being 
present in a spectrum was estimated as 1 in 20.  As affected spectra can be 
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identified and corrected during analysis and as the total time fresh samples can 
undergo analysis is limited, it was concluded more useful data could be gathered 
without using the triple measurement median spectrum removal technique (chapter 
4.1.3.1). Cosmic rays were therefore identified and removed during data analysis, as 
described later. 
7.5.4.4 Spectral acquisition depth 
Histopathological and therefore biochemical changes associated with vulval disease 
do not typically occur at the surface of epithelium where the stratum corneum is 
found (Chapter 1). Pathological changes in benign and malignant vulval disease 
occur primarily at the level of the junction between the dermis and the epidermis 
(Nucci, 2013). Within vulval skin this area is situated a varying distance from the 
superficial surface of the stratum corneum. It is therefore sensible to acquire Raman 
spectra at different depths within the samples. This approach is limited by the 
reduced signal to noise as the laser spot is focused into the sample and experiments 
revealed a significant drop off in the signal to noise ratio when the focus was 
advanced beyond 150 microns into the tissue. 
7.5.4.4.1 Tissue modelling 
To further gain insight in to the depth of tissue a Raman signal can be acquired from, 
an experimental phantom was produced to simulate the signal returned from skin at 
different depths.  For light of wavelength 830 nm the reduced scattering coefficient of 
skin was calculated to be 22.39 cm-1 and the absorption coefficients of the epidermis 
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and dermis were calculated to be 1.715 cm-1 and 0.249 cm-1 respectively.  These 
values were calculated using the methodology and experimental tissue properties 
from Jacques et al. (Skin Optics; Jacques, 2013). The reduced scattering coefficient 
was matched to a 2.48% solution of Intralipid® (Sigma-Aldrich).  
To investigate the depth at which spectra could be acquired a cuboid piece of 
polytetrafluoroethylene (PTFE) was place in a petri dish on the stage of the 
spectroscope and the petri dish filled with 2.48% intralipid solution until the PTFE 
was entirely covered.  Due to the highly hydrophobic nature of the PTFE this 
required a layer of intralipid approximately 1400 µm thick to cover the PTFE.  This 
layer could be reduced to 500 µm before the surface of the intralipid broke over the 
PTFE. This allowed analysis of the signal from the PTFE block at varying focal 
depths through varying thickness of intralipid skin phantom.  The resultant spectra 
were green glass corrected and normalised and the height of the largest PTFE peak 
at 732 cm-1 (Figure 7-11) was isolated to represent the changing signal from the 
PTFE block (Figure 7-12). The results of this show that even when the depth of the 
intralipid is over 1 mm the PTFE Raman signal can be detected.  This depth is 
equivalent to the thickest combined stratum corneal and epidermal layer in vulval 
skin.  An adjustment is required for the absorption of light within skin, which is not 
satisfactorily accounted for in this model. 
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Figure 7-11 – PTFE spectrum, x50 objective, 10 sec integration time 
 
Figure 7-12 – Normalised counts of the 732 cm-1 peak as the microscope focus advances towards the 




7.5.4.5 Final acquisition parameters 
A two-stage approach was chosen for the acquisition of spectral measurements from 
blocks of fresh/ fresh frozen vulval tissue. The first stage was applied to spectral data 
collected for comparison one and the second stage applied to the additional spectral 
data collected for comparison two. 
7.5.4.5.1 Acquisition parameters – comparison one 
Comparison one investigates both the spectral differences between different vulval 
pathologies and the depth of laser focus most likely to produce diagnostic spectral 
information. Spectra were acquired in a line across the central 2 mm of the fresh 
vulval 4 mm punch biopsy samples at intervals of 50 µm with the laser focused on 
the surface of the sample and an acquisition time of 20 seconds. In order to assess 
the optimal focal point for acquiring spectra in this type of tissue this process was 
repeated after the microscope stage was advanced towards the objective. The stage 
was advanced in steps of 15 µm and spectra measured at each position until the 
sample had been advanced 150 µm towards the objective (Table 7-1). An average of 
440 spectra were measured from each sample. 
Table 7-1 – Acquisition parameters for comparision one 
Parameter Value 
Acquisition time 20 secs 
Stage z increments 15 microns 
Total z displacement 150 microns 
Lateral increments 50 microns 
Lateral displacement 2000 microns 
Total Spectra 440 
Total acquisition time 3 hours 
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7.5.4.5.2 Acquisition parameters – comparison two 
The second stage of the data acquisition for comparison two was based on the 
results of the first comparison between LS and other inflammatory conditions 7.6.1. 
As the optimum depth for spectral acquisition for the purposes of classification 
(Chapter 7.6.1) was found to be 15 microns, spectra were only collected at this depth 
in comparison two (Table 7-2). 
Table 7-2 – Acquisition parameters for comparision two 
Parameter Value 
Acquisition time 20 secs 
Total z displacement 15 microns 
Lateral increments 50 microns 
Lateral displacement 2000 microns 
Total Spectra 40 
Total acquisition time 15 minutes 
7.5.5 System calibration 
System calibration was carried out as described in chapter 6.5.1. 
7.5.6 Histopathological correlation 
Histopathological correlation was achieved with an agreed protocol for marking of 
punch biopsies.  Designated histopathologists familiar with the protocol cut all 
samples sent to the histopathology laboratory.  Samples underwent Raman 
spectroscopy along a line through the sample and were marked with ink on one side 
of the skin surface with a black dot.  This allowed the pathologist to cut the sample 
into two parts (Figure 7-13) and cut sections for staining and histological analysis 
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along the line explored with the spectroscope. All samples underwent 
histopathological assessment by a specialist gynaecological pathologist blinded to 
the results of the spectroscopic analysis. The results of this assessment were then 
used in building and validating a PCA LDA based classification model (chapter 4.2). 
 
Figure 7-13 – Marking of punch biopsies (ink dot on left of the biopsy allows the pathologist to cut the 
specimen along the solid line, mount section A in paraffin and cut sections for staining and histology 
at the level marked with the dashed line) 
7.5.7 Spectral preprocessing and analysis 
Spectral data points outside of the 400 to 1800 cm-1 biomolecular fingerprint range 
were excluded from the analysis and all spectra underwent an instrument response 
correction using the spectrum measured from the green glass as described in 
chapter 6.5.1 (Grimbergen et al., 2010). Autofluorescence was removed using a 
second order polynomial fitting and subtraction (chapter 4.1.3.2) (Lieber and 
Mahadevan-Jansen, 2003) and the spectra were then vector normalized. Cosmic 
rays were identified by isolating spectral points where the difference between the 
spectra and the median spectra for that sample at the given depth deviated from the 
median absolute difference by greater than 4 standard deviations (chapter 4.1.3.1). 
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Where cosmic rays were identified the affected region of the spectrum was removed 
and substituted by a reconstruction using principal component loadings from analysis 
of spectra free from cosmic rays. The resultant spectra were then analysed with 
principal component analysis (PCA) to reduce the dimensionality of the data in 
preparation for linear discriminant analysis (LDA). 
As expected on visual inspection the spectral data obtained using the transepidermal 
approach appeared to contain a more significant contribution from sources of noise 
than the data collected through streamline Raman spectroscopy median filtered and 
binned. Analysing this spectral data using the cross validated classification approach 
outlined in chapter 6.5.5 resulted in the inclusion of multiple principal components 
that were found to be significantly different between the pathology groups using 
ANOVA but that on inspection appear to contain predominantly noise with little 
evidence of biological Raman signal. In order to select principal components for LDA 
that were biological relevant, alternative data analysis methodologies were 
developed and evaluated and compared to the method outlined in chapter 6.5.5. 
The first alternative analytical method used a sub cross validation loop to determine 
the number of PCs to use in each cross validation loop.  In this approach, after 
exclusion of the test set in cross validation loop and filtering by the D and Q statistic 
a further analytical sub loop was undertaken to assess the number of principal 
components that contribute to improved disease classification (Figure 7-14). Within 
the sub loop each sample in the training set was excluded in turn and a further round 
of PCA and LDA undertaken using the remaining data as the sub training set and the 
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excluded sample as the sub test set. The diagnostic performance of the classification 
model was then assessed after adding each PC in turn starting with the most 
discriminatory and ending with the least discriminatory (Figure 7-15). The number of 
principal components that resulted in the maximum number of correct predictions in 
the sub test set was then noted and the sub loop was then repeated for the next sub 
test sample and the mean number or PCs that resulted in the maximum number of 
correct predictions applied to the test sample in the primary cross validation loop. 
Mean of each sample mean centered 
PCA 
PC loadings 
All data centered to mean of training 
sample averages 
Scores for PC loadings 
Scores for PC loadings 
ANOVA to select significant PC 
loadings (95% confidence) Significant PC loadings 
Scores from significant PC loadings 
LDA 
Classification of spectra and 
assignment to pathology group  
Complete set of corrected data 
Mean centered TRAINING set 
(individual spectra) Mean centered TEST set 
(mean of training set) 
PCA of mean spectrum from each 
sample 
Scores and loading of training set 
DQ exclusion of spectra that are not 
well described by training PCs 
DQ filtered training set 
DQ exclusion of spectra that are not 
well described by training PCs 
DQ filtered test set of individual 
spectra 
Mean of training sample means 
(Each	sample	excluded	in	turn)	
Exclusion of whole sample test set 
Recombination of data 
Number of PCs required for maximum 
number of correct predictions 
Sub test loop to determine number of 
PCs to be used in final cross 
validation 
Combined classification of spectra 
and assignment to pathology group  
Exclusion of predictions by 
Mahalanobis distance from mean of 
each group 
 
Figure 7-14 – First alternative method for selecting principal components within leave one sample out 
cross validated PCA LDA classification 
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Mean of each sample mean centered 
PCA 
PC loadings 
All data centered to mean of training 
sample averages 
Scores for PC loadings 
Scores for PC loadings 
ANOVA to select significant PC 
loadings (95% confidence) Significant PC loadings 
Scores from significant PC loadings 
LDA 
Classification of spectra and 
assignment to pathology group  
Complete set of corrected training 
data 
Mean centered TRAINING set 
(individual spectra) Mean centered TEST set 
(mean of training set) 
PCA of mean spectrum from each 
sample 
Scores and loading of training set 
DQ exclusion of spectra that are not 
well described by training PCs 
DQ filtered training set 
DQ exclusion of spectra that are not 
well described by training PCs 
DQ filtered test set of individual 
spectra 
Mean of training sample means 
(Each	sample	excluded	in	turn)	
Exclusion of whole sample subtest set 
Recombination of data 
Number of PCs required for maximum 
number of correct predictions 
Exclusion of all but single most 
discriminatory PC 
PC Scores for LDA 
Recording of number of correct 
predications for number of PCs used 
Addition of next most discriminatory 
PC  
DQ filtered training set 
 
Figure 7-15 – Sub loop for determining the number of biological relevant PCs in the first alternative 
method for selecting PCs within leave one sample out cross validated PCA LDA classification 
The second alternative cross validation methodology uses a sub loop and stepwise 
selection of the actual principal components to be used in the final analysis to reduce 
the significance of noise in the classification model and reduce the risk of a type 2 
error (Figure 7-16). 
In the stepwise cross validation cycle the data from a whole tissue sample (test set) 
was removed from the complete data set. After this a randomly selected 25% of the 
remaining full spectra were then removed from the data set as a stepwise sub test 
set. PCA fed LDA was then performed on the remaining data. The resultant model 
was then tested on the stepwise sub test set using each principal component (PC) in 
turn to identify the PC that resulted in the highest proportion of correct predictions 
(Figure 7-17). This PC then remained in the PCA-LDA model and the remaining PCs 
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were tested alongside this PC in the same manner to identify the next best 
performing PC. This process was repeated adding the next best performing PC to 
the model each time. Only those PCs that improved the performance of the PCA-
LDA model were then selected for classification of the whole sample test set. The 
classification performance of the PCA-LDA model was assessed on its ability to 
correctly classify the histological diagnosis of the whole sample test set. This leave 
one out stepwise cross validation loop was then repeated evaluating each sample in 
turn. 
This method had the advantage of removing principal components that described 
variation in the data not useful for classification such as those that described noise. 
This approach allowed improved classification performance without compromising 
the integrity of the leave one sample out cross validation and without increasing the 




Figure 7-16 – Second alternative method for selecting principal components within the leave one 
sample out cross validated PCA LDA classification 
 
Figure 7-17 – Sub loop for identifying the biological relevant PCs in the second alternative method for 
selecting PCs within leave one sample out cross validated PCA LDA classification 
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The classification performance of individual spectra was assessed using the receiver 
operator characteristic to simulate measurements that could be acquired in a clinical 
setting. The probability of obtaining a false positive result was evaluated using the 
method described by Obuchowski et al. (Obuchowski and McClish, 1997; 
Obuchowski, Lieber and Wians, 2004). 
Comparing the three different methods for cross validation in the context of spectra 
with significant noise using the data collected using the transepidermal approach 
demonstrated the effect on the diagnostic performance of applying the different 
analytical approaches. A sample comparison of the areas under the ROC curve 
(AUC) when differentiating SCC from VIN using the three approaches using all the 
data was undertaken. Improved classification performance was seen with the second 
alternative (boot strap) classification approach (AUC 0.88) when compared with both 
the approach applied in chapter 6.5.5 (AUC 0.86) and the first alternative approach 
(AUC 0.85). The second alternative (boot strap) classification approach was 




7.6.1 Comparison one - diagnosis of clinically inconclusive 
vulval lichen sclerosus 
7.6.1.1 Summary of measurements 
Samples from 27 women with suspected LS were subject to spectroscopic and 
histopathological analysis. Of these, 15 women had a histological diagnosis of LS. Of 
the remaining 12 women, the majority had findings of nonspecific inflammation only, 
some had no specific histological abnormality and there was one case of mild 
dysplasia (Table 7-3). 
Table 7-3 – Histopathological diagnoses of study samples 
Histological Diagnoses N % 
Lichen sclerosus 15 56 
Other diagnoses: 12 44 
Non specific inflammation (8)  
Mild Dysplasia (1)  
No specific histological abnormality (3)  
   
Spectra were measured from all samples between 30 minutes and 7 hours of the 
samples being collected. A mean of 440 spectra were collected from each sample. A 
two group analysis of the data was performed to differentiate those samples from 
women with LS from those with other diagnoses as this was the most clinically 
relevant comparison possible using the available data. 
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7.6.1.2 Diagnostic classification 
The initial PCA LDA analysis demonstrated that the technique was able to correctly 
classify the majority of samples based on the spectra acquired using the linear 
discriminant scores (Figure 7-18). This result was replicated in the leave one out 
stepwise cross validation. The bimodal distribution of linear discriminant scores in 
the lichen sclerosus group (Figure 7-18) suggests there may be separate 
biomolecular subtypes of the disease although no correlation between the scores 
and histological features could be identified. 
 
Figure 7-18 – Histogram of score values from linear discriminant function 
Analysis of the spectra from different focal points within the samples revealed the 
diagnostic performance was optimal when the focal point was advanced 15 microns 
into the samples (Figure 7-19). Only data from this depth (40 spectra from each 



























Figure 7-19 – PCA LDA classification performance (area under receiver operator curve) using spectra 
obtained from different depths of focus. 
Defining the biochemical constituent peaks responsible for discrimination within the 
LDA model is challenging, as Raman spectroscopy does not allow simple 
biochemical quantification of target tissues. This is due to the compound effect on 
the Raman spectra from the numerous molecular constituents of the tissue. 
The dominant histological feature of LS is hyalinisation of the dermis typically seen 
alongside epidermal atrophy and subdermal inflammatory cell infiltrate. The dermis 
primarily consists of collagen fibres with smaller quantities of elastin fibres and other 
extracellular proteins. In human skin type 1 collagen accounts for 80% of all dermal 
collagen, in LS significant biochemical alterations occur around the zone of 
hyalinisation with changes in the organisation and expression of type I, III collagen 
fibers, a relative increase in the expression of type V collagen and a decrease in the 
expression of extracellular matrix protein 1 and elastin. These changes may form the 












Figure 7-20 – A - Composite of all principal component loadings weighted by contribution to the linear 
discriminant classification model; B – Collagen type I (Sigma C7774) and elastin (Sigma E1625) 
spectra; C - Most significant principal component loading; D - Second most significant principal 
component loading. 
 
Examining the two most significant principal component loadings (ANOVA) and the 
composite of all principal component loadings weighted by contribution to the linear 
discriminant classification model (Figure 7-20) spectral differences between the two 
groups (Figure 7-21) can be seen to occur in the regions associated with collagen, 
elastin and other structural proteins (Table 7-4). Changes are also seen in the lipid, 
fatty acid, nucleic acid and carbohydrate regions of the spectra (Table 7-4). These 
changes may well be associated with epidermal atrophy, vacuolar degeneration and 




Figure 7-21 – Mean Raman spectra of pathology groups, lichen sclerosus and other pathologies 
(Table 7-3).  
 
Analysis of diagnostic performance after cross validation demonstrated Raman 
spectroscopy combined with multivariate analysis was able to differentiate vulval 
samples from women with LS from those with other diagnoses with a sensitivity of 
91% and specificity of 80%. The area under the receiver operator curve was 0.95 




Table 7-4 – Putative assignment of key Raman spectral bands seen in vulval skin. 
Wavenumber (cm-1) Suggested biomolecular constituent allocation 
Type 1 Collagen  
815 C-O-C stretching 
722 C-S stretching 
856 and 920 Proline ring 
875 Hydroxyproline ring 
938 C-C stretching 
1004 & 1033 Phenyalanine 
1043 Proline 
1082 Carbohydrate residues of collagen 
1668 Amide I 
1246 Proline rich region 
1271 Proline poor region 
1448 CH deformation 
Nucleic acids  
722 DNA 
785 DNA/ RNA 
1325-1330 Nucleic acids 
Carbohydrates  
477 Polysaccharides 
Other protein and amino 
acids  
918 Proline, hydroxyproline 
935 C-C stretching mode of proline and valine and protein backbone / glycogen  
1000 Phenylalanine 
1053 C-O stretching, C N stretching (protein) 
1126 C-N stretching vibration (protein vibration) 
1200-1300 Amide III (proteins) 
1307 CH3/CH2 twisting, wagging, and/or bending mode of collagens and lipids 
1528 Carotenoid 
1554 Amide II 






Figure 7-22 – Receiver operator curve for the detection of LS from other pathologies, area under 
curve 0.95, type 1 error rate <0.05 
7.6.2 Comparison two – identification of premalignant and 
malignant disease of the vulva 
7.6.2.1 Summary of measurements 
In this comparison 91 tissue samples from the 64 participants previously identified 
for streamline Raman (chapter 6.4) mapping were measured using the standardised 
parameters (Figure 6-6). The histopathological classification of the samples 
measured are summarised in Table 7-5. 











Non-neoplastic vulval tissue 30 1,200 
Vulval intraepithelial neoplasia 30 1,200 
Squamous cell carcinoma 31 1,240 
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40 Spectra were collected from each of the of the 91 tissue samples giving a total of 
3,640 spectra.  
7.6.2.2 Spectral processing and exclusion 
All spectra underwent an instrument response correction, baseline correction and 
cosmic ray removal (chapters 6.5 and 7.5.7). Potential cosmic rays were identified 
and corrected in 22% of the 3,640 measured spectra. An example of a single 
sample’s spectra before and after cosmic ray removal is given in Figure 7-23 
demonstrating effective removal of easily identifiable cosmic rays. 35% of spectra 
were excluded by PC reconstruction error (Q statistic) and difference from the mean 
spectrum (D statistic) combined (chapter 4.2.6.1). This resulted in the complete 

























































Figure 7-23 – Raman spectra from a tissue block before (A) and after (B) cosmic ray removal 
7.6.2.3 Diagnostic classification 
A three group analysis of the data was performed to assess the performance of the 
technique for differentiating between vulval SCC, VIN and non-neoplastic vulval 
disease as outlined in Table 13-1 as this mirrored the clinical needs identified. 
Initial PCA demonstrated that 78% of the variance in the spectral data could be 
explained in the first four principal components (Figure 7-24). In the bootstrap cross 
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validation loops between 12 and 21 principal components were ultimately selected 
for use in the LDA classification model in each cycle of the loop (Figure 7-25) 

















Figure 7-24 – Variance in data described by each principal component, 78% of variance described in 
the first four principal components. 
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Figure 7-26 illustrates the distribution of the LD scores for each classified spectrum. 
As expected, compared to the LD scores from the spectra of the highly selected 
epidermal streamline mapping (Figure 6-20) there is significantly more overlap 
between the pathology groups. Greater overlap between the groups would be 
expected as the trans epidermal approach to spectrum acquisition and inability to 
select spectra from solely the area of interest means there is a great contribution to 




















Figure 7-26 – Histogram of linear discriminant scores. Non-neoplastic vulval tisse, SCC – squamous 
cell carcinoma, VIN – vulval intraepithelial neoplasia 
 
The principal components that are used to distinguish the pathology groups are not 
those that account for the greatest variability between the spectra (Figure 7-28) and 
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the importance of more subtle spectral difference in the classification may in part be 
responsible for the significant overlap between the groups. 
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Figure 7-28 – Weight of each principal component score within the linear discriminant model created 
from non-cross validated analysis. 
 
Table 7-6 shows the results of the cross-validated classification model when 
analysed by individual spectra. The classification performance is significantly poorer 
than the results obtained by streamline mapping tissue sections with overall 
sensitivity for the detection of VIN or SCC from non-neoplastic vulval skin of 75% 
with a specificity of 67% when the linear discriminant boundary lies midway between 
the pathology groups. When analysing by sample (Table 7-7) the specificity is 





Table 7-6 – Confusion matrix for spectra based on modal classification of spectra with linear 
discriminant boundary midway between the pathology groups, rows are true pathology group and 
columns are predictions. 






Non-neoplastic 602 209 86 
Vulval intraepithelial 
neoplasia 422 388 173 
Squamous cell 
carcinoma 82 215 723 
Sensitivity 67 39 71 
Specificity 75 78 86 
 
Table 7-7 – Confusion matrix for whole samples based on modal classification of spectra with linear 
discriminant boundary midway between the pathology groups, rows are true pathology group and 
columns are predictions. 






Non-neoplastic 22 5 2 
Vulval intraepithelial 
neoplasia 13 10 5 
Squamous cell 
carcinoma 2 7 21 
Sensitivity 76 36 70 
Specificity 74 80 88 
 
Figure 7-29 shows a ternary plot of the predicted probabilities of a sample belonging 
to each of the three pathology groups. There appears to be separation between the 
neoplastic and non-neoplastic tissues. No samples of non-neoplastic tissue have a 
high predicted probability of being cancer with most samples having a predicted 
probability of belonging to the cancer group of less than 5% and all samples having a 
probability of belonging to the cancer group of 41% or less. Conversely no samples 
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of SCC had a high predicted probability of belonging to the non-neoplastic group. 
This indicates the technique has promise in identifying SCC from non-neoplastic 
vulval skin. The distinction between the VIN and cancer groups and the VIN and 
non-neoplastic groups is significantly less clear. Some samples of VIN have high 
predicted probability of being in the non-neoplastic or SCC group; some samples of 
non-neoplastic tissue have high predicted probability of being in the VIN group and 
some samples of SCC have high predicted probability of being in the VIN group. This 
is seen in the inverted clustering in the ternary plot (Figure 7-29). This would suggest 
that the technique is able to detect a continuum of physiological changes that lead to 
the development of cancer (chapter 1.4.1). This may account for the poor 














































Figure 7-29 – Ternary plot of the predicted probabilities of a sample belonging to each of the three 
pathology groups under analysis. NON – non-neoplastic perilesional vulval skin, VIN – vulval 
intraepithelial neoplasia, SCC – squmous cell carcinoma. Legend indicates actual pathology of 
samples, axes are probability of group membership based on linear discriminant distance. The 
shaded area indicates the clustering of probabilities in a pattern that suggests the detection of 
biomolecular changes associated with carcinogenesis. 
By altering the linear discriminant boundaries that define the predicted pathology 
within the model we can assess what diagnostic performance can be achieved with 
this approach. The receiver operator curve for the detection of non-neoplastic tissue 
from SCC and VIN is shown in Figure 7-30, this shows that by varying the linear 
discriminant boundary sensitivities between 80 to 90% can be achieved with 
corresponding specificities of 66 to 54% with an area under the curve of 0.85. For 
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distinguishing SCC from VIN and non-neoplastic tissue the performance is better 
and sensitivities of 85 to 90% can be achieved with specificities of 78 to 68% and an 
area under the curve of 0.90. In the identification of SCC from VIN sensitivities of 84 
to 88% for specificities of 72 to 65% can be achieved with an area under the curve of 
0.88 (Figure 7-32). Although the threshold of acceptability of diagnostic performance 
will of course vary by the application these results show promise for the technique in 
the applications previously described. 















Figure 7-30 – Receiver operator curve for the 
detection of non-neoplastic tissue from SCC and 
VIN per spectrum. Area under curve, 0.85,  Risk 
of falsely rejecting null hypothesis, <0.05 















Figure 7-31 – Receiver operator curve for the 
detection of SCC from VIN and non-neoplastic 
vulval tissue per spectrum. Area under curve, 
0.90,  Risk of falsely rejecting null hypothesis, 
<0.05 















Figure 7-32 – Receiver operator curve for the 
detection of SCC from VIN per spectrum. Area under 





7.6.2.4 Spectral analysis of biomolecular differences 
between pathologies 
As previously explored (chapter 6.7) the identification of specific biomolecular 
changes in the spectra between the different groups is challenging. In the streamline 
model several spectral changes were seen in line with the published literature. In this 
model the previously reported changes seen with malignant transformation, including 
a right shift in the 1661 cm-1 Amide I band a widening of the peak at 1451 cm-1 and 
an increase in peak intensity at 1080 cm-1 are again seen (Gniadecka et al., 1997; 
De Gelder et al., 2007).  




















Figure 7-33 – Mean spectra of the pathology groups. Non-neoplastic, VIN – vulval intraepithelial 
neoplasia and SCC – squamous cell carcinoma. +/- one standard deviation marked by shading either 
side of line. 
Similarly to the streamline model a number of other additional spectral differences 
can be identified when comparing neoplastic to non-neoplastic tissue. These include 
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increased prominence of the peaks at 723 cm-1, 782 cm-1, and 1101 cm-1 likely to 
represent DNA (720-722 cm-1, 782 cm-1, 1101 cm-1), RNA (782 cm-1) and nucleic 
acids (724 cm-1, 830 cm-1) and again this would be consistent with the increase rate 
of cell proliferation in neoplastic tissue (Talari et al., 2015).  
As expected there is some additional signal seen in the spectra from the wider 
sampling area from the trans epidermal approach. In Figure 7-34 the position of the 
main peaks of the type one collagen are shown on transepidermal Raman spectra 
(Appendix B).  In these spectra we can see increased prominence of some of the 
key collagen peaks at 749 cm-1, 814 cm-1, 1245 cm-1, 1266 cm-1 and 1419 cm-1. This 
is consistent with a sampling volume that includes the dermis of the vulval tissue. 
































































































































Figure 7-34 – Mean Raman spectra of pathology groups using a transepidermal approach showing 
the position of peaks relating to collagen type I. 
The previously seen increased prominence in the peak at 830 cm-1 is not clearly 
seen in this data due to the presence of a new large peak at 814 cm-1 likely from the 
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collagen within the sampling volume obscuring the smaller peak seen at 830 cm-1. In 
addition the previously seen reduction in the mono/disaccharide peak at 899 cm-1 is 
not clearly identifiable. The increased prominence in the amino acid and protein 
peaks at 756 cm-1, 855 cm-1 and 1558 cm-1 is again seen alongside the reduction in 
peak prominence at 1622 cm-1. It is not clear what specific biomolecular changes are 
responsible for these spectral changes seen in association with malignant 
transformation however they appear consistently in spectra collected using the 










Figure 7-36 – Composite PCA LDA loading with putative peak assignments 
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These identified spectral differences are also reflected in the composite PCA LDA 
loading (Figure 7-36) and the changes identified appear to be significant in the 
predicted classification of the pathology groups as determined by deviation in the 
combined PCA LDA loading. 
7.7 Interim discussion 
[Summative discussion and conclusions relating to the investigations outlined in 
Section C relating to Raman spectroscopy for the assessment of vulval disease can 
be found in Chapter 13] 
7.7.1 Comparison one - diagnosis of clinically inconclusive 
vulval lichen sclerosus 
The aim of this investigation was to use Raman spectroscopy to differentiate lichen 
sclerosus from other vulval pathologies in the women where a diagnosis of lichen 
sclerosus is suspected but where biopsy is required to make the diagnosis. This 
study is the first reported application of this technique for the diagnosis of lichen 
sclerosus at any body site. Other studies using Raman spectroscopy to assess 
dermatological conditions have not included this important pathological group in their 
analyses.  
The results demonstrate Raman spectroscopy combined with multivariate analysis 
has real potential as a useful tool in the diagnosis and monitoring of women with 
lichen sclerosus, a common vulval skin condition. In this study of patients who 
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required invasive tissue biopsy for diagnosis, Raman spectroscopy was able to 
correctly diagnose LS with clinically applicable performance. 
Further research is required to validate this technique using probe-based systems 
(Chapter 8). The design of probes for in vivo trials should consider that laser focus 
beneath the surface of the skin will likely yield improved diagnostic performance, 
compared to probes that focus at the surface. 
7.7.2 Comparison two – identification of premalignant and 
malignant disease of the vulva 
In this comparison the aim was to evaluate Raman spectroscopy applied to whole 
blocks of fresh frozen tissue for the purposes of classifying non-neoplastic vulval 
skin, premalignant and malignant disease of the vulva. This is the first reported study 
to attempt classifying these pathologies using Raman spectra collected from whole 
vulval tissue blocks. In this investigation it was possible to use individual Raman 
spectra to classify the pathology present within the tissue with clinically relevant 
classification accuracy. This replicated the results of the experiment outlined in 
Chapter 6. Comparing the streamline spectroscopic mapping of epidermal cells and 
transepidermal methods a predictable decrease in the diagnostic accuracy was 
demonstrated as shown in Table 7-8. In this analysis the Raman spectra also 
appears to define a continuum of biomolecular changes from non-neoplastic tissue 
through VIN to frank SCC (Figure 7-29). This fits with our understanding of the 
carcinogenic processes leading to the development of vulval SCC (chapter 1.4.1.3). 
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Table 7-8 – Comparision of the diagnositc accuaracy of streamline spectroscopic mapping of 
epidermal cells and transepidermal Raman measurements 
 
Although the trans-epidermal approach used in this investigation yielded good 
classification performance it is necessary, within the bounds of ex vivo 
experimentation, to evaluate the technique in conditions that are a closer 
approximation to in vivo application. The bench based microscope spectrometer 
system used in this analysis is capable of producing high quality spectra but cannot 
be used in vivo as the objective cannot easily be applied to the vulva. In the following 
chapter the technique is evaluated under conditions that would be easier to apply in 
the clinical environment. 
Further discussion of future work and the steps necessary to translate these finding 













1 SCC and VIN from non-neoplastic vulva 0.95 0.85 
2 SCC from VIN 0.92 0.88 







Chapter 8 Evaluation of Vulval Skin Using 
Fibreoptic Raman Spectroscopic Probe 
8.1 Introduction 
In the investigations outlined in Chapter 6 and Chapter 7 it was demonstrated that 
Raman spectroscopy coupled with multivariate analysis is capable of objectively 
identifying malignant from premalignant and non-neoplastic vulval disease with 
clinically acceptable diagnostic performance. Both of these investigations were 
performed using large microscope based laboratory spectrometers. This approach is 
not suitable for in-vivo use as it would be very technically challenging to collect 
Raman spectra in the clinic or theatre environment using these laboratory bench 
based systems (Kallaway et al., 2013; Old et al., 2014). 
To apply the technique in-vivo it is necessary to have a portable spectroscopic 
system with excitation and collection optics that can be positioned flexibly and freely 
on the patients’ vulva to improve access to tissues. To apply a fibre optic Raman 
probe to the classification of disease in the vulva it is necessary overcome a number 
of key challenges. The Raman signal is comparatively weak, and only 1 in 106 to 109 
photons undergo inelastic scattering and fibre optic probes used in vivo need to 
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overcome the fundamental signal to noise challenge of Raman spectroscopy. 
Clinical environments are not currently optimised for Raman spectroscopy and 
environmental light may produce unwanted spectral noise (Kendall et al., 2009). In 
addition the photoluminescence from the optics and delivery fibres of the probe itself 
can contribute to further undesirable spectral noise (Day et al., 2009).   The use of 
fibre optic probe based spectroscopic systems has been reported for the 
classification of skin disease but these studies have not demonstrated the use of 
probes for disease classification for premalignant or malignant vulval disease. The 
largest study to date to use a fibre optic probe was that of Lui et al. and is discussed 
in detail in chapter 3.2.3 (Lui et al., 2012). In this study the authors use a fibre optic 
probe optimised for diagnosis rather than margin assessment. The probe illuminates 
and collects Raman signal from a 3.5 mm diameter spot on the surface of the skin. 
While this is appropriate for the diagnostic purposes it is not optimal to have such a 
large spot size when assessing surgical excision margins as more precise 
delineation of the margin is required if the size of the excision and therefore surgical 
morbidity is to be minimised. In addition these larger probes only allow the 
assessment of superficial surface surgical margins and do not permit the insertion of 
the probe through the skin to assess deep margins. Nijssen et al. evaluated a 
simplified Raman probe design with a single 200 micron excitation and collection 
fibre for the classification of BCC from perilesional skin taken from 17 patients 
(Nijssen et al., 2014). This study demonstrated that the small diameter probe was 
able to correctly classify tumour with reported 100% accuracy and non-involved 
tissue with reported 99% accuracy. In the study Nijssen et al. coupled the probe to a 
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modified Renishaw 1000 spectrometer like that used in the study in Chapter 7. This 
bench based system is not portable and not suitable for clinical use. To demonstrate 
Raman spectroscopy can be applicable to the clinical purposes outline in Chapter 5 
it is necessary to reproduce the classification accuracy demonstrated in Chapter 6 
and Chapter 7 using a probe system capable of taking measurements in the clinic or 
theatre environment with the spatial and classification accuracy required to 
determine disease margins.  Such a system requires narrow gauge fibre optic 
probes to be used alongside a portable spectrometer system. In this investigation the 
disease classification capability of a Raman spectroscopic probe applied directly to 
the surface of vulval epithelium was evaluated. This was accomplished by the 
analysis of blocks of vulval epithelium taken at the time of surgical excision as 
outlined in chapter 6.4. 
8.2 Objectives 
This investigation assesses objective 3 of the aims and objectives outlined in 
Chapter 5. 
To evaluate the ability of a fibre optic probe and portable Raman spectrometer in 




8.3 Overview of investigation 
In this investigation the disease classification capability of Raman spectroscopy 
applied directly to the surface of blocks of vulval tissue was evaluated. This was 
accomplished by analysing blocks of fresh frozen vulval tissue collected at the time 
of surgical excision. These tissue blocks underwent Raman spectroscopy prior to 
routine histopathological analysis.  An outline of the investigation is shown in Figure 
8-1. 
 




8.3.1 Participant identification, sample collection and sample 
preparation 
Participants were identified and samples were collected from women undergoing 
vulval excisional surgery as described in chapter 6.4. Prior to analysis all samples 
were fully defrosted at 21oC and washed in 0.9% physiological saline to remove any 
residues present on the surface of the epithelium. 
8.4 Instrumentation and experimental methods 
8.4.1 Spectrometer 
A Headwall (Diegem, Belgium) Explorer Raman Spectrometer coupled to an Andor 
(Belfast, Northern Ireland) iDus CCD was used for this study. In compact 
spectrometers geometric distortions such as keystone can lead to spatial 
misregistration on the detector. The spectrometer uses an aberration-corrected retro-
reflective design to reduce the effects of keystone and to provide a short focal length 
spectrometer with a compact and portable design (Figure 8-2). The iDus DU420A-
BR-DD CCD used for this investigation has a back illuminated deep depletion CCD 





Figure 8-2 – Aberration-corrected retroreflective spectrometer (reproduced from Andor inc. technical 
specifications) 
The back illumination of the CCD allows photons to directly strike the photosensitive 
part of the detector without having to first pass through the polysilicon electrodes 
(Figure 8-4). This configuration increases the quantum efficiency of the detector but 
does make the detector susceptible to constructive and destructive optical 
interference when illuminated with coherent photons. This results in optical etaloning 
that is especially problematic in the near infrared wavelengths used for this study, 
this will be described in more detail in later chapters.  
The CCD was controlled using the Andor Solis for Spectroscopy software version 
4.27 2014 (Belfast, Northern Ireland) 
This spectrometer configuration results in a portable closed system suitable for use 




Figure 8-3 – Probe spectrometer system (Headwall Explorer Raman spectrometer coupled to an 






Figure 8-4 – A - Typical front illuminated CCD (cross section),  B - Typical back illuminated 




8.4.2 Probe design 
In selecting an appropriate design of fibre optic probe for the purposes outlined in 
Chapter 5 the optical characteristics of the probe including the Raman scattering and 
photoluminescence created within the probe were considered alongside the potential 
clinical applications. In this study the objective was to assess the classification 
accuracy of the technique using measurements taken from the surface of the vulva 
skin with a spatial accuracy that allows the determination of disease margins at the 
time of surgery. In practice vulval cancer not only affects the surface of the skin but 
also invades deep into the subcutaneous tissues. The design of a Raman probe 
needs to consider the likely need to assess disease margins at depth through the 
vulval skin although evaluating this is outside the scope of this thesis. Considering 
the need for spatial precision and the potential future need to take invasive 
measurements a fine bore needle probe similar to those proposed by Day and Stone 
and Komachi et al. suits both these purposes (Komachi et al., 2009; Day and Stone, 
2013).  
The probe evaluated comprised two 62.5 µm core 15 cm lengths of metal-coated, 
fibre with low concentrations of hydroxyl groups (Oxford Electronics, Oxford, UK). 
These two lengths of fibre were fixed adjacent to each other at the distal tip of the 
probe and polished at 90O to the fibres. This assembly is narrow enough to fit within 
a 20 gauge needle as is suitable for the identification of disease margins and 
subcutaneous application. One of these fibres was connected to the spectrometer 
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and the other to an 830 nm stabilised semiconductor laser (Innovative Photonics 










Figure 8-5 – Optical layout of probe system 
To reduce the Raman scattering and photoluminescence in probe systems it is usual 
to incorporate interference filters as close to the signal source as possible. As it is 
not possible to incorporate these filters within the tip of such a narrow probe the 
filters were inserted close to the tip of the probe at 10 cm from the distal tip. At 10 cm 
from the tip of the probe the filters would not interfere with the operation of the probe 
in vivo. The excitation path consisted of a single 62.5 µm core fibre patch lead 
connected to a gradient-index (GRIN) lens, short wavelength pass filter and second, 
identical GRIN lens which was coupled to the excitation fibre of the probe. The 
collection path had the identical arrangement of GRIN lenses with a long wavelength 
pass filter (Figure 8-5). 
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8.4.3 Probe evaluation and tissue modelling 
The laser power at the distal end of the excitation fibre sample was 60 mW. The 
signal background of the entire experimental setup was measured by recording a 20 
second spectrum from the surface of a polished stainless steel slide. This 
demonstrated significant background signal in the bio-relevant region of the Raman 
spectrum that is especially pronounced at 436 cm-1 490 cm-1, 603 cm-1, 803 cm-1, 
1049 cm-1, 1184 cm-1 and 1605 cm-1 (Figure 8-6). 
































Figure 8-6 – 20s spectrum from polished stainless steel slide 
 
The sampling volume of the probe in tissue was explored using a two-layer tissue 
phantom consisting of a 3 mm thick block of polytetrafluoroethylene (PTFE) fixed to 
the bottom of 5 ml glass beaker filled with a scattering and absorbing liquid placed 
on a micrometer stage (Figure 8-8). This arrangement allowed the Raman signal 
acquired from tissue layers at different depths in tissue to be simulated. PTFE was 
chosen to provide the test signal as it has a refractive index and scattering properties 
similar to those of biological tissues (Iping Petterson et al., 2015). The PTFE also 
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provides a distinctive Raman signal in the biorelevant region of the spectrum and is 
therefore well suited to simulate tissue signal in phantom simulations (Iping 
Petterson et al., 2015).  

















Figure 8-7 – 10 second PTFE Raman spectrum acquired using probe system 
 
The second layer of the tissue phantom was a solution of Intralipid® (Sigma-Aldrich, 
20 %), India ink (American MasterTech Scientific, Lodi, CA, USA) and water 
matched to the scattering and absorption properties of human skin. Intralipid was 
used at the scattering agent as it has well characterised optical properties in the near 
infrared spectral region (Pogue and Patterson, 2006; Ninni, Martelli and Zaccanti, 
2011; Aernouts et al., 2014). India ink is a well suited phantom as it has well 
characterised optical properties, a broadband absorption spectrum and is easily 
incorporated into Intralipid solution (Madsen, Patterson and Wilson, 1992; Pogue 
and Patterson, 2006; Di Ninni, Martelli and Zaccanti, 2010).  The ink used came from 
a solution used by Iping Petterson et al. who had previously characterised the ink by 
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UV-vis absorption spectroscopy (Iping Petterson et al., 2015). The absorption and 
scattering characteristics of human skin at 830 nm were calculated from reference 
values and methodology described by Jacques et al. (Jacques and Pogue, 2008; 
Jacques, 2009, 2013). For the purposes of this simulation the optical properties of 
the dermis and epidermis were considered to be the same within the phantom. 
Whilst it is technically feasible produce a phantom with multiple layers with different 
optical properties for simplicity a uniform liquid phantom was used. The scattering 
coefficient of epidermis was estimated to be 22.39 cm-1 and absorption coefficient 
estimated to be 1.715 cm-1. It should be noted the absorption coefficient of dermis is 
estimated to be 0.249 cm-1 using S Jaques methodology with tissue properties from 
Jacques, (2013). Optical properties of biological tissues: a review. Physics in 
Medicine and Biology, 58(11), R37–61. The probe was fixed from above allowing the 








Ten second spectra were taken at 50 µm intervals between 0 and 1500 µm from the 
PTFE within the phantom liquid. The counts at the prominent 732 cm-1 peak (Figure 
8-7) were plotted against depth and are shown in Figure 8-9. This demonstrated that 
in the tissue phantom model the signal from the PTFE was detected at depths of up 
to 1000 µm. This demonstrates that if the optical characteristics of the vulval tissue 
are similar to that of the phantom model then the probe should be able to acquire 
Raman signal from the full thickness of the epidermis in almost all tissue samples. 
The probe should therefore be able to detect the tissue area of interest within the 
samples. 
0 200 400 600 800 1000 1200 1400
























Figure 8-9 – Counts at 732 cm-1 peak from 10s acquisition with distance from PTFE in intralipid and 
India ink phantom. 
The acquisition time for the probe measurements was assessed by evaluating the 
performance of the probe on a sample of chicken skin used as a biological model for 
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human skin. The signal to noise ratio was assessed in a range of acquisition times 
between one and twenty-five seconds. Above twenty-six seconds, detector 
saturation occurred across the wavenumber range rendering longer acquisition times 
unsuitable. The spectra measured were normalised and the signal was determined 
from the CH2 bending peak at 1440 cm-1 and the noise from the signal poor area of 
the spectrum between 2309 cm-1 and 2369 cm-1 using the methodology described in 
chapter 4.1. The results of this evaluation are shown in Figure 8-1 where a rapid 
increase in the signal to noise ratio is seen that plateaus between acquisition times 
of 17 and 23 seconds. Based on this and the need to avoid detector saturation an 
acquisition time of 20 seconds was selected for the measurements of the vulval 
tissue. 

















Figure 8-10 – Signal to noise ratio with increasing acquisition time for speactra measured from 




Instrument calibration was performed on each use of the spectrometer by measuring 
a 0.2 s spectrum from crushed aspirin tablet in a quartz cuvette. This gave a reliable 
standard to calibrate the Raman shift measured by the instrument using set peaks 
within the aspirin Raman spectrum (Figure 8-11) calibrated against the spectrometer 
used in Chapter 7. The Raman shift was then corrected to the CCD pixel position by 
the Solis software using third order polynomial. An instrument response correction 
was performed using a spectrum measured from a sample of green glass during 
calibration as previously described (chapter 6.5.1).  












































Figure 8-11 – 0.2 s Aspirin spectrum demonstrating calibration peaks 
8.4.2 Sample measurement 
For the purposes of measuring tissue samples the probe was mounted on an optical 
bench within a hypodermic needle to allow control of the angle of the probe tip 
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against the surface of the tissue samples (Figure 8-12). An adjustable stage was 
placed beneath the probe to allow the specimen to be advanced toward the probe 
until contact was made between the tissue and the probe. Tissue samples were 
placed on a calcium fluoride window to prevent unwanted interference with the bio-
relevant area of the Raman spectrum from surrounding material. When positioning 
the samples, the stage with the calcium fluoride slide and specimen resting on top 
was advanced toward the probe until contact was made and the probe displaced 
ensuring good contact between the specimen and probe. During measurements the 
probe tip was allowed to rest on the surface of the tissue with no additional pressure 
other than the mass of the probe to maintain contact between the tissue and the 
probe. Raman spectra were measured at ten positions on each of the vulval 
samples. The spectral acquisition time was set at 20 s and to avoid the need for 
cosmic ray removal in the analysis the median of three measurements was taken at 
each point on the vulval sample 
 




8.4.3 Data preprocessing and analysis 
After spectral acquisition the data were optimised to reduce the contribution of non-
tissue signal within the spectra. The optical etaloning from the back illuminated CCD 
was found to be especially apparent in the tissue samples measured due to the 
relatively low signal obtained from biological tissues. This etaloning alongside the 
background signal from the apparatus and fluorescence was addressed through a 
combined correction applied to all the measured spectra. 
In order to identify the contribution of the etalon to the data a 3rd order polynomial 
fitted to the green glass spectrum was subtracted from the green glass spectrum 
(Figure 8-13). This gave and approximation of the etalon spectrum present within the 
tissue spectra (Figure 8-14). 
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Figure 8-13 – Spectrum measured from a sample of green glass and 3rd order polynomial fitted to the 
spectrum. 














Figure 8-14 – Etalon spectrum after correcting for instrument response. 
The background spectrum as measured from the stainless steel slide and the etalon 
approximation was considered to account for the main sources of non-tissue signal 
within the raw data. In order to identify the tissue signal from the background, etalon 
and fluorescence an iterative least squares fit was performed using a modification of 
the technique described by Lieber et al. (Lieber and Mahadevan-Jansen, 2003). The 
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background, etalon and a third order polynomial fitted to the spectral data underwent 
the modified iterative least squares fit to the measured spectral data. The resultant 
fitted spectrum was then taken as an approximation of the contribution of the 
background, etalon and fluorescence to the measured data and subtracted from the 
data to isolate the underlying tissue signal. An example of a corrected and 
uncorrected spectrum is given in Figure 8-15. Correction removes the variation in the 
data caused by the background and etalon and allows clearer visualisation of tissue 
peaks, for example the amide I band at 1661 cm-1, the protein and lipid band at 1451 
cm-1 and the amide II protein band at 1273 cm-1. 
A 


































Figure 8-15 – Example uncorrected probe spectrum (A) and the same spectrum after baseline, 
instrument response and etalon correction (B) 
After this combined correction the spectral data was filtered for outlying spectra 
using the D and Q statistic technique described in chapter 4.2.6.1. The schema for 
the preprocessing steps applied to the raw spectral data is outlined in Figure 8-16. 
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Unprocessed spectral data with 
associated pathologies 




D statistic exclusion 
Q statistic exclusion 
Normalisation 
Combined spectral and pathology 
data ready for analysis  
Figure 8-16 – Preprocessing algorithm for probe spectral data 
After pre-processing the classification accuracy achievable was assessed using the 
boot strap cross validation PCA LDA method outlined in chapter 7.5.7, Figure 7-16 
and Figure 7-17. 
8.5 Results 
8.5.1 Summary of measurements 
In this comparison 910 spectra were measured from 91 tissue samples from the 64 
participants previously identified for transepidermal Raman analysis. The 
histopathological classification of the measured samples is summarised in Table 8-1. 
In nine instances (1% of spectra measured) individual spectral measurements 
needed to be repeated to obtain ten spectra per sample. The most common reasons 
 
 269 
for repeat measurements were software failure and accidental movement of the 
apparatus. 
Table 8-1 – Samples measured for probe investigation 
 
 
8.5.1 Spectral processing and exclusions 
In the cross validation classification analysis a mean of 34.18% (± 42.02, 95% CI) of 
spectra were excluded by the DQ statistic from the training set and 33.38% (± 66.01, 
95% CI) of spectra were excluded from the test sets in each loop. This resulted in 
the complete exclusion of 5 whole samples from the test analysis using the D and Q 
statistic methods. In addition, detector saturation occurred in a small number of 
spectra below 700 cm-1 and for this reason the spectra were truncated for analysis 
and the spectral data below 700 cm-1 was excluded from the analysis. 
8.5.2 Diagnostic classification  
A three group analysis of the data was performed to assess the performance of the 









Non neoplastic vulval epithelium 30 300 
Vulval Intraepithelial Neoplasia 30 300 
Squamous cell carcinoma 31 310 
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disease as outlined in Table 13-1 as this mirrored the clinical needs identified and 
the aim of the investigation. 
Initial PCA demonstrated that 77% of the variance in the spectral data could be 
accounted for by the first four principal components (Figure 8-17). In the boot strap 
cross validation analysis (chapter 7.5.7) the minimum number of principal 
components used was 4 and the maximum was 17 (Figure 8-18). 



















Figure 8-17 – Variance in data described by each principal component, 77% of variance described in 
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Figure 8-18 – Number of principal components used in each of the bootstrap crossvalidation loops 
 
The distribution of the LD scores for each of the classified spectra is illustrated in the 
LD scores plot in Figure 8-19. There does appear to be separation of the three 
groups but as expected this is less pronounced than with the investigations in 
Chapter 6 and Chapter 7 given the lower signal to noise in the spectra measured 
from the Raman probe and the inevitable contribution of signal from less relevant 


























Figure 8-19 – Histogram of linear discriminant scores, non-neoplastic vulval tissue, SCC – squamous 
cell carcinoma and VIN – vulval intraepithelial neoplasia  
 
The four principal components that accounted for the greatest variability between the 
pathology groups are shown in Figure 8-20. These components do not account for 
the greatest variability in the spectral data but they are all in the top six components 
by percentage variance suggesting that a significant proportion of the variation in the 



















































Figure 8-20 – Principal component loadings of four most significant scores as determined by ANOVA. 
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Figure 8-21 – Weight of the contribution of each principal component score to the linear discriminant 
model. In a three group model two linear discriminant functions are required to separate the groups 
and these are represented by function1 (blue) and function 2 (yellow).  
Table 8-2 and Table 8-3 show the confusion matrices for the cross-validated 
classification model when analysed by individual spectra and as whole samples 
respectively. The classifications in these tables are a representation of the 
classification performance when the linear discriminant boundary is midway between 
the pathology groups. Given the relatively small number of spectra taken from each 
sample the results by spectra and by group are quite similar. The classification 
performance is similar to that obtained in the previous investigation with an overall 
sensitivity for the detection of VIN or SCC from non-neoplastic vulval skin of 81% 
with a specificity of 57% when the linear discriminant boundary is midway between 
the pathology groups. When analysing by sample the specificity is improved but the 





Table 8-2 – Confusion matrix for spectra based on classification with linear discriminant boundary 
midway between the pathology groups, rows are true pathology group and columns are predictions. 






Non-neoplastic 99 64 11 
Vulval intraepithelial 
neoplasia 56 59 46 
Squamous cell 
carcinoma 19 15 190 
Sensitivity 57 37 85 
Specificity 81 80 83 
 
Table 8-3 – Confusion matrix for samples based on modal classification of spectra with linear 
discriminant boundary midway between the pathology groups, rows are true pathology group and 
columns are predictions. 
 
 
The ternary plot in Figure 8-22 shows the predicted probabilities of a sample 
belonging to each of the three pathology groups with the sample’s actual pathology. 
There appears to be continuum between the neoplastic and non-neoplastic tissues in 
keeping with the pathogenesis of SCC rather than clearly separable groups by 
probability of group membership. No samples of SCC tissue have a high predicted 






Non-neoplastic 15 9 1 
Vulval intraepithelial 
neoplasia 11 9 10 
Squamous cell 
carcinoma 3 2 26 
Sensitivity 60 30 84 
Specificity 77 80 80 
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probability of being in the non-neoplastic group with all samples having a predicted 
probability of belonging this group of less than 50% and all samples having a 
probability of belonging to the cancer group of 41% or less. Likewise no samples of 
non-neoplastic tissue have a greater than 55% probability of belonging to the SCC 
group. This corroborates the findings in the previous chapter that the technique has 
significant promise in identifying SCC from non-neoplastic vulval skin. The distinction 
between the VIN and SCC groups and the VIN and non-neoplastic groups is less 
clear. Some samples of VIN were found to have a high predicted probability of being 
in the non-neoplastic or SCC group and some samples of non-neoplastic tissue were 
found to have a high predicted probability of being in the VIN group with some 












































Figure 8-22 – Ternary plot of the predicted probabilities of a sample belonging to each of the three 
pathology groups under analysis. Non-neoplastic vulval tissue, VIN – vulval intraepithelial neoplasia, 
SCC – squamous cell carcinoma. Legend indicates actual pathology of samples, axes are probability 
of group membership based on linear discriminant distance.  
The receiver operator curves demonstrating the diagnostic performance of the 
Raman probe with varying linear discriminate boundaries are shown in Figure 8-23, 
Figure 8-24 and Figure 8-25. These figures demonstrate that by altering the linear 
discriminate boundary between the groups sensitivities of 86% to 95% can be 
achieved with specificities of 72% to 57% respectively for the detection of non-
neoplastic tissue from SCC or VIN (Figure 8-23). Likewise sensitivities of 81% to 
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89% can be achieved with specificities of 85% to 60% respectively for the detection 
of SCC from VIN (Figure 8-24) and sensitivities of 84% to 92% can be achieved with 
specificities of 84% to 64% respectively for the detection of SCC from non-neoplastic 
tissue and VIN (Figure 8-25). 















Figure 8-23 – Receiver operator curve for the 
detection of non-neoplastic tissue from SCC and 
VIN per spectrum. Area under curve, 0.85,  Risk 
of falsely rejecting null hypothesis, <0.05 















Figure 8-24 – Receiver operator curve for the 
detection of SCC from VIN per spectrum. Area 
under curve, 0.87,  Risk of falsely rejecting null 
hypothesis, <0.05 
 















Figure 8-25 – Receiver operator curve for the 
detection of SCC from VIN and non-neoplastic 
tissue per spectrum. Area under curve, 0.91,  




8.6 Spectral peak assignments 
As previously discussed the exact nature of the biomolecular changes that leads to 
disease classification using Raman spectra are difficult to identify with confidence 
(chapter 6.7). In both the streamline investigation (Chapter 6) and the transepidermal 
investigation in Chapter 7, spectral differences between the pathology groups were 
identified that were consistent with the published literature investigating malignant 
processes at other skin sites. These included a right shift in the 1661 cm-1 Amide I 
band, a widening of the peak at 1451 cm-1 and an increase in peak intensity at 1080 
cm-1 with malignant progression (Gniadecka et al., 1997; De Gelder et al., 2007). In 
the current data obtained using the fibre probe the right shift in the 1661 cm-1 band is 
less clearly seen although the changes at 1451 cm-1 and 1080 cm-1 are replicated 
(Figure 8-26). 
A number of the novel spectral differences between the malignant and non-
malignant groups seen in the streamline model and the transepidermal investigation 
in Chapter 7 are again replicated in the spectra obtained using the fibre optic probe. 
These include the increased prominence of the peaks at 723 cm-1, 782 cm-1, and 
1101 cm-1 likely to represent DNA and RNA consistent with the increase rate of cell 
proliferation in neoplastic tissue. Increased prominence in the peak at 830 cm-1 
(nucleic acids) is again seen in this data but it is partially obscured by the peak at 
814 cm-1 likely from the presence of dermal collagens within the spectra. The 
previously seen reduction in the mono/disaccharide peak at 899 cm-1 in the 
streamline investigation is not clearly identifiable due to masking from adjacent 
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spectral peaks. Other amino acid peak changes previously seen including the 
increased prominence of the amino acid peak at 756 cm-1 and the reduction in the 
prominence in the peak at 1622 cm-1 are again seen but the changes are subtler in 
the data acquired through the probe system. In the spectra obtained with the probe 
system there is a striking difference in the Amide III region of the spectrum between 
1224 cm-1 and 1269 cm-1. In this region there is increased prominence of the spectral 
peaks in the VIN and non-neoplastic groups. This could be accounted for by the 
signal from dermal collagens or from changes in other structure proteins. The 
change in structural proteins can be explained by the desmoplastic/ fibroblastic 
response that can be seen in association with carcinoma formation (Holthoff et al., 
2017). In the adjoining region 1287 cm-1 to 1342 cm-1 there is a significant increase 
in prominence of the peaks in the SCC group and to a lesser extent the VIN group. 
This is likely due to amide II proteins (1283 cm-1 & 1311 cm-1), lipids (1283 cm-1), 
elastin (1273 cm-1), collagen (1323 cm-1) carbohydrates (1342 cm-1) and RNA (1328 
cm-1). It is not clear why this feature was not seen in the trans-epidermal spectra 
collected by the microscope system but it is likely that there is a significant difference 
in sampling volume between the microscope and probe systems. The microscope 
system has a degree of confocality due to the use of microscope objectives and a 
relatively narrow spectrometer slit. This results in inclusion of signal from only a 
narrow volume in the collected spectra, as previously demonstrated. By contrast the 
probe system has no focusing objectives and no confocality, so signal from a wider 
tissue area will be included in the collected spectra. The changes seen in the spectra 
measured with the probe system between 1224 cm-1 and 1342 cm-1 were also noted 
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by Ferreira et al. in an ex vivo and in vivo study of Raman spectra collected from 
normal tissue, basal cell carcinoma, actinic keratosis and SCC (Ferreira Lima et al., 
2019). In this study the authors compared the in vivo and ex vivo Raman spectra of 
seven SCC lesions and ten areas of normal skin using a dispersive Raman 
spectrometer. The areas of greatest variability between the SCC and normal group 
were found in the regions between 1250 cm-1 and 1350 cm-1 and between 1440 cm-1 
and 1670 cm-1. These same variations in peak intensity are seen in this current study 
confirming these changes are likely due to changes in the pathology rather than as a 
result of interference from the experimental technique. The identified spectral 
differences are also reflected in the difference spectrum between overtly malignant 
and non-neoplastic tissue (Figure 8-27) as well as the composite PCA LDA loading 
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Figure 8-26 – Mean spectra of the pathology groups. Non-neoplastic vulval tissue, VIN – vulval 
intraepithelial neoplasia and SCC – squamous cell carcinoma. +/- one standard deviation marked by 
shading either side of line. 
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Figure 8-27 – Difference spectrum: mean of the non-neoplastic group spectrum subtracted from the 
mean of the SCC group spectrum 
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Figure 8-28 – Composite PCA LDA loading 
8.7 Interim discussion 
[Summative discussion and conclusions relating to the investigations outlined in 
Section C relating to Raman spectroscopy for the assessment of vulval disease can 
be found in Chapter 13] 
The aim of this investigation was to evaluate the ability of a fibre optic probe and 
portable Raman spectrometer to classify non-neoplastic, premalignant and malignant 
disease of the vulva. This is the first study to demonstrate classification of vulval 
disease using Raman spectra collected using a probe based system. In this 
investigation it was possible to use individual Raman spectra to accurately classify 
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the pathology of the tissue being investigated with clinically relevant accuracy. This 
has replicated the results of the previous two analyses of this tissue set as outlined 
in Chapter 6 and Chapter 7. When comparing the probe technique with the mapping 
approach (Chapter 6) and the point measurement approach (Chapter 7), a significant 
fall in diagnostic accuracy would be expected as the probe system is associated with 
more noise and other sources of interference for example the optical etaloning 
outlined above. The study demonstrated that the ability of the probe technique in 
differentiating the pathology groups was found to be comparable to that of the point 
measurement approach (Chapter 7) as outlined in Table 13-2. The areas under the 
ROC curves were very similar for all three of the main diagnostic comparisons 
demonstrating a portable probe based system is capable of diagnostic performance 
similar to that of the bench based laboratory system. The relatively good 
performance of the probe in relation to the trans-epidermal spectra collected in 
Chapter 7 may be due to differences in sampling volume of the probe compared to 
microscope system as suggested by the additional spectral features identified as 
outlined in chapter 8.6. The same samples were analysed using both techniques. 
Further discussion of future work and the steps necessary to translate these finding 




Section D: Fourier Transform Infrared 





Chapter 9 Introduction, Aims and Objectives 
9.1 Introduction 
As previously discussed in chapter 3.4.3.1 there are currently no established 
methods for automating elements of the histopathological diagnostic pathway in 
vulval disease. Histopathologists’ time is a valuable and finite resource and the 
increasing incidence of cancer and the growing complexity of referrals are leading to 
a potential crisis in this key diagnostic resource (Bainbridge et al., 2016). The ability 
to automate elements of the histopathological pathway or triage tissue samples has 
the potential to speed up the diagnosis of patients with vulval cancer. The 
improvements in the diagnostic pathway could arise out of ability to rapidly triage 
samples at high risk of cancer to full pathology review or in providing an automated 
rapid double reporting of specimens (Hirschowitz, Wells and Lowe, 2013). Recently 
there has been a great deal of interest in spectroscopic methods for the identification 
of malignancies. The use of FTIR for differentiating between different tissue types 
has been gaining significant research interest because of its potential as a tool in 
histological and cytological diagnosis. FTIR is a non-destructive method that can 
detect changes in molecular functional groups in tissues under assessment, in the 
mid infrared region. The technique has been demonstrated to be an accurate 
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instrument for the discrimination of malignant and non-malignant tissue in the colon, 
breast, prostate, cervix, stomach, skin and oesophagus. To date there have been 
only a small number of studies exploring the role of FTIR in the assessment of skin 
disease. Tfayli et al. demonstrated that the areas of FTIR spectra relevant to melanin 
and DNA could be used to differentiate spectra of melanoma and pigmented naevi 
collected from paraffin fixed tissue sections (Tfayli et al., 2005). Hammody et al. 
differentiated melanoma from surrounding epidermal tissue using markers found in 
the regions of the IR spectrum associated with nucleic acids (Hammody et al., 2008). 
Ly et al demonstrated IR spectroscopic micro-imaging of paraffin fixed tissue 
sections could be used to differentiate BCC, SCC, Bowen’s disease and normal or 
reactional epidermis (Ly et al., 2009). More recently Kryriakidou et al showed IR 
spectral changes in samples of BCC, melanoma and benign naevi however the 
study was too small to demonstrate the classification ability of the technique 
(Kyriakidou et al., 2017). These studies suggest FTIR has promise for the 
differentiation of skin pathologies and for the identification of malignancies. To date 
there are no published studies evaluating the use of FTIR for the assessment of the 
unique set of pathologies present in the human vulva. 
In addition to simply distinguishing between different histopathological diagnoses 
FTIR like Raman spectroscopy has the potential to offer a unique biomolecular 
assessment of tissue in a way that can be easily integrated in the normal diagnostic 
pathway. FTIR can be used to assess the protein, carbohydrate, nucleic acid and 
lipid content of human tissues. The composition of these constituents will change 
during the process of carcinogenesis (chapter 1.4) and these changes have the 
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potential to be an early marker for the development of cancer (Bhargava, 2007; 
Kumar et al., 2013). Detecting these changes could allow the identification of cancer 
before the typical histopathological morphological changes are seen, leading to 
earlier diagnosis and treatment. Kumar et al used FTIR to detect changes in key 
structural proteins within breast tissue that where found to be present in tumour 
tissue, in adjacent histologically normal tissue and with decreasing intensity with 
increasing distance from the primary tumour (Kumar et al., 2013). Detectable 
changes in tissues adjacent to tumours raises the possibility of detectable 
biomolecular changes associated with cancer that could be used for early diagnosis 
or risk assessment. 
As well as early diagnosis, biomolecular assessment of tissues using FTIR has the 
potential to provide useful information on disease course or prognosis not provided 
by traditional histopathology. Baker et al associated FTIR based spectral 
characteristics with clinically aggressive behaviour in prostate cancer (local and 
distant spread) (Baker et al., 2008). This study importantly demonstrates that FTIR 
has the potential to enhance traditional histopathology with information not currently 
accessible, such as enhanced assessment of aggressive tumour behaviours. 
Mackanos et al demonstrated that histopathological grading score (Gleason grading) 
could be determined from FTIR spectra with 92.3% sensitivity and 99.4% specificity 
(Mackanos and Contag, 2009). The authors also demonstrated that tumour staging 
could be predicted from FTIR spectra of the primary tumour with 91.2% sensitivity 
and 93% specificity. It should be noted that this study was an exploratory analysis 
with only 39 patients included with no validation of the classification model. Minnes 
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et al showed that ATR-FTIR could be used to identify metastatic and non-metastatic 
melanoma cell lines, information not currently available using histopathology or 
cytology (Minnes et al., 2017). 
As previously discussed FTIR spectroscopy is particularly well suited to these 
applications as the technique can be used to assess biomolecular features of tissue 
prepared in a routine manner in a timely fashion and could be integrated into the 
standard sample processing pathway. 
9.2 Aims 
To investigate the ability of FTIR Spectroscopy to classify vulval pathology including 
lichen sclerosus, vulval intraepithelial neoplasia and vulval squamous cell carcinoma.  
To investigate the potential of FTIR spectroscopy to work as an adjunct to 
histopathology to aid in the early diagnosis of cancer and offer additional information 
about the molecular risk profile of vulval tissue. 
To achieve this aim, the following objectives were set to progress experimentation 
with the technique. 
9.3 Objectives 
1. Evaluate the ability of FTIR spectroscopy to classify significant vulval 
pathologies including vulval intraepithelial neoplasia, vulval squamous cell 
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carcinoma & non-neoplastic vulval tissue and explore underlying spectral 
differences. 
a. To investigate the ability of FTIR spectroscopy applied to routinely fixed 
and embedded tissue sections for the triage of vulval pathologies. 
b. To investigate the ability of FTIR spectroscopy to act as a second 
opinion to confirm routine histological diagnosis. 
2. Evaluate the ability of FTIR spectroscopy and multivariate analysis to identify 




Chapter 10 FTIR General Technical 
Considerations and Ethical Approval 
10.1 Ethical approval and consent 
Research ethics committee approval was gained for the use of archived fixed vulval 
tissue from the East of Scotland Research Ethics Service (14/ES/1066). 
10.2 Instrumentation 
The Fourier transform infrared spectroscopy presented in this thesis was performed 
using a FTIR spectrometer linked to an imaging system. The system used was a 
Perkin Elmer Spectrum One spectrometer together with a Perkin Elmer Spotlight 400 
microscope system (Ohio, USA).  This system has a liquid nitrogen cooled linear 
focal plane array detector (16x1) that can be used in imaging mode to produce 
spectral maps of tissue sections.  This system can be used in a reflectance or 
transmission mode and for this study all samples were analysed in transmission. 
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10.3 Sample indentification 
The Gloucestershire Hospitals NHS Foundation Trust pathology database was 
screened to locate relevant samples and review of the accompanying H&E stained 
tissue sections was used to locate the fixed tissue blocks of interest. Tissue sections 
from these blocks were cut for FTIR analysis. Tissue blocks with visible tissue ink 
were avoided to prevent contamination of the ink onto the tissue during cutting. All 
tissue analysed was embedded within paraffin and no chemical deparaffinisation 
was undertaken prior to spectral acquisition. 
10.4 Sample preparation 
Samples prepared for analysis by FTIR spectroscopy must meet the criteria outlined 
in Table 10-1 to ensure the biomolecular information contained within the infrared 
absorbance spectra is effectively recorded and available for analysis. 
10.4.1 Sample substrate 
Circular 20 mm diameter calcium fluoride slides were chosen as the most 
appropriate tissue substrate. The low absorption of calcium fluoride in the infrared 
range means the tissue signal is not adversely affected by the slide. In addition 
circular slides mounted for analysis in a custom made slide tray (Figure 10-1) 
allowed orientation of the slide to make best use of the rectangular mapping area of 
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the FTIR system. The fabrication workshop, department of physics and astronomy, 
University of Exeter, manufactured the custom slide tray. 





Samples should not be completely opaque to infrared 
radiation as this will result in saturation of the absorption 
spectrum and loss of spectral information. 
The infrared 
spectrum of the 




If the spectra peaks of the substrate overlap the tissue 
related spectral peaks the tissue signal may be obscured 
and relevant biomolecular information lost. 
Should not contain 
other substances 
that will obscure the 
bio-relevant spectral 
range 
Other substance within the tissue such and inks and paraffin 
may result in spectral signal that obscures relevant 
biomolecular information. 




The ability to map the measured spectrum to 
histopathological classifiable stained sections allows 
correlation of spectral and histological information. 
Should be 
orientatable to allow 
efficient use of the 
rectangular 
measurement 
window of the 
spectrometer 
The FTIR system used was limited to acquisition of 
rectangular maps of samples and therefor the ability to 
securely orientate the samples is key to make most efficient 





Figure 10-1 – Custom built slide tray for 20 mm calcium fluoride slides 
10.4.2 Sample tissue section thickness 
An initial experiment was undertaken to ascertain the optimal thickness for tissue 
sections to undergo FTIR mapping. As external vulval skin like skin elsewhere in the 
body forms a protecting barrier it is highly keratinised.  This keratin layer is dense 
and relatively opaque to light.  For this reason an assessment of the limit of the FTIR 
spectrometer’s ability to detect photons penetrating through tissues of different 
thicknesses was undertaken.  This was done to ensure that the spectra collected 
from mapping the tissue sections would not be adversely affected by high 
absorbance in the tissues and the limit of the FTIR detector. 
The assessment was formed of two parts.  The first was to establish the FTIR 
detector’s response to decreased signal due to an increasing absorbance by the 
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sample under analysis.  Spectral maps were obtained of semi opaque polymer 
windows that were added together to form and increasingly absorbent layer.  
Spectral maps were collected for an increasing number of windows up to a total of 
twelve.  The absorbance at the wavenumber with the greatest absorbance in the 
spectra (1600 cm-1) (Figure 10-2) was plotted against the increasing number of semi 
opaque windows.  This revealed that the response of the detector is linear to a limit 
after which no light is detected by the spectrometer, the saturation point (Figure 10-
3). 
  
Figure 10-2 – FTIR absorbance spectra in the 
region 1540 to 1645 cm-1 with increasing 
numbers of semi opaque windows (Spectral 
resolution 4 cm-1; Scan per pixel 16; 
Interferometer Speed 2.2 cm/s) 
Figure 10-3 – Absorbance plotted against 
increasing numbers of semi opaque windows 
(Spectral resolution 4 cm-1; Scan per pixel 16; 
Interferometer Speed 2.2 cm/s) 
This process was then repeated for increasing thicknesses of tissue sections taken 
from a block of normal vulval skin ranging from 1 to 8 microns.  The greatest 
absorbance peak (Figure 10-4) (1650-1660 cm-1) was plotted against the thickness 
of the tissue sections and the same linear relationship was seen (Figure 10-5).  The 
thickness of tissue sections chosen for the analysis was 4 µm as this thickness of 
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section is readily prepared and correlated with adjacent H&E stained sections and it 
lies firmly within the detection range of the FTIR system.  If tissue section density 
varies between different samples and pathologies at 4 µm, denser tissues should still 
be within the range of the detector. 
  
Figure 10-4 – FTIR absorbance spectra in the 
region 1560 to 1745 cm-1 with increasing 
thickness of tissue section (Spectral resolution 4 
cm-1; Scan per pixel 16; Interferometer Speed 
2.2 cm/s) 
Figure 10-5 – Absorbance plotted against 
increasing numbers of semi opaque windows 
(Spectral resolution 4 cm-1; Scan per pixel 16; 
Interferometer Speed 2.2 cm/s) 
10.5 Optimisation of acquisition parameters for spectral 
measurement 
Initial experiments were undertaken to determine the optimal parameters for spectral 
measurement.  The aim of the optimisation was to maximise the signal to noise ratio 
in the spectra collected (chapter 4.1.2), preserve useful detail in the spectra and 
allow the measurements to be undertaken in a technically feasible timeframe.  
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For the purposes of determining the optimal acquisition parameters the signal to 
noise ratio was calculated from the signal height of the main tissue peak between 
1600 and 1800 cm-1 over the adjacent spectrum at 1692 cm-1 divided by the noise.  
The noise was calculated by estimating the noiseless spectrum by applying a 
median filtering technique at a section of the spectrum where there is no significant 
tissue signal. The mean of the absolute difference between the actual spectrum and 
the estimated median filtered spectrum was then taken to be the noise (chapter 
4.1.2).  
10.5.1 Maximum length of aquisition 
The length of spectral acquisition with the Perkin Elmer Spotlight 400 system is 
limited by the size of the liquid nitrogen Dewar flask within the instrument.  An 
experiment was performed to evaluate the length of acquisition that was possible. 
The liquid nitrogen Dewar flask was filled from room temperature and a 7 hour map 
of homogeneous tissue commenced. The signal to noise ratio was calculated and 
plotted (Figure 10-6). After around five and a half hours acquisition, the detector 
starts to warm and the signal to noise ratio decreases and eventually at around six 




Figure 10-6 – Signal to noise ratio in mapping model with increasing time from filling of liquid nitrogen 
dewar in Perikin Elmer Spotlight 400 FTIR system 
10.5.2 Acquisition parameters 
Using a 4 µm thick paraffin fixed section of normal vulval epithelium a comparison 
was undertaken of the effect of the scans performed per pixel, spectral resolution 
and interferometer speed on signal to noise and acquisition time. 
To assess the role of the spectral resolution, spectra were collected from normal 
vulval epithelium for resolutions of 2, 4, 8 and 16 cm-1.  At the higher resolutions, the 
spectra have increased spectral detail however a reduced signal to noise ratio 
(Figure 10-7).  At 16 cm-1 the spectra is significantly smoothed and the noise in 
spectrum is difficult to assess accurately.  At the lower resolutions the noise reduces 
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however the detail spectra information is lost.   At resolutions below 4 cm-1 the ability 
to distinguish the paraffin peaks between 450 cm-1 and 480 cm-1 is lost (Figure 10-7).  
The resolution of the spectra collected significantly impacts on the time taken to 
collect the spectra.  The greatest reduction in time taken for map acquisition is seen 
between a spectral resolution of 2 and 4 cm-1 (Figure 10-9).  In order to record good 
quality spectra with a high spectral resolution and signal to noise ratio in an 
acceptable time frame a spectral resolution of 4 cm-1 was chosen for the analysis. 
  
 
Figure 10-7 – Signal to noise ratio with 
decreasing spectral resolution 
Figure 10-8 – Tissue absorbance spectra for 
different spectral resolutions 
Spectra were collected for the two different interferometer speed settings 1 cm/s and 
2.2 cm/s.  There did not seem to be any difference in the resultant spectra or signal 
to noise ratio (Figure 10-10).  The time taken for spectral acquisition is directly 
proportional to the speed of the interferometer with a typical tissue map of 750x750 
microns area at resolution of 6.25microns, 16 scans per pixel and spectral resolution 
taking 301 minutes and 153 minutes at interferometer speeds of 1 cm/s and 2.2 cm/s 
respectively. Therefore as the absorbance of the light though 4 µm sections of tissue 
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does not approach the detection limit of the detector (Chapter 10.3) an 
interferometer speed of 2.2 cm/s was chosen for the analysis. 
  
Figure 10-9 – Acquisition time for a typical map 
of a 750x750 microns area at spatial resolution of 
6.25 µm,16 scans per pixel, interferometer speed 
2.2 cm/s   
Figure 10-10 – Tissue spectra for different 
interferometer speeds, 16 scans per pixel, 
spectral resolution of 4 cm-1 
The number of scans per pixel (SPP) was evaluated by the acquisition of spectral 
maps of normal vulval epithelium at a 2, 4, 6, 16, 32, 64 and 128 SPP using an 
interferometer speed of 2.2 cm/s, a spectral resolution of 4 cm-1 and spatial 
resolution of 6.25 microns.  The signal to noise ratio of individual spectra was then 
calculated and is shown in Figure 10-11.  Overall the signal to noise ratio for all the 
spectra collected across all numbers of SPP was high and visually there is little 
noticeable difference between the spectra.  However the signal to noise increases 
significantly when the SPP increases from 2 to 32 with the majority of the increase 
happening between 2 and 16 SPP.  Beyond 32 SPP there is not such a pronounced 
increase in the signal to noise ratio.  The spectral acquisition time is directly 
proportional to the number of SPP and doubling of acquisition time between 16 and 
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32 SPP does not produce such a rise in the signal to noise ratio.  Therefore for the 
purposes of this study, 16 SPP was used when analysing tissue samples. 
 
Parameter Optimised Setting 
Resolution 6.25 µm 
Spectral resolution 4 cm-1 
Scan per pixel 16 
Interferometer Speed 2.2 cm/s 
 
Figure 10-11 – Signal to noise ratio with 
increasing scans per pixel for spatial resolution of 
6.25 µm, interferometer speed 2.2 cm/s  and 
spectral resolution of 4 cm-1 
Table 10-2 – Optimised parameters for 
acquisition of FTIR spectral maps 
The optimised parameters selected (Table 10-2) allowed for the collection of high 
quality spectra of histological relevant regions of tissue in an acquisition time that is 
within the constraints of the FTIR system. 
10.6 Management of non tissue FTIR absorption 
FTIR absorption due to substances other than tissue has the potential to obscure 
tissue signal and confound spectral analysis. Two main sources of non-tissue 
absorption were considered in this study: paraffin absorption and absorption due to 
atmospheric water. In both cases steps were taken in the processing of the spectral 
data to minimise the impact of this absorption on the analysis. 
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10.6.1 Paraffin correction 
Spectra obtained from FTIR of sections of paraffin embedded fixed tissue contain 
large variations due to the variation in paraffin content.  In order that the 
classification model developed did not classify pathology groups based on the 
differences in paraffin content, a spectral correction was undertaken. This was done 
to ensure the inter- and intra-sample variation in the areas of the spectrum 
associated with paraffin was minimised. 
To correct for the paraffin, representative areas of tissue free paraffin were scanned 
using an identical technique as the tissue samples.  The resultant spectra underwent 
principal component analysis (chapter 4.2.1) to identify the key variation in the 
spectra.  The principal component loads were then used with an extended 
multiplicative signal correction (EMSC) to correct the tissue spectral data for paraffin 
content.  This method neutralised the variability in the signal from the paraffin by 
constraining the paraffin bands in the spectra to the same amplitude, regardless of 
the measured spectra (Tfayli et al., 2009; Nallala, Lloyd and Stone, 2015). 
10.6.2 Atomospheric water correction 
Water vapour signal is typically seen in FTIR spectra between 1300 and 2000 cm-1 
and again between 3500 and 4000 cm-1. Several precautions are taken to reduce the 
variation in the impact of atmospheric water on spectral measurements. The FTIR 
spectrometer was situated in an air-conditioned room with low and stable relative 
humidity. In addition, the sample stage of the spectrometer is enclosed to reduce 
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variation in humidity due to the presence of the operator and the spectrometer 
undergoes continual active dehumidification with desiccant within the apparatus. 
Despite these measures, artefacts from IR absorption from water are still seen within 
the tissue spectra. 
The control and data acquisition software of the Perkin Elmer spectrometer 
(Spectrum Image, Perkin Elmer, Ohio, USA) contains an algorithm for the automatic 
correction of background absorption based on the measurement of a background 
signal undertaken prior to the acquisition of a spectral map. This background was 
measured from a clean area of the calcium fluoride slide on which the tissue section 
was mounted. The intention is that this built in correction algorithm should correct for 
water vapour. The persistence of a water vapour artefact in the corrected data and 
principal component loadings suggested the correction algorithm was not adequate 
and further correction was required. Algorithms for the correction of water vapour 
artefact have been developed and a technique previously established for the 
correction of water vapour artefact from this instrument was applied to the collected 
data prior to analysis (Bruun et al., 2006; Old, 2015). This correction technique uses 
background measurements taken while the spectrometer is purged with nitrogen to 
reduce the water vapour present within the spectrometer. The second derivative of 
the ratio of the background spectrum measured in normal atmosphere and the 
background spectrum measured during a nitrogen purge underwent a least squares 
fit to the second derivative of the measured spectra. The area of the spectrum 
associated with carbon dioxide (2280-2394 cm-1), which is the other major 
contributor to the atmospheric spectrum was excluded from the fit. This prevented 
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the fit from under correcting for water vapour and preferentially correcting for 
atmospheric carbon dioxide. The resultant coefficient of fit for each individual 
spectrum was then used to correct for the water content in the spectrum (Figure 10-
12 and Figure 10-13).  

























Figure 10-12 – Example mean tissue spectrum before and after water vapour correction 



























Chapter 11 FTIR Spectroscopic Aided 
Detection of Disease 
11.1 Introduction 
As previously discussed (chapter 3.4.3.1 and chapter 9.1), there is the need for an 
objective technique for the classification vulval disease. Such a technique would 
enable the triage of cases to enable the histopathologist’s workload to be prioritised 
and would offer a second opinion of the histopathological diagnosis to help reduce 
reporting errors and reduce the burden of double histopathological reporting. The 
following comprises a preliminary evaluation of FTIR spectroscopy as a suitable 
technique for this purpose.  
11.2 Objectives 
This investigation assesses objective 1a and 1b of the aims and objectives outlined 
in Chapter 9. 
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11.3 Sample selection, preparation and measurement 
Three tissue groups were selected for the analysis based on their common 
pathological origins and development. The first tissue group selected was non-
neoplastic tissue comprising normal vulva and lichen sclerosus affected vulva as 
these represent the benign pre-neoplastic state of the vulva. The second group 
chosen was vulva affected by vulval intraepithelial neoplasia (VIN) as this represents 
an important premalignant vulval condition that often requires treatment to avoid 
progression to vulval cancer. The third group chosen for the comparison was vulval 
squamous cell carcinoma (SCC) as this is an important diagnosis to be accurately 
made and a condition that can follow as a consequence of lichen sclerosus and VIN.  
The electronic pathology database of Gloucestershire Hospitals NHS Foundation 
Trust was interrogated to identify vulval tissue samples from each of the three 
selected pathology groups. The H&E stained slides from the identified cases were 
reviewed by an expert gynaecological histopathologist to select the areas in the 
tissue blocks containing the pathologies of interest. In cases where the presence of 
pathology of interest was confirmed the paraffin blocks containing the tissue were 
identified and four µm sections cut onto circular 20 mm calcium fluoride slides 
(Chapter 10.4). A 4 µm section was also cut on to a glass slide for H&E stain before 
and after a section was cut on to calcium fluoride. This was completed to allow 
accurate correlation of the unstained section and the pathology present. In total 32 
sections were cut on to calcium fluoride from each of the pathology groups. This 
number of samples was selected to account for failures in sample processing aiming 
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to have 30 completed IR maps of each pathology group. As the significance of the 
spectral changes between the pathology groups was not known, it was not possible 
to perform a meaningful sample size calculation to estimate the number of samples 
required. 
The H&E stained tissue sections cut from either side of the unstained sections were 
reviewed by a pathologist and the area containing the pathology of interest marked 
on the slide. The unstained sections on calcium fluoride then underwent FTIR 
spectroscopic mapping. When mapping the unstained sections a white light image of 
the samples was measured on the Perkin Elmer Spotlight system and the image 
compared to the area selected by the pathologist on the H&E stained section (Figure 
11-1). The relevant area was then selected for spectroscopic analysis. The area 
selected for spectroscopic analysis included the full thickness of the epidermis and 
an area of paraffin for EMSC correction of the paraffin peaks (chapter 10.6.1) (Figure 
11-1). Due to the irregular and heterogeneous nature of the samples and the need to 
collect spectra from the full thickness of the epidermis the shape and size of the 
spectroscopic maps varied according to the sample under analysis. Approximately 
four and a half hour long maps were taken from each sample using the acquisition 
parameters outlined in chapter 10.5. This resulted in varied number of spectra 
acquired due to the variable dimensions of the acquisition area. Prior to each map a 











Figure 11-1 – White light image of unstained section of a sample of VIN (A) and corresponding H&E 
stained section (B) 
11.4  Spectral preprocessing and analysis 
Following acquisition of the spectral data map, the measured transmission was 
converted to absorbance by logarithmic transformation and corrected for 
atmospheric water vapour and paraffin as described in chapter 10.6.2. After 
correction for water, a two-stage k means clustering was applied isolating the 
spectra from the paraffin, epidermis, dermis and stratum corneum where present 
(Duda, Hart and Stork, 2001). The first stage was used to isolate the paraffin spectra 
in the map using a k means clustering with two centroids. The two centroids were 
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seeded with a manually selected tissue spectrum and a manually selected paraffin 
spectrum. This split the spectral map into paraffin and tissue spectra and spectra 
only containing paraffin signal. The paraffin spectra were saved for analysis and 
removed from the spectral map for the second stage of the k means clustering. In 
the second stage eight centroid clustering was performed with seed spectra from 
manually selected epidermis, dermis and stratum corneum and five other tissue 
spectra randomly selected from the spectral map. This enabled isolation of the 
spectra measured from the epidermis, dermis and stratum corneum as illustrated in 
Figure 11-2. The spectra from the resultant k means were then saved for analysis. 
 
Figure 11-2 – Example of k means clustering for the isolution of differnent tissue layers in a sample of 
lichen sclerosus. H&E stained section for comparision (top) and k means clusters (bottom) 
Earlier work on the differentiation of normal and pathological abnormal tissues have 
suggested that the wavenumber range 800 to 1800 cm-1 contains the most bio 
relevant area of the infrared spectrum (D Naumann, 2001; Eikje, Aizawa and Ozaki, 
2005; Sahu and Mordechai, 2005; Hammody et al., 2008; Movasaghi, Rehman and 
ur Rehman, 2008a). For this reason and to exclude the contribution of atmospheric 
water (1300 - 2000 cm-1 and 3500 - 4000 cm-1) and carbon dioxide (2220 - 2390 cm-
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1) the wavenumber range was restricted to 800 – 1800 cm-1 for the analysis. It has 
been suggested that the high wavenumber range (2800 – 3000 cm-1) where 
stretching vibration of CH2 and CH3 groups in some proteins and lipids are detected 
can be useful in the classification of disease however in paraffin embedded tissue 
this spectral range is masked by a strong paraffin signal. Initial inspection of the 
resultant significant loadings from the PCA and ANOVA revealed that some of the 
loadings described what appeared to be noise at the lower extreme of the 
wavenumber range (Figure 11-3). To prevent this from having a negative impact on 
the classification accuracy the wavenumber range used for the analysis was 
shortened to 850-1800 cm-1. This excluded the noise between 800 and 850 cm-1 
whilst retaining the bulk of the bio relevant spectral data. 












Figure 11-3 – Example principal component loading describing variance due to noise at the lower end 
of the wavenumber range (main paraffin spectral peaks at 880-898 cm-1, 1358-1394 cm-1 and 1428-




The paraffin spectra isolated from all the samples underwent PCA and the mean 
spectra combined with the PCA loads were used to correct for the variation in 
paraffin content of the combined tissue spectra as described in chapter 10.6.1. In 
addition to this, the areas of the spectrum associated with the main paraffin spectral 
peaks at 880-898 cm-1, 1358-1394 cm-1 and 1428-1498 cm-1 (Figure 11-4) were 
excluded from the analysis to reduce the impact of non tissue signal contributing to 
the classification.  














Figure 11-4 – Mean paraffin spectrum 
The tissue spectra were then filtered for outlying spectra using the D and Q 
classifiers (chapter 4.2.6.1). Classification performance was assessed using PCA 
LDA in a leave one sample out cross validation loop (chapter 4.2.5) and the final 
prediction filtered by Mahalanobis distance to the mean of each of the LDA groups 




Figure 11-5 – Data analysis flow chart for the analysis of FTIR spectral maps for evaluation of 
spectroscopic assisted diagnosis. 
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11.5 Summary of measurements 
A total of 93 FTIR spectral maps were collected from 93 tissue samples (Table 11-1). 
These tissue samples came from the specimens from 81 patients as some of the 
larger specimens originating from women undergoing surgery for VIN or SCC 
contained multiple pathologies (e.g. VIN or LS and concurrent SCC) and so 
contributed more than one tissue type for analysis (Figure 11-6).  
 
Figure 11-6 – Summary of the participants included in the investigation (VIN – vulval intraepithelial 
neoplasia, SCC – squamous cell carcinoma & NON – non-neoplastic vulval skin) 
There were no instances where more than one sample of the same pathology 
originated from the same patient. The tissue maps were designed to completely 
sample the epidermis of the tissue sections. In order to achieve this map dimensions 














Non-neoplastic 30 245662 
Vulval intraepithelial 
neoplasia 31 881406 
Squamous cell 
carcinoma 32 1328825 
 
After pre-processing (Figure 11-5), the mean spectra from each of the samples were 
visually reviewed to identity any technical errors in spectral acquisition prior to the 
inclusion of the data in the classification model.  The mean spectra from all of the 
samples exhibited typical features of a tissue spectrum and therefore were all 
included in the analysis (Figure 11-7). 
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Figure 11-7 – Mean  epidermal spectra from each of the 93 samples measured 
11.6 Results 
The initial analysis assessed the classification performance of model for 
discriminating between non-neoplastic vulval skin, VIN and vulval SCC. The reason 
for this approach is that biopsies from women with either non-neoplastic vulval skin 
or VIN will often be taken to investigate for the presence of vulval SCC. The ability to 
use FTIR to triage or offer a second opinion on biopsies taken in this situation would 
be advantageous as previously discussed (chapter 3.4.3).  
As described (chapter 11.4), PCA was used to explore the variance in the data set 
with up to 24 PCs calculated. The PCs that reach the 95% confidence threshold set 
by ANOVA when comparing the PCA scores between the pathological groups as 
determined by the critical value of the F ratio were included in the LDA. The ability of 
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FTIR to differentiate between the tissue types was assessed in a leave one sample 
out cross validation loop (chapter 4.2.5).  
The initial PCA of the spectral data revealed that 95% of the variance in the data was 
accounted for in the first ten PCs with 85% of the variance in the first five PCs 
(Figure 11-8). When ANOVA was applied to the PC scores and the known pathology 
groups of the whole data set the significance of each PC for the classification of the 
disease state was assessed. The ANOVA F ratios for each PC are shown in Figure 
11-9. As much of the variance in the data set is due to variation within individual 
samples or between samples of the same pathology the most significant PCs as 
selected by ANOVA do not correspond to those that describe the most variance in 
the data (Figure 11-8 & Figure 11-9). 









































Figure 11-9 – ANOVA F ratios for principal component scores 
 
LDA of the significant PC scores revealed the pathology groups could be separated 
by LD scores as shown in the histogram of the LD scores by pathology group (Figure 
11-10). The LD scores plot showed some overlap between the groups that is most 
significant between the non-neoplastic group and the VIN group, the model 


























In order to separate the three pathology groups the LDA requires two linear 
discriminant functions. Each of these functions uses the PC scores to separate the 
pathology groups. The weighting given to each PC loading by the linear discriminant 
functions are illustrated in Figure 11-11.  











Figure 11-11 – Weight of each principal component score to the linear discriminant model. 
The leave one out cross-validated PCA LDA classification model with DQ filtering of 
outlying spectra (chapter 4.2) showed good classification of the three pathology 
groups. The confusion matrix for the classification of the samples analysed with the 




Table 11-2 – Confusion matrix for whole samples based on modal classification of spectra with linear 
discriminant boundary midway between the pathology groups, rows are true pathology group and 
columns are predictions. 






Non-neoplastic 27 2 1 
Vulval intraepithelial 
neoplasia 5 23 3 
Squamous cell 
carcinoma 2 4 26 
 
The overall probabilities of group membership were calculated from the combined 
individual discriminant distances of the spectra in each group and plotted on a 
ternary plot to allow visualisation of the distribution of correctly and incorrectly 
classified samples (Figure 11-12). The ternary plot demonstrates that it is possible to 
define alternative discriminatory boundaries to tailor the classification to the clinical 
need. In Figure 11-12 an alternative classification boundary is shown that increases 
the sensitivity of detecting cancer, the result of which are shown in Table 11-3. With 
the modified boundary SSC is detected with a sensitivity of 100% and specificity of 
85% with a positive predictive value of 0.78 and false positive rate of 0.15. This 














































Figure 11-12 – Ternary plot of the predicted probabilities of a sample belonging to the three pathology 
groups under analysis. Non-neoplastic vulval skin, VIN - vulval intraepithelial neoplasia , SCC - 
squamous cell carcinoma. Legend indicates actual pathology of sample shaded areas show 
classification of samples based on discriminant boundary midway between groups. Solid lines 
indicates alternative discriminatory boundary.	 
Table 11-3 – Confusion matrix for whole samples based on combined probability of spectra with 
modified discriminatory boundary between the pathology groups, rows are true pathology group and 
columns are predictions. 






Non-neoplastic 27 2 1 
Vulval intraepithelial 
neoplasia 1 22 8 
Squamous cell 




To further assess the classification performance of the technique receiver operator 
curves were plotted whilst varying the linear discriminant boundary. Comparisons 
were undertaken of the most clinically useful classifications as outlined in chapter 
3.4.3.1. The first comparison looked at the ability of the technique as a technique for 
triaging samples and highlighting those that are likely to contain SCC for urgent 
histopathological assessment. The performance of the technique for the correct 
identification of SCC from non-neoplastic skin and VIN on a per spectrum basis is 
shown by the receiver operator curve in Figure 11-13. For individual spectra the area 
under the receiver operator curve is 0.89 and sensitivities of 81-90% can be 
achieved with specificities of 82-66%. In the context of triaging whole samples it is 
more useful to consider the diagnostic performance in relation to all spectra 
measured from each sample and this more analogous to true histopathological 
assessment. Each sample was classified as SCC or not SCC based a threshold 
number of spectra that were classified as SCC. Using this approach and varying the 
threshold proportion of spectra to classify the sample as SCC, a receiver operator 
curve was produced (Figure 11-14). The area under the curve is 0.96 indicating good 
performance for the identification of samples of SCC from benign pathologies. Using 
this approach a sensitivity of approximately 100% can be achieved with a 
corresponding specificity of 79%. 
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Figure 11-13 – Receiver operator curve for the 
detection of SCC from non-neoplastic skin and 
VIN per spectrum. Area under curve, 0.89,  Risk 
of falsely rejecting null hypothesis, <0.05 















Figure 11-14 – Receiver operator curve for the 
detection of SCC from non-neoplastic skin and 
VIN per sample. Area under curve 0.96,  Risk of 
falsely rejecting null hypothesis <0.05 
 
The second comparison undertaken assessed the role of FTIR for correctly 
identifying SCC from VIN to confirm or assist the histopathologist in making the 
correct diagnosis using a spectroscopic second opinion. In this comparison the 
receiver operator curves for the technique is shown in Figure 11-15 and Figure 
11-16. For individual spectra the area under the receiver operator curve is 0.89 and 
sensitivities of 84-90% can be achieved with specificities of 80-70%. Using the whole 
sample approach outlined above the area under the receiver operator curve is 0.96 
and a sensitivity of approximately 100% can be achieved with a corresponding 
specificity of 77%. These results indicate that the technique shows promise as an 



















Figure 11-15 – Receiver operator curve for the 
detection of SCC from VIN per spectrum. Area 
under curve, 0.89,  Risk of falsely rejecting null 
hypothesis, <0.05 















Figure 11-16 – Receiver operator curve for the 
detection of SCC from VIN per sample. Area 
under curve 0.94,  Risk of falsely rejecting null 
hypothesis <0.05 
 
11.7 Spectral analysis of biomolecular differences between 
pathologies 
Analysis of the spectral differences between pathology groups was undertaken to 
understand the basis for disease classification from FTIR spectra. Understanding 
which biomolecules contribute to which peaks can be achieved though consulting the 
relevant literature and measurements of pure biomolecules made on the same FTIR 
spectrometer. Identification of specific biomolecular contributions to the spectra can 
be challenging, as at many wavelengths there is significant overlap between a 
number of possible bond vibrations and hence possible biomolecules present within 
the tissue. This overlap means that a given spectral appearance may have more 
than one possible molecular cause and hence assignment of spectral peaks to 
individual molecules is purely tentative. 
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11.7.1 Spectral peak assignment 
The mean spectra from each pathology group were analysed to identify the key 
spectral peaks present. The largest peak seen in all pathology groups is the amide I 
peak at 1650 cm-1. The amide I peak is primarily due to protein and the stretching of 
the C=O bond however there are also contributions from DNA, glycogen and 
glycoproteins demonstrating the complexity of spectral peak assignment (Barry, 
Edwards and Williams, 1992). The second largest peak excluding the paraffin peaks 
between 1358 and 1394 cm-1 is the Amide II peak at 1547 cm-1. The Amide II peak is 
produced from the C-N and N-H stretching in tissue proteins (Movasaghi, Rehman 
and ur Rehman, 2008a). Peaks attributable to DNA are broadly spread across the 
spectrum and can be found at 965, 980, 1071, 1084, 1095 and 1245 cm-1 (Skrebova, 
Aizawa and Aras, 2003; Eikje, Aizawa and Ozaki, 2005). Other putative peak 

























Figure 11-17 – Mean normalised spectra of the pathology groups. Non-neoplastic; VIN – vulval 
intraepithelial neoplasia and SCC – squamous cell carcinoma. 
 








DNA & Amide III (Skrebova, Aizawa and Aras, 2003; 
Eikje, Aizawa and Ozaki, 2005) 
980 Ribose group of 
nucleic acids 
(McIntosh et al., 1999; Eikje, Aizawa 
and Ozaki, 2005) 
995, 1028, 1157 Glycogen (Movasaghi, Rehman and ur Rehman, 
2008a) 
1080 Phosphate group 
of nucleic acids 
(McIntosh et al., 1999; Eikje, Aizawa 
and Ozaki, 2005) 
1084 Glycogen  
1000-1150 DNA/protein 
(chromatin) 
(Eikje, Aizawa and Ozaki, 2005) 
1240 Phosphate group 
of nucleic acids 
(McIntosh et al., 1999; Eikje, Aizawa 
and Ozaki, 2005) 
1278 Collagen and 
Amide III 
 
1480-1575 Amide II (Eikje, Aizawa and Ozaki, 2005) 
1600-1700 Amide I (Eikje, Aizawa and Ozaki, 2005) 
1634 Collagen (McIntosh et al., 1999) 




11.7.2 Spectral differences between groups 
As the differences between the mean spectra of the different groups were found to 
be subtle and not easily identifiable from the mean spectra (Figure 11-17) the 
spectral differences between the groups were assessed in more detail by subtracting 
the mean spectrum from each pathology group and creating a difference spectrum. 
The spectral differences used by the classification model were explored by 
examining the composite PCA LDA loadings and individual PCA loadings. 
The difference spectra of the mean of the non-neoplastic spectra from the mean of 
the SCC (Figure 11-18) spectra indicates stronger peaks at 964, 1066, 1094, 1184 
and 1220 cm-1 consistent with changes in the protein content between the two 
groups and a higher signal from nucleic acids as you would expect from an increase 
in nuclear material in SCC. Shifts in the Amide I and II bands are also seen in the 
higher wavenumber range consistent with changes in proteins and amino acids with 
the transition to SCC. Similar changes can be seen in the difference spectra of the 
mean of the non-neoplastic spectra from the mean of the VIN group indicating an 

















































Figure 11-18 – Difference spectrum of the mean of the non-neoplastic group spectrum from the mean 
of the SCC group spectrum 







































Figure 11-19 – Difference spectrum of the mean of the non neoplastic group spectrum from the mean 
of the VIN group spectrum 
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Composite loadings for each of the linear discriminant functions were created (Figure 
11-20) using the weighting given to each PC by the linear discriminant functions 
(Figure 11-11) combined with all respective PC loadings. Examining these composite 
PCA LDA loadings together with the four most significant PC loadings identified by 
ANOVA (Figure 11-21) we can assess areas of the spectrum important in separating 
the pathology groups. These plots indicate that shifts in the Amide I and II peaks 
combined with changes in the absorption from regions of the spectrum associated 
with DNA, glycogen and other proteins are important in the classification of the 
different pathology groups. 
The most significant PC loadings were examined in more detail by considering their 
contribution to the classification of the three pathology groups. The LD scores plot 
(Figure 11-10) shows a positive LD score from the first LD function is associated with 
classification of VIN from non-neoplastic vulva and a positive score from the second 
LD function is associated with classification of SCC from VIN and non-neoplastic 
tissue. Using the LD scores and the LD weighting (Figure 11-11) of the PC loading to 
this we can deduce the significance of a positive or negative shift in the PC loading 
in the LDA classification. 
For PC loading 12 (Figure 11-21) the weighting for both the first and second LD 
functions is negative therefore a negative shift in the loading is associated with 
classifying a spectra as being from and area of SCC or VIN. As the weighting of LD 
function one is greater than the weight for function two for the loading it is likely it is 
more strongly associated with classifying VIN from non-neoplastic tissue. The 
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loading contains negative shifts at 925-9 cm-1 (left handed helix DNA), 1040 cm-1 
(Symmetric phosphate stretching in RNA and DNA), 1086 cm-1 (phosphate 
stretching modes from the phosphodiester groups in nucleic acids), and 1121 cm-1 
(RNA) which is suggestive of an increase in the nucleic acids in premalignant and 
malignant tissues. Positive peaks in the loading at 972 cm-1, 1018 cm-1 and 1204 cm-
1 known to be associated with polysaccharides may indicate a decrease in 
polysaccharides in premalignant and malignant tissue which is consistent with the 
higher metabolic activity of these tissues (Movasaghi, Rehman and ur Rehman, 
2008a).  
Both the LD weightings of PC 16 loading (Figure 11-21) are strongly positive 
suggesting a positive change in the loading is associated classifying a sample as 
containing SCC. Strong negative peaks on this loading at 1110 cm-1, 1122 cm-1 and 
1419 cm-1 associated with polysaccharides and carbohydrate may indicate 
decreased signal from these molecules in SCC. A positive peaks at 1200 cm-1 within 
the Amide III region, 1586 cm-1 within the Amide II region and 1652 cm-1 within the 
Amide I region with negative peaks at 1620 cm-1 and 1670 cm-1 suggests a change 
in protein composition within SCC. The positive peak at 1040 cm-1 (Symmetric 
phosphate stretching in RNA and DNA) is consistent with the changes seen in PC 
loading 12.  
In PC three (Figure 11-21) the situation is more complicated with a positive weight 
for the first LD function and a negative weight for the second. Therefore a positive 
shift in the loading is associated with classifying a sample as VIN. In this loading we 
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see shifts in the Amide III band at 1184 cm-1, Amide II band at 1558 cm-1 and Amide 
I band at 1670-1690 cm-1. More specific changes are difficult to interpret.  
In PC seven (Figure 11-21) a negative weighting in the first LD function and a 
positive weighting in the second LD function imply a positive shift in this loading is 
associated with classifying non-neoplastic vulva from VIN and SCC from VIN. This 
does not link well with the known pathophysiological understanding of the 
pathologies and biomolecular interpretation of the loading is unlikely to be useful in 
understanding the molecular basis for classification. 
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Figure 11-21 – Principal component loadings of four most significant scores as determined by 
ANOVA. 
11.8 Interim discussion 
[Summative discussion and conclusions relating to the investigations outlined in 
Section D can be found in Chapter 13] 
In this investigation the aim was to evaluate FTIR spectroscopy for the purposes of 
classifying non-neoplastic vulval skin, premalignant and malignant disease of the 
vulva. This was accomplished with the mapping of sections of tissue that had 
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undergone the standard fixation and paraffin embedding required for routine 
histopathology. This is the first reported study to attempt classifying these vulval 
pathologies using FTIR spectra collected from fixed tissue sections. In this 
investigation it was possible to use the individual spectra and spectral maps to 
accurately classify the pathology present within the tissue with clinical relevant 
classification accuracy. 
In the first comparison it was demonstrated that the technique could be used to 
differentiate SCC from VIN and non-neoplastic vulval tissue using individual 
epidermal spectra with sensitivities of 81-90% and specificities of 82-66%. On a per 
sample basis the sensitivity can be improved to approximately 100% with specificity 
of 79%. This demonstrates the technique may have a useful roll in screening 
samples for urgent histopathological review. 
In the second comparison the ability of the technique to identify SCC from VIN was 
demonstrated. Using individual spectra the technique could achieve sensitivities of 
84-90% with specificities of 80-70%. Using the whole sample map a sensitivity of 
approximately 100% can be achieved with a corresponding specificity of 77%. The 
differentiation of SCC from VIN is important in the accurate diagnosis of SCC as the 
neoplastic changes in VIN can be difficult to differentiate from SCC and a second 
opinion is often required. This investigation demonstrates FTIR has promise in 
offering the opportunity to provide an automated second opinion.  
In addition, the analysis of the FTIR spectra also appears to demonstrate a 
continuum of biomolecular changes from non-neoplastic tissue through VIN to frank 
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SCC (Figure 11-12). This fits with our understanding of the carcinogenic processes 
leading to the development of vulval SCC (chapter 1.4). 
Further discussion of future work and the steps necessary to translate these finding 




Chapter 12 FTIR Augmented Pathology 
12.1 Introduction and objectives 
There are thought to be two distinct subtypes of vulval SCC each with unique 
identifiable precursor disorders (Ueda et al. 2011). The first is linked with oncogenic 
subtypes of the human papilloma virus (HPV) and HPV associated vulval 
intraepithelial neoplasia (VIN). The second is keratinising SCC which is associated 
with lichen sclerosus and non HPV associated (differentiated) VIN and typically 
occurs in older women (van de Nieuwenhof, van der Avoort and de Hullu, 2008). 
Each type of vulval SCC has a unique set of molecular changes that occur as vulval 
tissue is driven towards a malignant phenotype (Dakubo et al., 2007). The ability to 
readily detect these molecular changes would be invaluable in the risk stratification 
of preneoplastic and malignant vulval disease and in the early diagnosis of vulval 
SCC. 
The current gold standard for the diagnosis of precancerous and malignant vulval 
conditions is histopathological examination. Traditional histological examination 
gives little information on the molecular profile of the tissue being examined and a 
novel technique is required to probe the molecular composition of vulval tissue to 
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augment the histological assessment. The molecular information obtained through 
FTIR spectroscopy has the potential to work as an adjunct to histopathology to aid in 
the early diagnosis of cancer and may offer additional information about the 
molecular risk profile of the tissue. 
Lichen sclerosus and vulval intraepithelial neoplasia are ideal subjects for 
investigating augmented pathological assessment with FTIR due to the established 
link between these conditions and vulval SCC and the need for indefinite follow up of 
patient with these conditions. The early identification of those women with these 
conditions who develop SCC or the molecular precursors to SCC has a clear clinical 
advantage over traditional histopathology. As previously discussed (1.4.1.1) in usual 
type VIN malignant transformation of vulval epithelial cells by high-risk HPV subtypes 
is mediated through integration of the HPV DNA with in the host genome leading to 
HPV induced expression of the E6 and E7 oncoproteins. These oncoproteins have 
numerous oncogenic effects including interference with control of the cell cycle, 
producing numeric and structural oncogenic chromosomal abnormalities (Vinokurova 
et al., 2005; Zekan, Sirotkovic-Skerlev and Skerlev, 2011). In addition, methylation or 
mutations of the hosts’ genome can occur that distorts transcriptional control, cell 
differentiation and viral gene expression. This results in altered molecular expression 
in tissues undergoing malignant transformation (Trietsch et al., 2015). 
LS is thought to develop into SCC through a HPV independent process which is not 
fully understood (1.4.1.2) (Ueda et al., 2011). Numerous genetic and epigenetic 
changes have been noted to occur in areas of LS associated with SCC that are not 
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present in LS found in isolation. These include mutation of TP53 and 
hypermethylation of MGMT and RASSF2A, suggesting a potential role for these 
genes in non HPV associated carcinogenesis however the exact mechanism is not 
well understood  (Guerrero et al., 2011; Trietsch et al., 2015). 
Overall the pathogenesis of vulval SCC is not as well described as that for more 
common cancers, however it is clear that in both the HPV dependent and HPV 
independent oncogenesis, biomolecular changes occur in the vulva that lead to the 
development of invasive cancer. Detecting these changes may give valuable 
prognostic information for women with precursor conditions such as LS and VIN as 
well as for those who have already developed SCC. 
This study explores the role of Fourier transform infrared spectroscopy (FTIR 
spectroscopy) and multivariate analysis in the evaluation of molecular changes in 
HPV dependent and HPV independent vulval carcinogenesis.  
12.2 Objectives 
This investigation assesses objective 2 of the aims and objectives outlined in 
Chapter 9. 
Investigate the ability of FTIR spectroscopy and multivariate analysis to identify 




This experiment is designed to establish if there are molecular changes detectable 
by FTIR spectroscopy in HPV related (uVIN) and HPV independent (LS) vulval 
disease that are associated with the development of vulval SCC. 
12.3 Sample preparation and FTIR spectral acquisition 
The pathology database at Gloucestershire Hospitals NHS Foundation Trust was 
interrogated and 24 cases of uVIN and 24 cases of LS with and without concurrent 
vulval SCC were selected. uVIN was chosen as the commonest identifiable HPV 
dependent precancerous vulval disease and LS was chosen as the commonest HPV 
independent preneoplastic vulval disease. The haematoxylin and eosin (H&E) 
stained slides from the cases identified were scrutinised by a gynaecology 
histopathologist and areas typical of uVIN and LS selected. Contiguous 4 µm tissue 
sections were cut from the corresponding paraffin embedded blocks onto a glass 
slide, a calcium fluoride substrate and a further glass slide. The sections cut onto 
glass were H&E stained and examined by a histopathologist blinded to the previous 
histological diagnosis to confirm the pathology present. The sections cut onto to the 
calcium fluoride substrates underwent FTIR spectroscopic mapping using a Perkin 
Elmer Spectrum One Spotlight 400 imaging system in transmission mode using the 
experimental conditions outlined in chapter 10.5. The number of spectra collected 
from each sample was determined by the size of the lesion identified on the tissue 





Figure 12-1 – Overview showing the four sample groups that underwent FTIR spectroscopic mapping 
and subsequent analysis (PCA - principal component analysis, LDA - Linear discriminant analysis) 
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Figure 12-2 – H&E stained tissue section (A) and corresponding spectral principal component scores 
plot (first principal component) (B) 
12.4 Data analysis 
Data collected for the LS group (1) and the uVIN group (2) were analysed 
independently (Figure 12-1). The measured spectra were converted into absorbance 
and data points outside of the 800 to 1800 cm-1 biological fingerprint range were 
excluded. The remaining spectra were then corrected for the paraffin content of the 
tissue using an extended multiplicative scatter correction (EMSC) to remove the 
effect of the variation in the paraffin in the tissue samples (Ly et al., 2008; Tfayli et 
al., 2009; Nallala, Lloyd and Stone, 2015) (chapter 10.5). The spectra were then 
vector normalized.  
In order to select the areas of epidermis (stratum germinosum and stratum 
spinosum) within the spectral maps (Figure 12-2) a two stage k-means cluster 
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analysis was performed as outlined in chapter 11.4. The areas of epidermis identified 
were then isolated for further analysis and the non-epidermal spectra excluded. 
These areas were selected as the bulk of molecular changes that result in malignant 
transformation occur within the cellular epidermis. Principal component analysis 
(PCA) was applied to reduce the dimensionality of the data into loadings and 
corresponding scores in preparation for linear discriminant analysis (LDA). ANOVA 
was performed on the principal component (PC) scores to determine which of the PC 
scores were significantly different between those tissue samples from women with 
concurrent SCC (groups 1a and 2a) and those without (groups 1b and 2b). The 
confidence level for the ANOVA was set at 95%. LDA was applied to the significant 
principal component scores and their associated sample groups (Figure 12-1). The 
resultant LDA model was then used to predict whether each spectrum was taken 
from a tissue sample from a woman with concurrent vulval SCC. 
The classification ability of FTIR spectroscopy to detect whether a tissue sample of 
either LS or uVIN was from a patient with concurrent SCC was evaluated using leave 
one sample out cross validation loop (chapter 4.2.5). The predicted groups from 
each cycle of validation were then collated for analysis. The specificity and sensitivity 
of the technique for detecting tissue associated with a SCC was calculated across a 
range of diagnostic thresholds (i.e. the proportion of spectra classified as being 





The diagnostic models for both group 1 (uVIN) and group 2 (LS) were each derived 
from 24 tissue samples. The total number of FTIR spectra included in each group 
was 509,000 for group 1 and 65,000 for group 2. The two stage k-means clustering 
analysis was able to correctly isolate the epidermal spectra in all but one case where 
manual selection of the epidermal spectra was successfully employed. The result of 
the initial PCA ANOVA LDA analysis demonstrated that the technique was able to 




Figure 12-3 – Histogram of linear discriminant distance of individual spectra for the uVIN group (A) 
and the LS group (B), (LD Distance-linear discriminant distance) 
Defining the biochemical constituent peaks responsible for discrimination within the 
LDA model is difficult. As previously discussed FTIR spectroscopy does not allow 
simple biochemical quantification of target tissues due to the compound effect on the 
absorption spectra from the numerous molecular constituents of the tissue. 
Examining the two most significant principal component loadings and the composite 
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linear discriminant loading we can speculate on the molecular basis for classification 
within the LDA model (Figure 12-4). The spectral differences between those with 
concurrent SCC and those without appear to occur primarily in the amide I, amide II 
and amide III regions of the absorbance spectra. In addition changes are seen in 
lipid, fatty acid, nucleic acid and carbohydrate regions. These findings are suggestive 




























Figure 12-4 – Mean spectra for the uVIN group (A) and the LS group (B) (offset to separate spectra), 
the two most significant principal components for the uVIN model (C and E) and for the LS model (D 
and F), and composite LDA loading for the uVIN group (G) and for the LS group (H) 
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Table 12-1 – Proposed principal spectral changes responsible for discrimination between 
uVIN and LS found in association with SCC and that found in isolation with suggested 
biomolecular constituent assignments 
Wavenumber (cm-1) Suggested biomolecular constituent allocation 
Group 1 (uVIN)  
966 C-O deoxyribose, C-C DNA 
968 Left-handed helix DNA (Z form) 
1000–1140 Protein amide I absorption 
1022-4, 1028 Glycogen absorption 
1040-100, 1025, 1107 Carbohydrates (including glucose, fructose, glycogen, etc.) 
1056/7 Stretching C-O deoxyribose 
1080 Collagen & phosphodiester groups of nucleic acids 
1117 C-O stretching vibration of C-OH group of ribose (RNA) 
1172 Serine, threonine, and tyrosine residues of cellular proteins 
1204, 1339 Collagen, proteins-amide III and polysaccharides 
1235 Composed of amide III as well as nucleic acids 
1236 Amide III and nucleic acids 
1236-42 Collagen and nucleic acids 
1307-17 Amide III band components of proteins 
1390 Carbon particle 
1451, 1455-6 Methyl groups of proteins 
1480-600, 1540, 1549 Amide II regions 
1545 Protein band 
1600-720, 1630–700 Amide I regions 
1730, 1743 Fatty acid esters and lipids 
Group 2 (LS)  
968 DNA 
985 polysaccharides-cellulose 




Protein Amide I absorption 
1030 Glycogen vibration, Collagen & phosphodiester groups of nucleic acids 
1040-100 Carbohydrates (including glucose, fructose, glycogen, etc.) 
1066, 1220, 1235 Nucleic acids 
1084–6 Phosphate of nucleic acids 
1164 Serine, threosine, & tyrosine of proteins 
1200, 1284, 1339 Collagen 
1235, 1284, 1307-17 Amide III 
1396, 1455-6 Methyl groups of proteins 
1419 Polysaccharides, pectin 
1470 Methylene chains in lipids 
1504 Phenyl rings 
1545 Protein band 
1480-600, 1517, 
1540, 1549 Amide II regions 
1670, 1750 lipids, fatty acids 




The ability of FTIR spectroscopy combined with multivariate analysis to identify 
tissue samples from women with SCC was evaluated using leave one sample out 
cross validation. After validation the discriminant model demonstrated FTIR 
spectroscopy was able to correctly differentiate spectra from uVIN associated with 
SCC from that not associated with SCC with a sensitivity of 75% and specificity of 
94%. Similarly FTIR spectroscopy was able to correctly differentiate spectra from LS 
associated with SCC from that not associated with SCC with a sensitivity of 82% and 
specificity of 93%. Each tissue sample was then classified as being associated with 
SCC or found in isolation by the number of spectra the LDA model classified as 
being associated with SCC. The threshold number of spectra to classify the tissue 
sample was adjusted and the receiver operator characteristic was determined for 
both groups. This demonstrated the sensitivities and specificities that can be 
achieved using this technique per sample. LS associated with SCC can be 
differentiated from LS found in isolation with a sensitivity of 100% and a specificity of 
84% with area under the curve (AUC) of 0.98. uVIN associated with SCC can be 
differentiated from uVIN found in isolation with a sensitivity of 100% and a specificity 
of 58% with AUC of 0.87. The specificity of the technique can be improved by 
conceding sensitivity (Figure 12-5). In the uVIN group, a higher threshold number of 
spectra to classify the samples can be used to give a sensitivity of 75% and a 
specificity of 83%. 
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A  B  
Figure 12-5 – Receiver operating characteristic for the identification of tissue associated with SCC in 
the uVIN group (A) and the LS group (B) 
12.6 Interim discussion 
[Summative discussion and conclusions relating to the investigations outlined in 
Section D can be found in Chapter 13] 
This preliminary study has demonstrated FTIR spectroscopy is able distinguish 
between LS or uVIN found in isolation and LS or uVIN found with concurrent SCC at 
another anatomical location on the vulva. Discrimination between these groups is 
based on the molecular variations detected by FTIR spectroscopy and multivariate 
analysis. This is the first reported study to demonstrate the classification of these 
groups of histologically similar vulval tissue and separate them based on the 
concurrence of vulval SCC. The ability to separate these groups according to the 
presence of concurrent SCC is suggestive of cancer associated molecular changes 
occurring across the vulva. Demonstrating the ability of FTIR spectroscopy to 
differentiate between vulval disease found with concurrent cancer and vulval disease 
found in isolation highlights the potential role FTIR spectroscopy could have as a tool 
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for assessing preneoplastic molecular changes in the vulva. Potential applications 
include the early identification of vulval cancer and molecular risk stratification of 
patients with VIN or LS and the identification of those at high risk of developing 
vulval cancer. 
Further discussion of future work and the steps necessary to translate these finding 
into clinical practice is located in Chapter 13. 
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Chapter 13 Summative Discussion and 
Conclusions. 
13.1 Discussion: Raman spectroscopy for the assessment 
of vulval disease 
The translational research presented in section C of this thesis aims to assess the 
potential of Raman spectroscopy for the discrimination of vulval SCC, VIN and non-
neoplastic vulval in the clinical setting. The technique was evaluated in both 
laboratory experimental conditions and in conditions that would be technically 
suitable for in vivo application using a probe based system. To our knowledge this is 
the first study that has assessed the use of Raman spectroscopy for disease 
classification in the vulva. In consideration of the data reported in Chapter 6, Chapter 
7 and Chapter 8 it is necessary to discuss how vulval Raman spectroscopy could be 
added to the clinician armamentarium for the benefit for patients with pre-malignant 
or malignant vulval disease. The potential role of Raman spectroscopy as a tool for 
assessing disease progression or monitoring response to treatment is also explored. 
The requirements for future refinements of the technique and for future research are 
also discussed and clinical and scientific conclusions drawn. 
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At the start of this investigation two areas of clinical need were identified. The first 
was the need for improved diagnostic tests to monitor and diagnose vulval conditions 
reducing the reliance on invasive tissue biopsy. The second was the need for a tool 
that is able to accurately determine disease margins at the time of surgical treatment 
of malignant or premalignant vulval disease. The translational research presented in 
Section C of this thesis aims to assess the potential role of Raman spectroscopy in 
addressing these needs. 
The use of Raman spectroscopy for the discrimination of non-genital benign and 
malignant lesions has been widely investigated (Table 3-1). In the largest in vivo 
study to date 655 cases of benign and malignant lesions were measured from 560 
patients incorporating the cohort from a previous study and an entirely new cohort of 
patients (Lui et al., 2012; Zhao et al., 2015). The study included 23 samples of in situ 
SCC and 41 samples of invasive SCC amongst a number of other benign and 
malignant skin lesions. The investigators found that after LOOCV and validation with 
an entirely separated training (518 lesions) and test group (127 lesions) that the 
technique was able to differentiate malignant from non-malignant lesions with high 
sensitivity and specificity, ROC AUC was 0.88. Interestingly the method of validation 
did not have a statistically significant impact on the performance of the technique 
suggesting in studies of this nature and scale LOOCV is a valid method for 
assessing the true accuracy of the technique. Other recent studies have also 
confirmed Raman spectroscopy combined with multivariate analysis can differentiate 
non-cancerous, pre-cancerous and cancerous skin conditions with high degrees of 
accuracy but none have demonstrated the technique in the vulva (Bodanese et al., 
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2010; Silveira Jr et al., 2012; Schleusener et al., 2015; Silveira et al., 2015; Wang et 
al., 2015; Ferreira Lima et al., 2019). Based on the studies assessing Raman 
spectroscopy for the diagnosis of skin cancers occurring in predominantly sun 
exposed areas we could be hopeful that the technique will be as successful in the 
vulva. There are however some important pathogenic differences between vulval 
cancers and cancers that occur elsewhere on the human body that necessitate 
experimental validation of the technique in the vulva and prohibit direct extrapolation 
of the results of studies performed on other skin types (Chapter 1.4.1). These include 
the different pathogenic pathways for carcinogenesis in the vulva compared with 
elsewhere in the body and the presence other conditions such as Lichen Sclerosus 
that occur predominantly in anogenital regions (Fleming et al., 1995; Yap et al., 
2017; Hinten et al., 2018). In this study we sought to explore if promising results 
achieved at other skin sites can be demonstrated in the vulva. 
Three clinically important classifications were assessed in this study. These were the 
ability of the technique to identify non-neoplastic vulval tissue from vulval SCC and 
VIN; the ability of the technique to identify SCC from VIN and the ability of the 
technique to identify SCC from VIN and non-neoplastic vulval skin (Table 13-1). 
Table 13-1 – Clinically relevant diagnostic comparisons 
Diagnostic 
comparison Comparator 1  Comparator 2 
1 SCC and VIN from Non-neoplastic vulva 
2 SCC from VIN 
3 SCC from VIN and non-neoplastic vulva 
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The ability to identify vulval SCC and VIN from non-neoplastic vulval skin is 
important in the surgical setting where the ability to accurately determine the 
difference in these tissues has the potential to facilitate the minimisation of the 
volume of the surgical excision whilst being able to excise all neoplastic tissue. The 
ability of the technique to identify SCC from VIN or non-neoplastic vulval skin and 
SCC from VIN (comparisons 2 and 3, Table 13-1) would be valuable for both the 
diagnosis of vulval SCC and the monitoring of patients with VIN undergoing medical 
or conservative management of their disease. In addition, the technique may have 
utility as a research tool in providing an objective measure of response to non-
surgical treatments of VIN or LS although this is beyond the scope of this thesis.  
13.1.1 Raman spectroscopy for reducing clinicians reliance on 
invasive tissue biopsy in vulval disease. 
Up to the present time clinicians have had to rely on their clinical impression of vulval 
lesions with recourse to invasive biopsy in order to diagnose vulval conditions. 
Although the established approach, the subjective evaluation of skin lesions lacks 
sensitivity and specificity (chapter 3.2.1). Furthermore, although a dependable 
approach, histological analysis necessitates invasive tissue biopsy combined with 
time consuming and expensive processing and reporting using subjective 
histological criteria. This diagnostic approach does not allow immediate diagnosis 
and therefore immediate treatment. In addition, invasive biopsies may not yield an 
accurate result if there are not taken from the most appropriate areas. Currently the 
site of biopsies is guided by the clinical appearances but this may miss areas of 
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more substantial abnormality and a non-invasive diagnostic technique could be used 
to guide the clinician to biopsy an area most likely to yield a diagnostically relevant 
result. 
In those with established pre-malignant vulval disease the role for a non-invasive 
diagnostic technique is particularly compelling as this group undergo regular follow 
up to detect malignant progression. If suspicious lesions are clinically identified then 
invasive biopsies are taken to confirm or refute the presence of cancer. A non-
invasive diagnostic technique could reduce the need for biopsies in this group. 
Previous studies discussed in Chapter 3 have shown that Raman spectroscopy can 
be applied to the accurate diagnosis of skin conditions at other body sites but none 
to date have demonstrated the role of the technique in the vulva and the unique set 
of pathologies present in this area of the human body. 
In this thesis the diagnostic capability of Raman spectroscopy was evaluated in two 
clinical scenarios. The first evaluated the role of the technique in diagnosing lichen 
sclerosus when the diagnosis was uncertain on clinical grounds alone. The second 
was an evaluation of the technique in the role of identifying VIN and SCC from non-
neoplastic vulval skin. These studies constitute the first reported Raman 
spectroscopic evaluation of premalignant and malignant vulval skin and the first 
reported Raman spectroscopic analysis of lichen sclerosus at any body site. 
The results from the first investigation demonstrate that in patients with clinically 
suspected lichen sclerosus, Raman spectroscopy was able to correctly identify 
lichen sclerosus from other diagnoses with clinically acceptable performance 
 
 356 
(sensitivity of 91% and specificity of 80%, area under the ROC curve 0.95). This is 
comparable to diagnostic accuracy of commercially available diagnostic tools 
currently in clinical use such as the SIAscope and the SolarScan. The SIAscope is 
based on narrow-band spectral imaging and can identify melanoma from benign 
pigmented lesions with a sensitivity of 83% and specificity of 80% (Moncrieff et al., 
2002). The SolarScan which uses image analysis of digital surface microscopy is 
able to identify melanoma from other pigmented lesions with a sensitivity of 85% and 
specificity of 65% (Menzies et al., 2005). 
In our investigation, assessing the diagnosis of LS, by analysing spectra on a per 
patient basis and selecting a diagnostic threshold that optimizes for specificity, a 
near zero false positive rate can be achieved with a clinically relevant true negative 
rate. Using this approach we were able to correctly identify all 12 patients that did not 
have LS (test negative) with a negative predictive value of 0.8. In clinical practice 
only those with an uncertain diagnosis require invasive biopsy. These results 
suggest that by using Raman spectroscopy and avoiding biopsy in those who have a 
positive optical diagnosis of LS we could expect to reduce the number of invasive 
biopsies required. Using this approach in the study group only the 66% of patients 
that tested negative for LS would require a biopsy, reducing the number of invasive 
biopsies required by 44%. This has the potential to reduce the morbidity for the 
women; reduce the time taken to diagnose the condition and reduce the significant 
direct and indirect costs of invasive biopsy. In addition, this technique would allow 
non-invasive assessment of multiple regions of the vulva, as assessment would not 
be limited by the morbidity associated with invasive biopsy.  
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Due to the limitations of the study design it was not possible to evaluate the 
identification of lichen sclerosus using a probe based system. The concordance of 
results between the probe system and the microscope based point measurement 
system when comparing neoplastic and non-neoplastic lesions suggests accurate 
identification of lichen sclerosus should be possible using probe based spectra 
measurements (Chapter 8.7). Further research is however required to validate this 
technique for the diagnosis of lichen sclerosus using probe-based systems. 
The second investigation evaluated the diagnostic role of the technique in two 
clinical scenarios. The first was the assessment of patients with vulval lesions 
suspicious for premalignant or malignant disease. In this clinical scenario it is 
important to be able to identify non-neoplastic lesions from neoplastic lesions and 
malignant disease from non-malignant disease. The second clinical scenario was the 
assessment of patients under long term follow up for VIN due to the risk of malignant 
progression. In this clinical scenario it is necessary to differentiate between SCC and 
underlying VIN so malignant progression can be identified appropriately and 
between neoplastic tissue and non-neoplastic tissue so new neoplastic lesions can 
be identified and treated. 
This second investigation was comprised of three distinct phases. The first phase 
was the evaluation of the technique under optimised laboratory conditions on tissue 
sections where the precise area of abnormality could be identified (Chapter 6). The 
second phase was an evaluation of Raman spectroscopy in optimised laboratory 
conditions as applied to whole tissue samples with a transepidermal approach to 
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spectral collection (Chapter 7). The third and final phase was an evaluation of the 
technique using a fibre optic probe using an experimental configuration that could 
technically be applied to in vivo spectral collection (Chapter 8). In each phase the 
spectral characteristics and diagnostic performance were assessed. 
In the first phase large numbers of spectra were collected from sections of vulval 
tissue and just those spectra from the epidermis were selected for analysis (Chapter 
6). This achieved the most accurate discrimination between the pathology groups. 
The technique was able to identify non-neoplastic tissue from VIN or SCC with 
sensitivities of 82-98% with corresponding specificities of 92-72% (area under the 
receiver operator curve is 0.95). The technique was also able to identify SCC from 
VIN with sensitivities of 84-95% with corresponding specificities of 86-61% (area 
under the receiver operator curve is 0.92). This demonstrated the technique had 
promise in the chosen applications in optimised laboratory conditions and that the 
diagnostic performance is comparable to other diagnostic technologies currently in 
clinical use. This streamline approach may be useful to augment histopathological 
analysis however it is clearly not suitable as a clinical tool to reduce the reliance on 
invasive tissue biopsy.  
To evaluate the technique in conditions closer to the clinical environment the second 
two phases of investigation were completed. In phase two the technique was able to 
identify non-neoplastic tissue from VIN or SCC with sensitivities of 80 to 90% with 
corresponding specificities of 66 to 54% (area under the receiver operator curve of 
0.85). The technique was also able to identify SCC from VIN with sensitivities of 84 
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to 88% with corresponding specificities of 72 to 65% (area under the receiver 
operator curve of 0.88). 
In the third phase probe measurements were taken from the tissue using a fibre optic 
probe with which it would be technically but not yet regulatorily feasible to take in 
vivo measurements. Using this approach the technique was able to identify non-
neoplastic tissue from VIN or SCC with sensitivities of 86% to 95% with 
corresponding specificities of 72% to 57% (area under the receiver operator curve of 
0.85). The technique was also able to identify SCC from VIN with sensitivities of 84% 
to 92% with corresponding specificities of 84% to 64% (area under the receiver 
operator curve of 0.87). The diagnostic performance obtained in each of these three 
phases is summarised in Table 13-2 where the area under the receiver operator 
curves for the different approaches are compared. 
Table 13-2 – Comparison of the diagnostic accuracy of streamline spectroscopic mapping of 
epidermal cells, transepidermal Raman measurements and Raman probe measurements. 
 
It is challenging to assess whether a diagnostic test possesses an acceptable 
diagnostic accuracy for clinical application.  When it comes to diagnosing or ruling 



















1 SCC and VIN from Non-neoplastic vulva 0.95 0.85 0.85 
2 SCC from VIN 0.92 0.88 0.87 




0.95 0.90 0.91 
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(Liang et al., 2003). There are no published studies reporting clinician or patient 
views on the accuracy of diagnostic tests for vulval cancer or pre-cancerous 
conditions. There is however reported accuracy data on other established diagnostic 
interventions for comparison. The diagnostic sensitivity achieved in this study is 
comparable to the SIAscope and the SolarScan devices used for the detection of 
melanoma, see above.  Cervical cytology is another example of a diagnostic test that 
is used to detect precancerous or cancerous changes and one that has widespread 
use. Cervical cytology combined with HPV virus detection appears to have 89% 
sensitivity and 94% specificity for the detection of high-grade precancerous changes 
or worse (Kitchener et al., 2009). In the detection of cervical cancer, cytology is often 
combined with colposcopy, a commonly used technique for the detection of cervical 
pre-cancer or cancer. Colposcopy achieves a sensitivity of 85% and a specificity of 
69% (AUC 0.80) for the detection of the normal cervix and low grade cervical 
intraepithelial neoplasia (CIN) from high-grade (CIN) and cancer (Mitchell et al., 
1998). Cytology / HPV detection and colposcopy are used in combination to increase 
the overall sensitivity and specificity for the identification of cervical cancer. By 
comparison to established and accepted elements of the cervical pre-cancer 
diagnostic pathway Raman spectroscopy appears to show promise in being a useful 
and sufficiently accurate test for vulval diagnostics. The sensitivities and specificities 
whilst not matching that of cervical cytology are close. It is feasible that with 
improved instrumentation; further optimisation of the technique for vulval tissue; 
tailored chemometrics and a larger training set, that improvements in diagnostic 
accuracy could be achieved to bring the technique in line with other commonly used 
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diagnostic tests used to identify cancer. It should be noted that the diagnostic 
accuracies described above relating to cervical assessment are determined from an 
asymptomatic screening population in contrast to the population in this study that are 
symptomatic and with identifiable vulval disease. The population in this study 
therefore have a higher pre-test probability of having detectable disease and this is 
not accounted for in the reported diagnostic performance. 
It is important to note that, in general, diagnostic tests in symptomatic patients are 
not interpreted in isolation. In the clinical setting the diagnosis of vulval precancer or 
cancer is actually solidified by considering all the available evidence collectively. This 
includes the symptoms the patient reports; any previous history of related disease; 
the appearances on examination and specialised investigations such as 
histopathology. This is all significantly influenced by clinical expertise and 
experience. No single element of the diagnostic process is perfectly accurate and it 
is taken in the context of the other information obtained. Without any individual 
element of the clinical assessment the diagnostic accuracy will suffer. Likewise 
adding a novel test into the diagnostic pathway can be used to increase the 
diagnostic accuracy.  If one element of the available information such as the 
histopathology does not fit with the remaining information this does not necessarily 
mean the diagnosis is abandoned. For example, if a clinician strongly suspects a 
vulval cancer but a biopsy and histopathology does not demonstrate cancer, then the 
clinician will repeat the biopsy or treat the patient to avoid missing an important 
diagnosis. Therefore the assessment of performance of an individual diagnostic test 
needs to be taken in the context of its clinical application. Raman spectroscopy 
 
 362 
should be regarded as a tool for assisting the evaluation of vulval lesions rather than 
being a final and definitive arbiter of diagnosis. 
In this study the diagnostic performance of the technique, as evaluated for the 
identification of lichen sclerosus, is to an extent clinically contextualised. Those 
selected for inclusion in the study were patients in whom a diagnosis of lichen 
sclerosus was suspected, but in whom there was insufficient clinical certainty to 
make the diagnosis without biopsy. In this context Raman spectroscopy performed 
well and correctly identify all 12 patients that did not have lichen sclerosus 
theoretically reducing the need for biopsy by 44% in this selected group. 
The evaluation of the diagnostic performance of Raman spectroscopy for the 
identification of vulval SCC and VIN was not clinically contextualised in the same 
way as the lichen sclerosus investigation. In this arm of the investigation, the tissue 
samples analysed were taken from patients undergoing surgical treatment for VIN or 
SCC. These patients are a subset of the original patient group in whom diagnostic 
biopsies are undertaken and as such the data obtained is an approximation to the 























Figure 13-1 – Illustration of the patient cohort who have been recruited to this study (VIN, SCC, Non-
neoplastic) in the context of all those undergoing diagnostic biopsy demonstrating the group of 
patients not evaluated in this study. 
Figure 13-1 illustrates the group of patients not evaluated in this study i.e. those 
undergoing diagnostic biopsy but not undergoing excisional treatment. Figure 13-2 
illustrates this within the diagnostic pathway for patients with suspected VIN or SCC. 
A and B are points at which Raman spectroscopy could be deployed as an optical 
diagnostic technique to reduce clinicians reliance on invasive tissue biopsy. Point C 
is however the point at which the tissue samples were collected in this study. Tissue 
collected at point C in the pathways is only an approximation to the types of tissue 
present at points A and B. It is probable that there are significant biomolecular 
differences in the tissue at points A and B when compared to that present at point C. 
In particular there is a subset of non-neoplastic tissue and VIN that is not subject to 
surgery (Figure 13-1) that is likely to possess a more benign biochemistry than the 
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non-neoplastic tissue and VIN found at point C. Further more all of the non-
neoplastic tissue measured was obtained from diseased vulvas with either 
concurrent VIN, SCC, adenocarcinoma, BCC, melanoma or Paget’s disease. 
Consequently given the field change found with vulval neoplastic disease (chapter 
1.4.1.3) it is likely there are biomolecular abnormalities in the non-neoplastic group 
that would not be found in tissue from vulvas that do not contain concurrent disease. 
Assuming equivalence of the tissue analysed to the clinical context of disease 
diagnosis at points A and B in Figure 13-2 is likely to have resulted in an 
underestimation of the diagnostic accuracy of the technique. 
 
Figure 13-2 – Diagnostic pathway showing the points A and B at which a diagnositc optical biospy 
would be applied and C the point of tissue collection for this analysis. 
In this study collection of tissue at point C (Figure 13-2) was necessary to permit the 
collection of sufficient samples of tissue of the three types included in the analysis. It 
was not possible to collect and store tissue from biopsies at point A and B for the 
reasons outlined in chapter 7.3.1.1. 
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The chemometric approach used in this study was tailored to allow identification of 
the biomolecular changes in the tissue that result in the classification of the different 
tissue types. This led to the choice of PCA combined with LDA as this combination 
allows for analysis of the spectral differences behind the classification and permits 
insight as to whether the classification is based on biomolecular changes or other 
noise within the data. The use of PCA also has the added advantage of producing 
orthogonal components so the contribution of the changes seen in any individual 
component should not be confused with any other component. This approach is well 
suited to an exploratory analysis such as that in this study as it avoids the analysis 
and classification becoming a black box from which the basis for classification 
cannot be not easily understood. This approach also enables the detection of 
incidences of over fitting to non-relevant spectral data. 
Over fitting resulting in a type one error is a real danger in this type of classification 
analysis and some elements of the diagnostic approach used in this study risk 
increasing the chance of over fitting the data to the desired result. Where possible 
these have been countered by measures to validate the result of the analysis. The 
variant of PCA LDA used in the final analysis was selected by comparison to the 
diagnostic performance of the technique (Chapter 7.5.7). Likewise the selection of 
the thresholds for data exclusion by the D and Q statistic was selected based on 
diagnostic performance of the technique (Chapter 7.5.7). Selecting analytical 
techniques based on the performance of the technique introduces the risk of over 
fitting. Steps were taken to reduce the risk of over fitting including exclusion of data 
based solely on the fit to the training data set and ensuring strict separation of the 
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training and test sets within the internal cross validation. In selecting the samples to 
be analysed, care was taken to avoid selecting two samples of the same pathology 
from the same participant. In the investigations assessing SCC, VIN and non-
neoplastic vulval skin, 21 participants contributed two samples each to different 
pathology groups and 3 participants contributed samples to all three pathology 
groups. This approach should not have increased the risk of a type one error and 
should have improved the validity of the resultant classification models by reducing 
any group separation based on differences in the biomolecular composition of 
individual patients rather than the pathology groups. 
In the analysis of the classification accuracy of the technique it became apparent that 
there appeared to be a continuum of disease progressing from non-neoplasic vulval 
tissue through VIN to SCC. This was evident in the spectra and the ternary plots 
resulting from each of the three spectral collection methods used (Figure 6-25, 
Figure 7-29 and Figure 8-22). In each of the plots there was overlap between the 
SCC and VIN groups and between the VIN and non-neoplastic group. There was 
however minimal over lap between the non-neoplastic group and the SCC group. 
This suggests that rather than detecting three distinct pathology groups it may be 
possible to detect a continuum of disease from low risk of malignancy to overt 
malignancy. A recent retrospective study of 201 cases of vulval SCC demonstrated 
epithelial neoplastic disorders (e.g. VIN) are found adjacent to vulval SCC in 72% of 
patients (Yap et al., 2016). The majority of vulval SCCs develop in these neoplastic 
lesions which precede the development of SCC by a variable period of time (Del 
Pino, Rodriguez-Carunchio and Ordi, 2013b). The findings of a continuum of spectral 
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changes from non-neoplastic to in situ neoplastic and malignant disease fit with this 
understanding of the carcinogenic process in the vulva. Longitudinal clinical studies 
would be required to assess if the spectral changes that lead to the classification of 
VIN as SCC or non-neoplastic tissue as VIN are associated with an increase risk of 
malignant progression. If this hypothesis was born out then Raman spectroscopy 
has the potential to offer clinicians an invaluable opportunity to perform real time in 
vivo biomolecular risk assessment of non-neoplastic vulval skin or VIN and target 
more intensive treatment or observation to this group. In addition these spectral 
changes could be used to non-invasively assess the extent of field change in the 
vulva (chapter 1.4.1.3). This in turn could be used to target medical or surgical 
management strategies to the wider vulva. 
13.1.2 Raman spectroscopy as an intraoperative tool to identify 
disease margins 
Obtaining adequate and complete excision during surgical management of vulval 
disease is important for both local disease control in patients with VIN and vulval 
SCC and for overall survival in patients with vulval SCC. Residual disease after 
excisional surgery is associated with the need for further surgery and adjuvant 
radiotherapy (Yap et al., 2016). Current guidelines suggest that when excising an 
area of SCC a margin of non-neoplastic tissue at least 10-15 mm should be taken to 
ensure a clear histopathological margin of greater than 8 mm and complete excision 
of the tumour (RCOG, 2014; European Society of Gynaecological Oncology, 2016). 
This recommendation is based on a small retrospective cohort study in which none 
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of the patients with pathological margins of greater or equal to 8 mm had recurrent 
disease and the only recurrences were seen in those with pathological margins of 
less than 8 mm (Heaps et al., 1990).  This study did not account for stage of disease, 
a major confounding factor. Most of the patients with a margin of less than 8 mm in 
the study had advanced disease and there are likely other factors contributing to the 
higher recurrence rate seen in this group. Recent cohort studies have questioned the 
traditional importance placed on the pathological margin and have suggested the 
most important prognostic factor in early stage vulval SCC is the completeness of 
the excision rather than the size of the tumour free margin (Woelber et al., 2011; 
Nooij et al., 2016; Micheletti et al., 2018; Te Grootenhuis et al., 2018).  The 
retrospective cohort study and meta analysis by Nooij et al. evaluated 148 patients 
undergoing surgical treatment for vulval SCC to assess the association between 
surgical margin and recurrence at two years. The study found that the only 
independent risk factor for recurrence was the presence of a tumour positive margin 
and not the size of the tumour free margin. Similarly Micheletti et al. did not find an 
association between an 8 mm pathological margin and recurrence in a retrospective 
cohort study of 114 patients with vulval SCC.  A retrospective cohort study by Yap et 
al. assessed 201 patients with surgically treated vulval SCC and found no 
association between tumour margin of less than 8 mm and local recurrence or 
disease specific survival over a five year period (Yap et al., 2016). Another 
contemporary series of 107 patients reported by De Simone et al. did not show an 
associated between disease recurrence and survival and margin status unless the 
pathological margins were less than 2 mm (DeSimone et al., 2006).  The extent of 
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the surgical margin is important in the excision of vulval disease, as small increases 
in the surgical margin are associated with significant changes in the area of vulval 
tissue that needs to be removed. For example, if we have a circular two centimetre 
tumour then the increase in tissue surface area that is removed with a 15 mm 
surgical margin is 36% larger than with a 10 mm margin. This is especially important 
adjacent to important structures that affect continence such as the urethra and anal 
sphincter as well as important functional structures such as the clitoris. Green et al. 
surveyed 41 women before and following vulvectomy and found the procedure was 
associated with a significant fall in sexual frequency alongside increases in arousal 
disorders and sexual aversion disorders (Green et al., 2000). Hazewinkel et al. 
reported the results of a cross-sectional study of 76 women that had undergone 
surgical treatment for vulval cancer and found that of the 43% that were sexually 
active 42% reported significantly worse sexual function after surgery (Hazewinkel et 
al., 2012). To date reported studies have not assessed the relationship between 
radically of excision and excision margin on post-operative psychosexual function. 
Although there is lack of evidence of the disutility of anxiety and psychosexual 
repercussions of vulval excisional surgery it is accepted that this type of surgery is 
associated with significant adverse effects (Cavanagh and Hoffman, 1996). 
The reasons for requiring a larger surgical margin as compared to the pathological 
margin appear to be twofold. Firstly specimens undergo shrinkage during fixation. 
DeSimone et al. studied surgical specimens from 19 women undergoing vulval 
resections and reported mean specimen shrinkage of 15% after fixation (DeSimone 
et al., 2006). Secondly the clinical assessment of disease margins at the time of 
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surgery through visual inspection and palpation can be imprecise and difficult. The 
ability to objectively assess disease margins at the time of surgery using Raman 
spectroscopy has the potential to reduce the size of surgical excisions, preserve 
important functional structures whilst ensuring all abnormal neoplastic tissue is 
removed preventing the need for further surgery or adjuvant radiotherapy. This is 
especially important when clinicians make decisions about the need to excise the 
clitoris, part of the urethra or part of the anal sphincter. 
Currently the only available support for the intraoperative assessment of resection 
margins is frozen section. Even though this procedure is successful for assessment 
of resection margins it has a number of key limitations that prevent its use in vulval 
cancer surgery. Frozen section is very time consuming which extends the duration of 
anaesthesia and surgery; sampling errors can occur as only a small part of the 
margin can be assessed and the rapid freezing required can make the final 
histopathological analysis more difficult (Santos et al., 2017). All these limitations can 
lead to false negative results. In recent years there has been a great deal of interest 
in the use of Raman spectroscopy for guiding oncological surgery. In the excision of 
neurological tumours an intraoperative Raman probe capable of direct measurement 
of brain tissues has be shown to distinguish cancer from benign tissue with 
sensitivity and specificity of 93% and 91% respectively (Jermyn et al., 2015). In 
breast cancer excision a Raman system was shown to be able to distinguish cancer 
from normal breast tissue on freshly excised specimens with a sensitivity and 
specificity of 83% and 93% respectively (Haka et al., 2014). Kong et al. used a two 
step auto-fluorescence and Raman system for the detection of basal cell carcinomas 
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(BCC) in skin at the time of surgery and demonstrated the automated detection of 
BCC with sensitivity and specificity of 95% and 94% respectively. Instigating Raman 
spectroscopy for margin assessment can have key benefits. It may facilitate 
representative sampling, avoiding sampling bias and objectively identify resection 
margins reducing incomplete excision and the need for further surgery or 
radiotherapy. In the surgical setting all neoplastic tissue needs to be excised during 
treatment so it is important to be able to reliably differentiate SCC and VIN from non-
neoplastic skin. In the current investigation, sensitivities of 86% to 95% were 
achieved with specificities of 72% to 57% using the probe based system. If applied 
clinically the technique could be optimised for sensitivity to ensure that all areas of 
cancer are detected. In this scenario tissue within the traditional clear resection 
margin that was characterised as non-neoplastic according to Raman spectroscopy 
could be left in in situ with increased confidence given the 95% sensitivity. The 
sacrifice in specificity could be overcome with a pragmatic approach to resection.  
This is illustrated in the schematic of a vulval resection in Figure 13-3. At area A the 
visually abnormal lesion will be excised irrespective of the Raman characterisation; 
at point B the tissue would be resected if the Raman characterised the tissue as 
cancer and tissue at point C would not be resected provided it is clinically normal.  
Using this strategy it should be possible to safely reduce the size of the area excised 
whilst ensuring complete excision of the abnormal area. In practice it may also be 
desirable to define a fall back clinical safety margin around the tissue to define the 
minimum extent of the incision (Figure 13-3). This could be used to prevent too small 





















Figure 13-3 – Schematic of vulval resection 
If subsequent studies improved the sensitivity and specificity then alternative 
strategies could be employed. A high specificity would enable a reverse of the 
approach where tissue in area B (Figure 13-3) could be left in situ provided Raman 
did not characterise the tissue as neoplastic. 
As described in chapter 13.1.1 the tissue types compared are not exactly equivalent 
to those that would be under investigation in vivo. The tissue used in this 
investigation was collected at point C on Figure 13-2, which is the same point in the 
pathway as the proposed application. There are however some important differences 
in the tissue as compared to margin assessment in vivo. The most relevant are that 
the tissue samples were taken so as to avoid disrupting the assessment of the 
margins by the histopathologist. Tissue was not taken from the closest surgical 
margin or from the edge of the specimen. The result of this is that the tissue 
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analysed did not include the tissue furthest from the abnormal lesion. This may have 
led to an underestimation of the diagnostic performance in the whole of the area 
between the traditional resection margin and abnormal lesion (Figure 13-3). In 
addition the classification accuracy given in this investigation does not reflect the 
combined diagnostic approach adopted with any investigation used to aid diagnosis. 
In the real world use of Raman spectroscopy for the identification of disease margins 
at the time of surgery the underlying pathologies present and clinical assessment 
would both contribute to decisions surrounding the extent of the surgery and the 
surgical margins taken. Clinical trials of the technique would be needed to assess 
the multimodal nature of clinical decision making with advanced diagnostic 
techniques such as Raman spectroscopy. 
13.1.3 Potiential role for Raman spectroscopy in detecting 
disease progression and monitoring response to treatment 
Although not directly evaluated in this study, Raman spectroscopy may have an 
important role in measuring response to non-surgical treatment of vulval conditions. 
This is particularly important in the two commonest vulval conditions known to cause 
an increased risk of progression to vulval cancer, VIN and LS (Chapter 1). 
Lichen sclerosus is associated with an increased lifetime risk of developing vulval 
SCC with the estimated risk varying between 3% and 7% in population based 
studies (Cooper et al., 2004; Bleeker et al., 2016). Non-randomised cohort studies 
suggest that good control of LS with ultra potent topical steroids may reduce the risk 
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of progression of LS to SCC (Cooper et al., 2004; Renaud-Vilmer et al., 2004; 
Andrew Lee, Bradford and Fischer, 2015). Lee et al. undertook the largest analysis 
assessing risk of disease progression in a prospective longitudinal cohort study of 
507 women with vulval lichen sclerosus.  This study demonstrated that treatment 
with ultra potent corticosteroids targeted towards maintenance of normal skin colour 
and texture was associated with a decreased rate of progression to vulval cancer (A 
Lee, Bradford and Fischer, 2015). This suggests a role for the treatment of LS in 
order to prevent progression to vulval cancer. Currently treatment of LS is targeted to 
symptoms or clinical response and many women with progressive LS will be 
asymptomatic. In this study we have demonstrated that Raman spectroscopy is 
capable of detecting patient with LS with high sensitivity and specificity 91% and 
80% respectively. After further study Raman spectroscopy may provide a valuable 
technique for the objective assessment of response to treatment of women with 
asymptomatic vulval LS. Raman spectroscopy could be used to direct treatment 
towards biochemical and histological response rather than symptomatic control of 
disease or clinical response. This in turn may further prevent the development of a 
cellular environment conducive to malignant transformation and prevent the 
occurrence of vulval cancer. Treatment of LS with ultra potent topical steroids is 
considered safe and so this strategy is associated with minimal risk to patients. 
Usual type VIN can be treated with topical treatments or surgical excision. 
Imiquimod, an immune modulator, and cidovir, an antiviral agent, are the primary 
topical agents used in the treatment or usual type VIN. Complete response to 
treatment occurs in 45% of those treated with imiquimod and 46% of those treated 
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with cidofovir (Ta et al., 2016). Both these treatments require administration over a 
prolonged period of time and are associated with significant and distressing side 
effects (Ta et al., 2016). Side effects include headaches, fatigue and vulval pain and 
are slightly more common with imiquimod than cidofovir. Currently response to 
treatment is assessed clinically with patients needing to complete a 16 to 24 week 
course of treatment to assess if it is efficacious. In the research setting phase II 
studies investigating novel agents often rely on histological response to treatment as 
a primary end point (Tristram et al., 2014). This limits the longitudinal assessment of 
disease response due to the morbidity associated with invasive biopsy especially 
during treatment. 
In this thesis we have demonstrated an apparent disease continuum between non-
neoplastic vulval tissue through VIN to overt malignancy using Raman spectroscopy 
(chapter 13.1.1). This suggests Raman spectroscopy may be able to identify patients 
with VIN who have disease progressing towards malignancy and those responding 
to topical treatments. Further in vivo longitudinal studies would be required to assess 
the efficacy of Raman spectroscopy for this application. As a research tool Raman 
spectroscopy has the potential to be used to assess response to novel treatments 
without recourse to invasive biopsy. This would mean objective assessment of 
response to treatment would not be limited by the morbidity of invasive biopsy and 
patient acceptability and objective longitudinal response could be assessed with 
increased precision.  
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13.1.4 Raman spectroscopy for improving prognosis 
assessment in vulval cancer  
Recurrent disease occurs commonly after the primary treatment of vulval SCC, 
affecting at least 25% of patients (Coulter and Gleeson, 2003; Te Grootenhuis et al., 
2018). Around half of recurrent cases recur locally within the vulva/ perineum and 
half at more distant sites (Salom and Penalver, 2002; Coulter and Gleeson, 2003). 
Currently our estimation of prognosis and risk of recurrence in vulval cancer is based 
on clinical and histopathological factors. Inadequate excision margins have been 
thought to be the main determinate of recurrent disease but this is increasingly being 
challenged as previously discussed. Other factors thought to have prognostic 
relevance include: presence of LS; groin lymph node metastasis and primary tumour 
characteristics. These tumour characteristics include:  tumour size, tumour focality; 
depth of invasion; grade of differentiation; tumour localisation; presence of HPV and 
lymphovascular space invasion (Yap et al., 2017; Te Grootenhuis et al., 2018). 
These factors are considered when making decisions about adjuvant radiotherapy to 
reduce the risk of disease recurrence. 
There has been increasing interest in Raman spectroscopy as tool for helping predict 
prognosis and response to treatment (Upchurch et al., 2018). In the management of 
vulval cancer Raman biomolecular assessment of tumour or residual tissue may help 
guide follow up and the use of adjuvant radiotherapy. Studies assessing the role of 
Raman spectroscopy for prognostic assessment have already been undertaken at 
other cancer sites. Analysis of Raman spectra from prostate cancer specimens 
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demonstrated the technique can identify those patients who would not respond to 
adjuvant hormone therapy with high sensitivity and specificity 88% and 88% 
respectively (Wang, He, et al., 2013). The same study also found the Raman spectra 
could be used to identify those patients who were initially hormone sensitive but who 
became hormone resistant in the following year with sensitivity and specificity of 86% 
and 89% respectively. Another study of patients with lung adenocarcinoma 
demonstrated Raman spectroscopy could identify patients sensitive to tyrosine 
kinase inhibitors with a sensitivity and specificity of 90% and 85% respectively 
(Wang, Zhang, et al., 2013). These studies illustrate the potential of Raman 
spectroscopy to go beyond replicating the results of histopathology and 
immunohistochemistry and to analyse molecular markers of response to treatment or 
prognosis. It is helpful to think about the words of Donald Rumsfeld when 
considering the role of Raman spectroscopy in prediction of prognosis or response to 
treatment.  Donald Rumsfeld said “there are known knowns; there are things we 
know we know. We also know there are known unknowns; that is to say we know 
there are some things we do not know. But there are also unknown unknowns”. In 
this context the “known knowns” are specific biomarkers that we know have a link to 
disease course such as oestrogen receptor immunohistochemistry and sensitivity to 
anti-oestrogen treatment. There are also “unknown unknowns” which describes 
tumour characteristics that are completely unknown to us. In the middle sits the 
“known unknowns” these are those biomolecular changes that can be speculatively 
identified using techniques such as Raman spectroscopy and that can be correlated 
with disease outcomes. These are changes that we can identify but that we cannot 
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precisely define due to the limitations of the technique, hence “known unknowns”. 
Identification of these “known unknowns” using Raman spectroscopy has the 
potential to yield useful prognostic information but is beyond the scope of this non-
longitudinal study. The ability to identify patients with high risk of recurrence could be 
used to identify those who would benefit from adjuvant treatment for example 
radiotherapy or possibly steroids, antivirals or immune modulators. 
13.1.5 Raman spectroscopy study limitations 
The investigation into the role of Raman spectroscopy in the management of vulval 
disease has methodological limitations that require highlighting. Many of the 
important limitations have been discussed at the relevant points in previous chapters 
and not all are repeated again in this chapter. The limitations in this study relate to 
the sample collection, spectral acquisition, data processing, multivariate analysis and 
core assumptions of the study. 
The tissue available for analysis in this ex vivo study was limited by the limits of 
acceptability for the study participants. It was not acceptable to take biopsies or 
excise tissue solely for research purposes. This limited tissue collection to the end of 
the diagnostic pathway in the assessment of neoplastic disease and to the uncertain 
category of patients in the assessment of LS. This is likely to be reflected in under 
estimation of the performance of the technique as a tool for diagnosis. The effect of 
this tissue selection bias is likely to be less marked in the margin assessment 
comparisons as the tissue analysed is a closer approximation to the real life clinical 
scenario under investigation. It should also be noted that tissue measured in vitro is 
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by its nature ischaemic and tissue in vivo has active blood flow and this may 
adversely affect the Raman signal as the endogenous fluorophores in blood are 
know to induce fluorescence. In addition the tissue hypoxia at excision may 
significantly alter the tissue biochemistry. A study of spectra collected in vivo and ex 
vivo in the same tissue by Lima et al. demonstrated a reduction in intensity of Amide 
I and II peaks in ex vivo measurements compared to in vivo measurements (Ferreira 
Lima et al., 2019). 
The fibre optic probe used in the final stage of the study (Chapter 8) had a significant 
background signal and this was apparent in all the spectra collected and may have 
masked tissue signal. In addition the background combined with tissue fluorescence 
caused detector saturation in the probe measurements. This resulted in the need to 
exclude spectral data acquired at less than 700 cm-1 from the analysis. This may 
have negatively impacted the classification performance due to the loss of 
discriminatory features below this point. 
The spectra taken using the probe were taken over an integration time of 20 seconds 
to optimise the signal to noise ratio in this proof of concept study. In the clinical 
environment the spectral acquisition time would need to be in the order of a few 
seconds to allow the assessment of multiple area of vulval skin. This should be 
achievable with improved collection optics in the probe and the application of 
multiple collection fibres around a central excitation fibre. The spectra acquired using 
the probe were also measured in a dark laboratory and the impact of ambient light 
was not assessed. The problem of ambient light interfering with the Raman signal 
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has been extensively investigated and a combination of selecting ambient light that 
does not interfere with the Raman signal and filtering the ambient light out of the 
collected spectra can be used to overcome this issue (Nyberg, Ramser and Lindahl, 
2013; Zhao et al., 2014). In addition this study did not assess inter-probe variability 
as all measurements were taken using one probe. 
13.2 Discussion: FTIR spectrosocpy for the assessment of 
vulval diease  
13.2.1 FTIR as an adjunct to aid routine histopathological 
assessment in the detection of vulval disease 
The role of FTIR spectroscopy as an automated diagnostic tool was investigated in 
the study outline in Chapter 11. The acceptable accuracy of an automated tool for 
translation into clinical practice depends on the role the tool is to take. Given the 
significance of the diagnosis of vulval cancer or VIN it is not likely an automated 
FTIR based diagnostic assessment would be considered sufficient for diagnosis 
alone until sufficient validation of the approach versus current techniques over many 
years was performed. Given the increasing workload faced by histopathologist and 
the need for second reporting in cases of vulval cancer, the most appropriate 
application of this new technology would be in triaging samples for analysis by 
histopathologists and acting as a second diagnostic assessment in women with 
suspected vulval SCC. 
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The results obtained with FTIR mapping of selected samples of non-neoplastic vulval 
tissue, VIN and SCC were found to be promising. Two diagnostic comparisons were 
evaluated reflecting the two potential roles for the technique outlined above. 
The first comparison assessed the ability of the technique to act as a triage tool to 
prioritise the histopathological workload. In this setting it is important to identify SCC 
with high sensitivity, as the consequence of delayed diagnosis is more severe than 
an inappropriately urgent histopathology review. Although the diagnostic accuracy 
was assessed on a per spectrum basis the only valid evaluation is that performed on 
a per sample basis. In practice the whole of a biopsy would need to be evaluated to 
be confident that it did not contain cancer. The use of individual spectra that are not 
necessarily representative of the whole specimen would not be acceptable. When 
analysing on a per sample map basis all of the cases of SCC were identified (100% 
sensitivity) and only 21% of samples were incorrectly classified as containing SCC 
(79% specificity). This indicates the technique has promise in the triage of diagnostic 
biopsies to enable histopathologists to prioritise those cases that are more likely to 
contain SCC. If FTIR mapping were to be translated into clinical practice for the 
purpose of triaging vulval pathology specimens several major limitations would need 
to be overcome. In this study only a small part of each tissue sample was assessed 
by FTIR. For the technique to be introduced into routine clinical practice it is likely 
that whole biopsy samples would need to be mapped to avoid missing a diagnosis of 
cancer due to a sampling error. This would be possible using the technique outlined 
in this study but it would take a prohibitively long time. The time of spectral map 
acquisitions could however be reduced by adjusting the collection parameters (e.g. 
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spatial resolution or wavenumber range) to allow faster spectral acquisition. Using 
different spectrometers with larger detector arrays or supercontinuum sources and 
detectors could also be used to increase the speed of acquisition (Naranjo et al., 
2015). Another approach to reduce the time taken to process samples would be a 
sampling only part of the epithelium. This could be done either using a random 
sampling technique or by using another technique to screen the sample for areas 
likely to contain cancer. Care would need to be taken with a random sampling 
technique for the reasons previously stated. Fluorescence spectroscopy would be a 
suitable technique for identifying areas for more detailed analysis by IR spectroscopy 
as it is rapid and highly sensitive, but lacks specificity (Kong et al., 2013). Another 
approach would be to limit the analysis to a smaller number of relevant 
wavenumbers rather than collecting the whole spectrum. This would lead to faster 
spectral acquisition and potentially reduce the high cost of the instrument needed to 
analyse the tissue. 
The second comparison evaluated the ability of the technique to act as a second 
reporter for samples of cancer. This was assessed by looking at the ability of the 
technique to differentiate between SCC and VIN as diagnostic uncertainty can arise 
between the classification of VIN and SCC when invasion is equivocal. As non-
neoplastic tissue and SCC should have more biomolecular differences than SCC 
and VIN it was expected that the technique would perform less well when 
differentiating SCC from VIN. When analysing on a per sample map basis all of the 
cases of SCC were identified (100% sensitivity) from those of VIN and only 23% of 
samples of VIN were incorrectly classified as containing SCC (77% specificity). 
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These results suggest the technique has promise for confirming case of SCC with 
accuracy when histopathology suggests SCC is present and therefore it has the 
potential to provide an automated second opinion in cases of SCC. As confirming a 
diagnosis of cancer only requires spectral mapping of the area thought to contain the 
cancer there is no need to map the entire sample. As a result of this the previously 
discussed limitations in relation to completeness of sample mapping and time taken 
to scan the sample are less significant in this application. A significant limitation in 
this comparison is that the tissue selected for analysis does not exactly match tissue 
that would be analysed if the technique were integrated into the clinical work flow. If 
the technique was to be implemented as a tool for confirming the presence of cancer 
then the tissue sections under analysis would be those where the presence of SCC 
was not clear and those with severe VIN where the presence of SCC was suspected. 
In this comparison all stages and grades of SCC were compared together with 
unrefined samples of VIN. It may therefore be the case that the classification 
performance seen in this comparison is an overestimation of the performance that 
would be seen in routine practice. 
Both these comparisons are only indicative of the potential of the technique to aid 
the histopathological workflow. Further work is required as outlined in chapter 13.4 to 




13.2.2 FTIR spectroscopy for augmenting histopathology 
This preliminary study has demonstrated FTIR spectroscopy is able distinguish 
between LS or uVIN found in isolation and LS or uVIN found alongside concurrent 
SCC at another anatomical location on the vulva. The ability to separate these 
groups according to the presence of concurrent SCC is suggestive of cancer 
associated molecular changes occurring across the vulva. The detection of these 
molecular changes supports the concept of preneoplastic field cancerisation in the 
vulva (Rosenthal et al., 2002; Braakhuis et al., 2003; Dakubo et al., 2007). In the 
development of a preneoplastic field of cancerisation, a stem cell acquires a genetic 
or epigenetic alteration that gives it a growth advantage over its neighboring cells. 
Replication of the stem cell results in an expanding patch of altered daughter cells. 
With additional genetic or epigenetic alterations this patch replaces the normal 
epithelium and develops into a field of cancerisation. Within the abnormal 
preneoplastic field the epithelium may appear histologically benign however 
molecular alterations within cells result in an increased risk of malignant 
transformation. The development of preneoplastic field change can be used to 
explain the multiple primary tumours and distant tumour recurrences that are often 
observed in the vulva. The molecular basis for field cancerisation in the vulva has 
previously been explored by examining the distribution of X-chromosome 
inactivation, TP53 mutations and viral integration sites (Rosenthal et al., 2002; Rolfe 
et al., 2003; Vinokurova et al., 2005). The data published demonstrated molecular 
monoclonality of anatomically distant vulval lesions supporting the concept of 
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preneoplastic field change in the vulva. These studies of specific molecular changes 
in the vulva only show us part of the picture as the transformation of normal cells to 
cancer is a complex multistep process involving more that just a few molecular 
variations. In this study we have used FTIR spectroscopy to demonstrate the 
molecular field changes associated with the development of vulval cancer. FTIR 
spectroscopy allows the analysis of a broad range of molecular changes within the 
vulva. This technique not only examines molecular changes resulting from known 
provocations (e.g. TP53 mutation and HPV integration) but also assesses other 
undescribed molecular changes (Ostrowska et al., 2011). This gives a broader 
picture of the molecular changes present, but at the expense of detailed 
biomolecular causation, as FTIR spectroscopy does not allow us to determine the 
exact molecular differences underlying spectral differences identified. 
Demonstrating the ability of FTIR spectroscopy to differentiate between vulval 
disease found with concurrent cancer and vulval disease found in isolation highlights 
the role FTIR spectroscopy could have as a tool for assessing preneoplastic 
molecular changes in the vulva. 
Traditional histopathological analysis gives limited information about the 
biomolecular changes associated with an increased risk of malignant transformation. 
FTIR spectroscopy has the potential to be used to augment traditional histopathology 
giving pathologists additional molecular information from the tissue under 
examination. The FTIR spectroscopic analysis of preneoplastic fields and molecular 
risk stratification of patients with VIN or LS may facilitate the identification of those at 
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high risk of developing vulval cancer. In addition, FTIR spectroscopy has the 
potential to be used as a histopathological adjunct to improve the early diagnosis of 
SCC through the analysis of molecular changes that identify those in whom further 
investigation is likely to find an occult malignancy. This early diagnosis would be an 
advantage as when vulval SCC is diagnosed early, when the depth of invasion is 
less than 1.0 mm (i.e. FIGO stage 1a), the risk of lymph node metastasis is very low 
(Hacker and Van der Velden, 1993). The absence of lymph node metastasis is an 
important prognostic factor in vulval SCC, with reported five-year survival in those 
who are node negative ranges from 70-93% compared with 25-42% in node positive 
women (Schilder and Stehman, 2012). 
13.3 FTIR spectroscopy study limitations 
The investigation into the role of FTIR spectroscopy in the assessment of vulval 
disease has methodological limitations that require highlighting. Many of the 
important limitations (e.g. time taken to perform the technique and cost of the 
technique) have been discussed at the relevant points in previous chapters and are 
not repeated again here. A significant limitation in this proof of concept study was the 
bias inherent in the sample selection. In this study tissue samples were 
retrospectively selected that displayed the typical characteristics of the pathologies 
of interest and were not representative of all the possible pathologies present in the 
vulva. Introducing a broader range of pathologies into the classification model may 
result in a poorer diagnostic performance and needs to be evaluated further. In 
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addition, the process for measuring and analysing spectra from the samples in this 
study was not fully automated and required skilled technical input to select the 
correct areas for mapping and then to select the epidermal layers after k means 
analysis. If the technique is to be implemented in to the routine diagnostic pathway 
then either all elements of the process will need to be automated or training provided 
to those delivering the service introducing the possibility of human error. 
13.4 Future work 
13.4.1 Development of an in vivo Raman probe 
The laboratory based ex vivo studies presented in this thesis demonstrate the 
Raman technique has real promise for delineating disease margins at the time of 
surgery and for the diagnosis of vulval conditions. The next proposed phase of 
research outlined below is the development and evaluation of a probe suitable for 
the in vivo assessment of vulval tissue within the clinical environment to allow the 
progression to large scale clinical trials. The aim would be to provide sufficient 
evidence to lead to large scale trials to assess if the technique can be used to 
minimise the mutilating and disfiguring surgery suffered by women with vulval cancer 
and VIN by accurately detecting disease margins at the time of surgery. In addition 
this phase of research would be needed prior to evaluating the ability of the 
technique to reduce the need for invasive tissue biopsies when diagnosing vulval 
conditions in the clinical environment. The main objectives of this next research 
phase are listed in Table 13-3. 
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Table 13-3 – Objectives for the next phase of research in the develpoment of Raman spectrscopy for 
the assessment of vulval disease. 
Objectives 
1. To develop a safe and reproducible non-invasive Raman spectroscopic probe 
for the assessment of vulval disease in vivo. 
2. To demonstrate the prototype probe can identify disease specific Raman 
spectroscopic signal characteristics (spectral fingerprints) ex vivo across a range of 
known vulval skin conditions within the clinical environment. 
3. Obtain regulatory and ethical approval for an in vivo feasibility study and 
demonstrate safety of the device in the first human pilot. 
4. To demonstrate the probe can be used in vivo to detect the molecular 
changes that occur at the margins of pre-cancerous and cancerous vulval disease. 
5. Develop the understanding of how the Raman probe will improve the care for 
women with vulval cancer and VIN. 
 
This research would build on the initial laboratory based proof of concept studies 
presented in this thesis and would lay the foundation for a full clinical trial to evaluate 
the efficacy of the technique in clinical practice.  
It is proposed that future research is split into five packages of work: 
13.4.1.1 Work package one - development of Raman probe 
prototype suitable for in vivo assessment of vulval disease 
and probe optimisation for manufacture. 
In this work package the design for a Raman probe suitable for in vivo evaluation 
should be developed. Data from analysis of ex vivo Raman spectral measurements 
of vulval tissue presented in this thesis would be used to inform the design of the 
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probe. The design should include features necessary for in vivo use, including the 
development of disposable sterile probe tips suitable for intraoperative use. A novel 
prototype probe device would then need to be evaluated with respect to interprobe 
and intersystem variability in preparation for human tissue studies. 
In collaboration with a commercial medical device design, development and 
manufacturing partner, the probe would need to be optimised to suit commercial 
production facilities. 
Production records would need to be kept and a technical file constructed to gain the 
necessary Medicines and Healthcare Products Regulatory Agency (MHRA) 
approval. Testing and quality criteria to be fulfilled at each stage of component 
procurement and production would need to be agreed. Sterilisation/ cleansing 
process to be used should be confirmed and dummy probes produced for bioburden 
tests to validate that process. 
13.4.1.2 Work package two - probe manufacture and testing 
/ regulatory (MHRA) and ethical approvals / initial ex vivo 
diagnostic study 
A commercial partner would manufacture the finalised probe design. The quality of 
probe spectral signal and reproducibility should be evaluated by testing on existing 
samples of excised vulval tissue, ensuring signals are of similar quality to those 
obtained using the tested prototype design. 
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An initial ex vivo diagnostic study of the existing human vulval tissue samples used 
in this study could then be completed under existing ethical approvals. This would 
ensure the diagnostic performance demonstrated in early laboratory studies could be 
replicated using the new probe device. A multivariate discriminant classification 
model would be developed to allow disease classification using the novel probe. The 
classification model should be evaluated with ‘leave one out cross-validation’ to 
optimise the use of the available spectral data. MHRA and ethical approvals would 
need to be obtained to allow evaluation of the probe in vivo. 
13.4.1.3 Work package three -  in vivo pilot, safety 
evaluation and in vivo feasibility study 
This work package would be used to identify and overcome the technical challenges 
of moving the technique from the laboratory and into the clinical setting (e.g. 
variations in lighting, temperature and humidity). 
An in vivo feasibility study should be undertaken. This would assess the technique 
for safety, practical implementation and diagnostic accuracy on volunteer patients. 
This would include basic safety for the patient and operator; logistics and 
ergonomics; tissue biochemical signal to noise versus time and anatomical location 
as well as a basic signal reproducibility evaluation. Clinician training materials for the 




This in vivo study should be conducted during conventional surgical excision of 
vulval tissue for treatment of VIN or vulval cancer. Before removal of the tissue from 
the patient Raman spectra should be measured radially at intervals from the centre 
of the disease lesion to the margin of the resection specimen, typically 10-15 
millimetres from the visible disease margin. The measurement sites should be 
marked and the spectra obtained correlated with the subsequent gold standard 
histopathological analysis. The aim would be to replicate the biochemical signals we 
have measured ex vivo within the clinical setting, thus providing evidence that the 
approach would provide in vivo real-time discrimination of disease. 
13.4.1.4 Work package four -  pathway to implementation 
and applications in clinical practice 
In parallel with the other work packages clinical viability and preference evaluations 
will be undertaken. This should include an assessment of clinicians’ preferences for 
probe design to ensure the probe is technically suited to the proposed application. 
Prototype probe hand pieces should be generated using rapid prototyping 
techniques and usability tests performed to ensure smooth ergonomic action of the 
probes within the clinical environment. Clinicians should also be engaged to co-
create instrument readout methodologies to ensure the spectral analysis can be 
presented to clinicians in a safe, accurate and clear format. 
Alongside this the barriers to implementation should be assessed through clinician 
engagement exercises with national and international clinical organisations. This 
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work programme would pave the way for stakeholder engagement with the wider 
clinical trials needed prior to implementation in clinical practice. 
13.4.1.5 Work package five -  PPI Involvement 
This work package involves engagement with gynaecological patients and would 
create a focus group of interested individuals from the patient population to 
collaborate on the experimental design of this and future studies. This will help 
develop the next phase of clinical studies to follow on from the research and create a 
drive for adoption of the technique from the patient base. The focus group would also 
be used to help understand the potential impact of novel diagnostic technology on 
patients and patients’ attitudes towards minimising vulval surgery. Patient 
representatives would need to be involved in the development of the recruitment 
packs and information leaflets key for any future studies. 
13.4.1.6 Summary 
The study suggested as the next phase of this research would translate the Raman 
technique from the laboratory to the clinical environment by creating and validating a 
novel diagnostic instrument ready for future clinical trials. This would be necessary 
for a large-scale multicentre in vivo clinical trial to evaluate the efficacy of the 
technique. The design of the large scale in vivo clinical trial is beyond the scope of 
this thesis and would be part of any future research. 
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13.4.2 Further FTIR spectroscopic diagnostic studies 
To further evaluate FTIR spectroscopy as a tool for aiding the histopathological 
diagnostic pathway studies are required to evaluate the performance of the 
technique in conditions closer to the standard pathological workflow. Additional types 
of vulval pathology and unclassifiable vulval tissue need to be added to the 
classification model to allow the true ‘real life’ performance of the technique to be 
assessed. In addition the role of the technique as a second opinion in the diagnosis 
of vulval SCC should also be assessed within the clinical pathway. This could be 
achieved by the FTIR spectroscopic evaluation of difficult to diagnose cases of 
possible SCC. This approach could more accurately assess the potential for the 
technique to act as a spectroscopic second opinion for the confirmation of the 
presence of SCC.  
13.4.3 Longitudinal studies 
In addition to the future research proposed in chapter 13.4.1 longitudinal studies 
should be undertaken to explore the role of Raman and FTIR spectroscopy as a 
biomarker of malignant progression from LS and VIN to SCC and as a biomarker for 
recurrence of VIN or SCC. This could be undertaken using high quality ex vivo 
spectra measurements using the methodologies described in Chapter 6 and Chapter 
12. To assess a correlation between Raman and FTIR spectra and malignant 
progression samples of tissue containing LS or VIN from patients receiving topical 
treatment rather than excisional surgery could be assessed with Raman and FTIR 
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spectroscopy at baseline and the patients followed up to monitor for recurrence. As 
the rate of progression from LS to vulval SCC is much lower than for VIN this is likely 
to prove difficult, as a large trial would be required. In addition the acquisition of 
tissue from all patients with LS would be challenging, as many do not undergo 
diagnostic biopsy. It is likely that longitudinal studies of the prognostic value of 
Raman spectroscopy in LS may need to be postponed until an in vivo probe is 
available. Assessing the correlation between Raman and FTIR spectral 
characteristics and recurrence of vulval cancer is less challenging given the 
availability of tissue from excisional surgery and the higher rate of recurrence 
compared with malignant progression in LS and VIN. The main challenge would be 
how to assess the biomolecular changes present in the residual tissue left in the 
vulva as this is the site of disease recurrence. The non-neoplastic tissue margin 
excised at the time of surgery could however be used as a proxy for the residual 





Raman spectroscopy is a sophisticated technique well suited as an adjunct to clinical 
assessment and histopathology. The technique has a well-established ability to 
accurately discriminate a variety of different skin pathologies in non-genital sites 
(Feng et al., 2018; Zhang et al., 2018; Ferreira Lima et al., 2019; Khristoforova et al., 
2019). The focus of these studies at non genital skin sites has been on common 
cancers at these sites, including basal cell carcinomas and melanomas which have 
different Raman spectral profiles to SCC (Feng et al., 2018). No other studies to date 
have demonstrated the ability of Raman spectroscopy in differentiating the unique 
set of pathologies present in the vulva. The research presented in the previous 
chapters of this thesis constitutes an exploratory analysis of Raman spectroscopy in 
vulval disease. This study has demonstrated the technique is effective at 
differentiating a core set of vulval diseases not previously evaluated by Raman 
spectroscopy. 
Considering the potential sources for type one and type two errors outlined above, 
on balance it appears that Raman spectroscopy has real potential as a tool for 
reducing clinicians reliance on invasive tissue biopsy and for targeting biopsies to 
greatest effect. The diagnostic accuracies achieved in this study do not match that of 
histopathology and may not be sufficient to replace invasive tissue biopsy entirely 
but they show the technique has the potential to reduce reliance on invasive biopsy. 
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Furthermore the technique has real potential for the determination of disease 
margins at the time of excisional surgery for neoplastic vulval disease and for 
increasing clinicians’ confidence in minimising surgical margins. In this context 
Raman spectroscopy would be used alongside clinical assessment in a multimodal 
approach to decide whether tissue needs to be excised.  
The data suggests a biomolecular continuum of disease is evident in the Raman 
spectra, from frank malignancy at one end to benign vulval tissue at the other. This 
suggests that the technique may be useful for monitoring disease progression and 
response to non-surgical treatments. 
Development of an in vivo probe and an in vivo trial is warranted and feasible. This 
would allow assessment of the potential impact of the technique on the care of 
patients with vulval disease. Further longitudinal studies are also warranted to 
assess if the technique has potential in monitoring risk of disease progression and 
response to treatment. 
FTIR spectroscopy offers a technique for molecular assessment that is 
straightforward to apply to routinely prepared tissue; that has a relatively low cost; 
that only requires a small amount of tissue and that can be performed in a relatively 
short amount of time (Old et al. 2014). These characteristics make FTIR 
spectroscopy suitable as an adjunct to routine histopathology where additional 
analysis of tissue samples is required. Previous research by Baker et al. 
demonstrated the potential of FTIR spectroscopy in evaluating the biopotential of 
prostate cancer, however to our knowledge this is the first time FTIR spectroscopy 
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has been used to assess the molecular changes associated with vulval cancer 
(Baker et al. 2008). 
FITR-S has the potential to provide a technique that detects the genesis of malignant 
disease rather than just the presence of cancer. Such a technique would be useful 
for early cancer detection and informing prognosis. This study highlights the potential 
of FTIR spectroscopy for the molecular risk stratification of women with LS or uVIN. 
Further work in the form of longitudinal studies is required to determine if this 
preliminary work can be transformed into a technique that will improve outcomes for 
women. 
In summary advanced diagnostic techniques show significant promise in improving 
the care of women with vulval diseases by reducing the reliance on traditional biopsy 
and histopathology and augmenting clinicians ability to differentiate different types of 
vulval disease. The work outlined in this thesis evaluates the role of emerging 
techniques in vibrational spectroscopy to address this need with three key themes 
underpinning the various aspects of this thesis: 
1. Development of a diagnostic technique to reduce the reliance on traditional 
biopsy and histopathological diagnosis 
2. Development of a diagnostic technique for improving the delineation of 




3. Evaluation of a tool for augmenting and automating aspects of histopathology 
to reduce the workload on busy histopathology departments. 
This thesis demonstrates the considerable potential of vibrational spectroscopy in 
this clinical setting. The research has made significant progress in each of the 
three themes outlined above and indicates that further work is warranted to 
develop the techniques towards routine clinical application. 
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Section F: Appendices 
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Appendix A Regulatory Issues 
A.1 Ethical approval 
Ethical approval for the analysis of fresh and fresh frozen vulval and lymph node 
tissue was granted by the National Research Ethics Service Committee South West 
– Exeter (REC reference - 14/SW/1077). 
Ethical approval for the analysis of archived vulval and lymph node tissue was 
granted by the East of Scotland Research Ethics Service (REC reference - 
14/ES/1066). 
A.2 Patient consent and patient information 
Consent was obtained for the use of fresh or fresh frozen vulval and lymph node 
tissue.  Consent was sought from each participant only after a full explanation had 
been given, an information sheet offered (Appendix 402) and time allowed for 
consideration. Signed participant consent (Appendix C.2) was obtained prior to 
analysis of tissue samples. The right of the participant to refuse to participate without 




The confidentiality of participants taking part in this study was preserved in accordance 
with the Data Protection Act 1998. 
A.4 Indemnity 
Gloucestershire Hospitals NHS Foundation Trust held standard NHS hospital indemnity 
and insurance cover with NHS Litigation Authority for NHS Trusts in England, which 
applied to this study. 
A.5 Adverse events 
Errors in processing fresh tissue samples required for histopathological diagnosis as part 
of patients routine care could have led to failure of diagnosis.  The failure to diagnose a 
patient’s condition has a significant impact on the care they receive.  In light of this 
sample processing errors made during the study and were reportable.  The impact of 
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